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Abstract
Heart disease (HD) is the leading cause of mortality worldwide. Currently, diagnosis is based
on clinical features, imaging, and circulating cardiac biomarkers. Cardiac imaging
technologies, such as echocardiography and cardiac magnetic resonance imaging (cMRI),
enable the non-invasive detection of changes in heart function. Although these modalities can
detect changes in structure and anatomy, it is usually at later stages, where prevention may not
be possible. In conjunction with imaging, circulating biomarkers of heart failure (HF), notably
B-type natriuretic peptide (BNP) and cardiac troponin I and T, can be detected with increased
levels in the blood. These biomarkers are associated with other comorbidities and may not be
specific to cardiac tissue. Thus, there is a critical need to develop imaging agents to detect the
biochemical and molecular changes that precede gross structural changes in HD. There is
evidence that the growth hormone secretagogue receptor (GHSR) and its ligand ghrelin, could
be a potential molecular imaging target where expression is increased in HF. The purpose of
my work was to characterize GHSR as a biomarker for the underlying biological mechanisms
involved in heart disease and heart.
To characterize GHSR in end stage HF and valvular HD in humans, I used quantitative
fluorescence microscopy with a custom far-red ghrelin analog to evaluate changes in the
ghrelin-GHSR system and its downstream signalling. In this way, the ghrelin-GHSR system
was elevated in HF and showed specific regional changes in HD. The ghrelin-GHSR system
was correlated to heart function through left ventricular ejection fraction in HF while this
system correlates regionally in only the left atrium in HD and no correlations are present in
healthy tissue. Therefore, the ghrelin-GHSR system shows scalability from healthy to HD to
HF.
After characterization of ghrelin-GHSR in the human heart, I evaluated this system using in
vivo imaging techniques to track the heart after a myocardial infarction in canines. A novel
molecular imaging agent demonstrated a unique binding pattern in the heart before and after a
myocardial infarction. This binding pattern did not simply reflect cardiac perfusion showing
specificity and correlated strongly with histological analysis of this system in the heart showing
ii

sensitivity. Therefore, I identified a novel in vivo imaging agent to bind specifically and
selectively in the canine heart.
In summary, my thesis describes the characterization of the changes in the myocardial ghrelinGHSR system using novel imaging agents in situ and in vivo. These findings have important
clinical application for the early detection of HD.

Keywords
Heart Disease/ Heart Failure, Biomarkers, Ghrelin - Growth Hormone Secretagogue
Receptor, Quantitative Fluorescent Microscopy, Molecular Imaging, Positron Emission
Tomography
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Summary for Lay Audience
Heart disease is the leading cause of death worldwide. It is defined by any condition that
negatively affects the structure or function of the heart. Heart disease may eventually develop
into heart failure, which is defined by a weakened or damaged heart muscle that cannot pump
blood throughout the body sufficiently. It is a difficult problem as there is no way to predict
who will proceed to heart failure, or who will respond to therapies. Currently, heart disease is
diagnosed using imaging methods, mainly ultrasound, that detect changes in the heart’s
anatomy and function. However, these changes are associated with late stages of the disease
when prevention may not be possible. In addition to imaging, other signs, or markers, of heart
failure can be measured in the blood, although they are not necessarily specific to cardiac
tissue. Thus, there is a need to detect heart disease at earlier stages with markers specific to
cardiac tissue using non-invasive imaging methods. I have used one such marker, called the
growth hormone secretagogue receptor (GHSR), as a tool to develop new methods of imaging
the heart. GHSR is known to be beneficial to heart health, as it helps to strengthen the heart
muscle and prevents heart tissue from dying. Changes in GHSR levels may indicate early
stages of heart disease. The purpose of my work was to identify how GHSR changes in heart
disease and heart failure, and to design new imaging methods that target GHSR in the heart. I
used advanced microscope techniques to show that GHSR increases in advanced heart failure,
and changes to a much smaller extent in mild heart disease. I then developed a non-invasive
radioactive imaging method to measure changes in GHSR in dogs before and up to 1 year after
a heart attack. I found that GHSR levels decreased in the area of the heart injured in the heart
attack, and increased specifically in the area surrounding the injured area immediately after the
heart attack, and these changes were sustained for a period of one year. Therefore, I developed
a new non-invasive imaging method that can evaluate specific changes in GHSR in the heart.
In summary, my thesis describes the changes in GHSR in the heart in human heart disease, and
the development of a specific imaging tool to detect these changes in GHSR non-invasively.
This is important as alterations in GHSR can indicate early stages of heart disease and therefore
will lead to improvements in early detection, which may lead to improved treatments and
management of heart disease, thus decreasing the likelihood of progression to heart failure.
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Chapter 1

1

Introduction

According to the Heart and Stroke Foundation report (2019) there are currently 2.4 million
Canadians living with heart disease (HD)1. HD includes impairment and damage to heart
muscles or structures that refer to cardiomyopathies including heart wall thickening, severe
inflammation, cardiac muscle rigidity, and conductivity derangements. If HD becomes
severe, heart function progressively worsens, leading to the clinical syndrome of heart
failure (HF). Of the 2.4 million people with HD, over 600,000 are living with HF2. HF
occurs when the heart cannot pump enough blood to provide sufficient oxygen to the rest
of the body, often caused by systolic heart failure where the heart muscle is too weak to
pump blood sufficiently1. HF places a significant burden on both the patient and the global
health care system’s limited resources as 40% of people admitted to the hospital are
readmitted for adverse cardiac events. Significant advancements in diagnosing and treating
patients with HF, specifically caused by myocardial infarction, have reduced the incidence
of death but have also led to increased risk of future cardiac events1,2.

1.1 Heart Failure Progression
The heart is one of the most efficient organs which contains the contractile force to pump
blood throughout the body. The wall of the heart is composed of three distinct layers;
epicardium (outermost layer of the wall), endocardium (inner most layer), and the
myocardium (intermediate and most prominent layer of the heart). The heart contains 4
distinct chambers; the left and right atria, which are small, thin-walled chambers, and the
left and right ventricles, the large thick-walled chambers where most of the work is
performed. The right atrium (RA) receives blood from the venous system where
contraction results in ejection of blood to the right ventricle (RV). The RV pumps blood to
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the lungs for oxygenation and is pumped back into the left atrium (LA). The blood is
ejected into the left ventricle (LV) which facilitates blood flow throughout the body.
Impairment in this process causes cardiac dysfunction; when impairment becomes chronic,
it can lead to HF. HF is a clinical syndrome characterized by impaired cardiac output and/or
volume overload resulting in the inability to meet the metabolic demands of the body. HF
is also commonly associated with structural abnormalities. The two most common forms
of HF are: 1) systolic HF where reduced ejection fraction is caused by weakening of the
ventricular wall and decreased contractile force; and 2) diastolic HF with preserved
ejection fraction and stiffened ventricular walls that are unable to fully relax and fill the
chamber with enough blood to pump to the rest of the body3. HF can originate from
different causes: 1) directly from the heart including congenital heart defects in the valves
or chambers of the heart; cardiomyopathies resulting from infection or pressure overload;
vasculopathies typically from coronary artery disease and myocardial infarction; and
arrythmias caused by electrical failure in the heart, and 2) whole body effects, such as
hypertension, lung disease, diabetes complications and drug misuse. In advanced stages of
HF, perfusion becomes severely limited, leading to fluid retention in the lungs and
peripheral tissues potentially resulting in renal failure. The body compensates through
cardio-protective events such as increasing heart rate, sympathetic activation, and upregulation of hormonal blood pressure through the renin-angiotensin-aldosterone system
(RAAS). However, once HF is established in an individual, the functional and structural
changes may respond to conventional treatments that manage patient symptoms until the
heart deteriorates to the point where advanced therapies/ interventions are needed4.
Predicting which patients proceed to HF after initial symptoms or trauma remains difficult.
There are many risk factors that are associated with the onset of HF. These include diabetes,
smoking, high cholesterol (specifically high low-density lipoprotein levels), high blood
pressure, physical inactivity, obesity, age, and previous cardiac conditions5. Thus, reduced
and preserved ejection fraction (HFrEF and HFpEF, respectively) present with these risk
factors which contribute to the progression of HF3. HFrEF is usually characterized by an
enlarged LV that results in global decreased cardiac output while HFpEF is usually
characterized by a normal-sized LV with global impairment of depressed cardiovascular
function6.
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HF has become a global health problem where prevalence is on the rise with enormous
health care expenditures. In industrialized countries, roughly 0.4-2.2% of the population
suffer from HF and rates increasing with age with 9.2 fold increases in prevalence in
individuals over 65 years of age7. In overall HF incidence, the elderly population accounts
for 80% of HF-related hospitalizations and 90% of HF-related deaths7. HF presence is
increasing in the population largely due to the aging population coupled with the
advancements in treatments and diagnostic technology that lead to improved outcomes for
patients. Therefore advancements in how HF is diagnosed and treated are necessary8. In
Sub-Sarharan Africa, cardiovascular disease is progressively taking over infectious disease
as the leading cause of mortality with mortality rates range variably from 60 days at 9.5%
up to 3 years with 67.1% mortality9. With worldwide HF prevalence increasing there is a
larger economic burden placed on health care systems both directly and indirectly.
Globally, the economic burden of HF is roughly $108 billion7 with the cost of Canada’s
health care system being $2.8 billion annually2. According to one study that evaluated the
readmission rates of Canadians after primary diagnosis of HF in 2015, 18.2% were
readmitted within 30 days where older patients were readmitted more frequently than
younger patients. Patients who were readmitted had high comorbidity burdens, more
hospitalizations in 6-months prior to HF diagnosis, and a longer length of stay at the
hospital10. With an increasing aging population, there is an expected increase of HF patients
with comorbid conditions which could ultimately increase HF mortality. HF rates may also
increase due to common trends including increases in physical inactivity, obesity, poor
eating habits, and diabetes11. Therefore, there is a need for more compelling and innovative
strategies to counter the effects of HF on the health care system.

1.1.1

Heart Failure Pathophysiology

Heart failure is a complex clinical syndrome that has a diverse path of progression. When
the heart starts to fail, many compensatory mechanisms are initiated, which eventually
contribute to the pathophysiology of HF12. Compensation occurs as the heart strives to
maintain overall cardiac output (CO) as declining mean atrial and ventricular pressures
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decrease cardiac perfusion. This increases the left ventricular (LV) end-diastolic pressure
with stretching of the myocardial wall and restoration of the CO13 through mechanisms of
sympathetic activation, neurohormonal regulation and cardiac remodeling, along with
alterations in biochemical signalling pathways13. The main signalling pathways used to
compensate for HF include calcium regulation for contractility, cellular death/ survival
pathways, and myocardial energy metabolism.
Cardiac output (CO) represents the amount of blood pumped out of the heart as a product
of heart rate and stroke volume. CO is also affected by ventricular contraction, chamber
wall integrity, and valvular competence12. Left ventricular (LV) dysfunction is commonly
associated with left atrial (LA) pressure and pulmonary congestion. Right ventricular
failure occurs with LV failure and similarly, alterations in right atrial pressures. When the
CO along with total peripheral resistance (TPR) decreases, the mean atrial pressure (MAP)
and, in turn, tissue perfusion, decrease. The body compensates for decreased CO by
increasing the heart rate with subsequent increases in neurohormone secretion12 and
increasing stroke volume via either LV dilation (muscle stretching and thinning) or LV
hypertrophy (muscle thickening). Chronically, this process becomes detrimental ultimately
resulting in impaired contractility, increases in cell death, a switch in metabolic substrates,
initiation of inflammation, all of which lead to further cardiac damage.
Another component of the compensatory mechanism is cardiomyocyte hypertrophy. Since
cardiomyocytes lack the ability to divide, cardiomyocyte hypertrophy is a compensatory
mechanism to trauma where cells increase in size and mass to normalize wall stress and
allow normal function of the heart at rest14. This increased size and mass are accompanied
by biochemical and molecular mechanism changes to help with cardiomyocyte
compensation including contractility, cell survival/ death, and cardiomyocyte metabolism.
The regulation of calcium (Ca2+) homeostasis within cardiomyocytes plays an important
role in contractile function (excitation-contraction coupling) in the cardiomyocytes.
Contractile function encompasses both contraction (systole) and relaxation (diastole). In
contraction, the cell membrane is depolarized through action potentials from neighboring
cells allowing for Ca2+ to enter the cardiomyocyte through the L-type calcium channel
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(LTCC) on the cell membrane. This Ca2+ binds to the ryanodine 2 receptor (RyR2) on the
sarcoplasmic reticulum (SR) membrane causing an efflux of Ca2+ from the SR to the
cytosol. The excess of Ca2+ in the cell causes contractile proteins to activate. Upon
relaxation, the cytosolic Ca2+ is pumped back into the SR using SR ATPase pump
SERCA2a, and the remaining Ca2+ is removed from the cell using the sodium-calcium
exchanger (NCX) on the cell membrane3,15. In HF, this process is disrupted through either
accumulation of excess Ca2+ in the cytosol or decreased Ca2+ in the SR during the
contraction and relaxation processes. Excess amounts of Ca2+ can be the result of defects
in the LTCC causing too much Ca2+ to enter the cell or NCX where Ca2+ cannot fully exit
the cell15. A dysfunction in the RyR2 can cause Ca2+ to leak from the SR and accumulate
in the cytosol3 while dysfunction in SERCA2a pump can cause reduced uptake into the SR
causing systolic dysfunction. SERCA2a dysfunction can also reduce the speed and quantity
of Ca2+ transport out of the cytoplasm, thus inhibiting relaxation and causing diastolic
dysfunction3,15,16. Therefore, Ca2+ flux in the cardiomyocytes, specifically in the SR, is
highly regulated and can provide therapeutic targets for LV dysfunction.
HF is commonly characterized by increased rates of cell death, commonly through
apoptosis, necrosis, or autophagy, ultimately leading to excessive depletion of
cardiomyocytes and HF. In the normal functioning heart, cycles of apoptosis and
autophagy occur at low basal levels during the process of cardiomyocyte turnover17. When
these processes become overactive and new cells cannot replace old cells at such rates, the
heart starts to fail.
Apoptosis is a highly regulated process of programmed cell death that occurs through
extrinsic and intrinsic pathways, characterized by blebbing of the cell membrane, cell
shrinkage and formation of apoptotic bodies. In the intrinsic pathway, hypoxia,
ischemia/reperfusion, or oxidative stress induce the opening of the mitochondrial
permeability transition pore (MPTP) on the mitochondrial membrane. This leads to a
release of proteins from inside the mitochondria (cytochrome C, endonuclease G, and
apoptosis-inducing factor) to form apoptosomes containing caspase-9, which activate
caspase-3 to initiate DNA fragmentation and cell death18. This is the most prominent
apoptotic process in cell death. The extrinsic pathway involves the “death receptors” Fas
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and tumor necrosis factor (TNF) receptors, which are upregulated during myocardial
ischemia and HF. When these receptors are bound and activated by their ligands, they form
signalling complexes that recruit caspase-8, leading to activation of caspase-3 for cell
death. It is still questionable today if apoptosis is the most prominent form of cell death in
common types of HF (ischemic and dilated cardiomyopathy)19.
Cell death in the form of necrosis occurs when there is trauma or damage to the
cardiomyocytes usually by nutrient shortage, or exposure to harsh environments. In early
stages of necrosis, there is organelle/ cytoplasmic swelling and disrupted cellular functions,
eventually leading to rupture of the cell membrane that releases all cellular contents. This
is not a form of programmed cell death as there is no formation of apoptotic cell bodies20.
Necrosis is commonly associated with myocardial infarction, cardiac ischemia/ reperfusion
and HF with a prolonged period of restricted blood flow resulting in a lack of nutrients for
cellular function21.
Autophagy is the process of intracellular organelle and protein enzymatic degradation that
alters nutrient homeostasis in the cell. Cellular stress triggers degradation of excess
organelles and proteins, which would otherwise lead to pressure overload-induced
hypertrophy, oxidative stress, and myocardial ischemia which can all lead to HF20. In
autophagy, deficiency in the lysosomal-activated membrane protein-2 (LAMP-2) causes
increased autophagosomes in cardiomyocytes. In a model of Danon’s disease (a lysosomal
glycogen storage disease) heart dysfunction and HF are common characteristics where
defects in autophagy caused by LAMP-2 deficiency in the myocardium causes cardiac
dysfunction22. The entire process of autophagy is not fully understood although there are
known activators, including phosphatidylinositol-3 kinase and Beclin-1, and suppression
of these activators causes disruption in the maintenance of metabolic requirements in the
cell. Treatments for HF have been developed to target the AMPK/ Akt/ mTOR pathway
where autophagic defects are restored and cardiac function is improved23–25.
Cardiac energy metabolism in the healthy heart encompasses primarily fatty-acid (FA)
oxidation used by mitochondria while glucose metabolism is responsible for minimal
energy production. FAs oxidation accounts for 60-90% of adenosine triphosphate (ATP)
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production in the healthy heart. FAs in the cytoplasm are converted to FA-acyl-coenzyme
A (FA-acyl-CoA) by fatty acyl-CoA synthase which gets esterified before entering the
mitochondria. Once in the mitochondria, it gets converted back to FA-acyl-CoA for betaoxidation. This process produces ATP but consumes oxygen in the process26. To produce
ATP, glucose enters the cell through glucose transporters on cell membranes and proceeds
through glycolysis, which uses less oxygen compared to FA oxidation. The products from
the glycolysis pathway are transferred to the mitochondria to continue with energy
production27. This ability to utilize energy substrates based on availability allows the heart
some metabolic flexibility through complex regulatory mechanisms.
HF is accompanied by derangements in all aspects of energy metabolism including
substrate uptake, utilization, and oxidative phosphorylation which ultimately decreases the
rate of ATP synthesis, resulting in LV dysfunction28. Substrate uptake and utilization
switches from primarily FA to glucose utilization, likely because FA oxidation uses 1012% more oxygen when compared to glucose metabolism to generate the same amount of
ATP. Therefore, FA usage in HF can waste oxygen and increase damage to the heart26. In
contrast, in advanced HF and in ischemia/reperfusion, there is decreased FA and glucose
metabolism which may be explained by decreased activity of mitochondrial enzymes for
FA oxidation and mitochondrial dysfunction27. It is not fully known whether the altered
substrate metabolism in HF is a cause or a consequence of LV dysfunction. It is suggested
that the accumulation of FA in the cytosol can lead to toxic lipid species that may contribute
to HF, meanwhile, the switch to glucose metabolism is an adaptive process to minimize
damage in the failing heart28. More research needs to be conducted to evaluate the causeand-effect relationship with energy metabolism and HF.
In summary, there are many complex and highly regulated signaling processes that function
in cardiac homeostasis. In the progression of HF, these processes become dysregulated and
can worsen the already present damage to the heart. Overall cardiac output is maintained
through regulation of both sympathetic and neurohormonal activation along with LV
remodeling and many biochemical signalling pathways (contractility/ calcium
homeostasis, cell death, and energy metabolism). Prolonged derangements in these
pathways lead to further damage and can be used as targets for HF management.
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1.1.2

Management of Heart Failure

Management of HF remains difficult as disease progression and response to therapy are
highly variable between patients, and diagnosis is usually made in the later stages of the
disease. HF with reduced ejection fraction (HFrEF) has been the largely studied and
historically is the most the predominant form of HF. Thus, the management and treatment
of HFrEF has improved substantially. HF with preserved ejection fraction (HFpEF) has
only recently been studied extensively for its pathophysiology and treatment stradegies29.
Three classes of drugs have been identified to aid in treatment: angiotensin converting
enzyme (ACE) inhibitors/angiotensin II receptor blockers (ARB), aldosterone antagonists/
diuretics, and beta-adrenergic blockers3. ACE inhibitors/ARBs prevent the conversion of
angiotensin I to angiotensin II and block the actions of angiotensin II to inhibit hypertrophy
in vascular tissues and narrowing of coronary vessels leading to decreases in cardiac
pressure and workload30. ACE inhibitors/ ARB drugs have been shown to improve
mortality and reduce hospitalizations, and thus are the first-line drugs for most patients
with HF.
Aldosterone antagonists, or diuretics, function to inhibit the production of aldosterone,
ultimately preventing aldosterone-induced sodium and water retention and potassium
secretion. Subsequent reduction in fluid retention improves kidney function, reduces
swelling and bloating, and lowers blood pressure to enhance cardiac function31.
Beta-adrenergic blockers are usually used in combination with ACE inhibitors/ARB drugs.
Beta-adrenergic blockers inhibit the binding of epinephrine to the adrenergic receptors in
the heart to reduce heart rate and blood pressure, and relaxes blood vessels to improve
blood flow. Beta-blockers have proven to reduce mortality and help regulate heart rate by
reduction of sympathetic nervous system activity32. ACE inhibitors/ARB and beta blockers
are often used together as a first line of HF therapy for all individuals, and aldosterone
antagonists/diuretics are used in patients with symptoms of congestion32.
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Some novel and emerging therapies for HFrEF include angiotensin receptor-neprilysin
inhibitors (ARNI) and sodium‐glucose cotransporter‐2 (SGLT2) inhibitors. ARNI are a
new class of medications that incorporate blocking of the angiotensin receptors and it
inhibits the enzyme neprilysin which degrades protective vasoactive peptides (natriuretic
peptides and bradykinin). Entresto is an example of this type of medication which has
shown to decrease cardiovascular death and first hospitalization compared to conventional
drugs (eg. Enalapril)33. SGLT2 inhibitors are approved for the management of type 2
diabetes mellitus and recently have been explored for their use in prevention and treatment
of diabetic cardiomyopathy. In diabetic patients with atherosclerosis, prevention with
SGLT2 inhibitors have shown to reduce future cases of HF where these results were
independent of glucose levels and renal function34. Treatment with SGLT2 inhibitors in
later stages of HF remain to be fully elucidated. In contrast to these evaluated drug therapies
for HFrEF, there is a lack of evidence-based medications for HFpEF and treatment is reliant
on the management of comorbidities and symptoms.
If drug therapy is not sufficient for maintaining optimal cardiac function, implantable
cardiac devices or extensive surgery may be required. Patients with coronary artery disease
(the most common form of HD) that have significant reduction in cardiac output and
reduced left ventricular ejection fraction (LVEF) <35%, require cardiac revascularization
surgery using a coronary artery bypass graft35. This procedure is used to redirect blood
flow past blocked arteries and restore normal blood flow to cardiac tissue. Coronary artery
bypass graft used in combination with drug therapies lowers mortality rate 2 years after
surgery and decreases subsequent myocardial infarctions36. Another treatment used is the
implantable left ventricular assist device (LVAD) that improves overall heart function by
assisting the LV to contract properly and pump sufficient blood across the body. These
devices help reduce LV mass and size, reduce levels of renin, angiotensin II, and
aldosterone, and improve contractility and subsequently calcium regulation3. LVAD
implementation has proven to decrease mortality rates and some individuals may even be
weaned off the device as the heart strengthens; others may be on the device permanently37.
In severe cases of end-stage HF, when there are no other options for cardiac improvement,
cardiac transplantation may be needed. The limitation with this procedure is the short
supply of donor hearts. Upon transplantation, there is a significant improvement in
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survival, exercise capacity, and quality of life4. In contrast to patients with HFrEF, patients
with HFpEF have no current approved device-based therapy for treatment29.
Novel treatments are emerging that offer new approaches for patients with HF. One
promising new technology is gene therapy. This therapy uses viral vectors to target a
specific gene that is either over or under expressed. Gene phenotyping can be used to
determine any abnormalities in the presence or regulation of genes in the heart29. Once
phenotyping has been established and a target of interest has been identified, the use of
targeted gene therapy could be used38. There are many viral delivery methods being
evaluated including coronary artery infusion, direct myocardial injection, and injection into
pericardial space. A variety of targets have been identified as possible opportunities for
treatment including beta-adrenergic receptors, calcium regulation proteins, and G-protein
receptor kinases3. Additionally, stem cell therapy has been examined for its role in cardiac
regeneration. The past decades researchers have examined various cell types and
mesenchymal stem cells have shown the most promise39. These cells have been tested in
animal models and clinical trials to revitalize cardiac stem cells or revascularize the arteries
and veins in the heart40. Although the idea of this technology is promising, there are major
issues including inefficient cell delivery to the target site and low cell retention with
minimal effectiveness of the stem cells that do implant in the target area41. There are
ongoing developments to improve the regenerative capacity of the cells and enhancement
of delivery techniques for the target area. Although the idea of gene therapy and cardiac
stem-cell regeneration are exciting novel ideas, the technology remains to be optimized to
allow for accurate and targeted treatment of HF.

1.2 Diagnosis of Heart Disease and Heart Failure
1.2.1

Clinical Diagnosis of HF

Diagnosis of HF is a very complex process including clinical examination, imaging
technology, and the measurement of an array of cardiac biomarkers. Clinical diagnosis of
heart failure is commonly initiated with the physical examination which is limited to non-
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specific symptoms (age, sex, obesity, smoking and drinking habits, along with other
comorbidities), laboratory tests with varying sensitivities, and characteristics not
necessarily associated directly with the heart.
The two most common diagnostic methods to evaluate the stage of HF are the New York
Heart Association (NYHA)42 classification and the American College of Cardiology
Foundation and American Heart Association (ACC/AHA)43.
The NYHA classification is based on clinical severity and prognosis with an emphasis on
exercise capacity and clinical symptoms. The classification ranges from functional class I
(not severe) to IV (most severe). Functional class I includes no limitations to physical
activity and no overt symptoms of HF. Functional class II has some limitations of physical
activity where ordinary physical activity leads to HF symptoms. Functional class III occurs
when less than ordinary activity causes symptoms of HF. Functional class IV refers to
patients who are unable to perform physical activity without severe HF symptoms and
possible HF symptoms while at rest43. One study evaluated the accuracy of this
classification method where it correlated with mid- to long-term mortality rates in patients
and thus, is a good method for HF classification42.
The ACC/AHA classification method emphasizes the development and progression of HF
and can provide complementary information on diagnosis when combined with NYHA
classification. The ACC/AHA classification system recognizes both risk factors and
cardiac structure abnormalities associated with HF. Stages range from A, at risk for HF but
no structural abnormalities or symptoms of HF; B, structural defects in the heart but no HF
symptoms; C, structural HF and prior or current symptoms; D, refractory HF that requires
special interventions. Once a patient progresses to the next stage it is not possible to regress
and increasing stages is associated with reduced 5-year survival43. In 2017, an update to
the ACC/AHA guidelines was published to aid in clinical diagnosis along with treatment,
medications, and therapies based on a combination of stage and clinical symptoms
present44. These new guidelines are aimed at diagnosing structural changes at earlier stages
(B or C) and targeting treatment to prevent progression of HF and ultimately reduce the
morbidity and mortality linked to HF. Although these guidelines have been developed to
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aid in early diagnosis, it remains based on patients to identify HF symptoms and a physician
to detect based on patient history. In addition, these diagnoses rely on structural and
physical changes of the heart which usually occur in the later stages of HF, while early
stages of HF progression remain difficult to detect.

1.2.2

Echocardiography in Clinical HD

Echocardiography (Echo) is a commonly used diagnostic tool for cardiac imaging. Echo
uses a transducer to send sound waves and generate moving images showing the structure
and movement of the heart43. It is widely used for its availability to quickly measure the
left ventricular size and dysfunction as well as to identify valvular abnormalities noninvasively. Echo is a low-cost technique that is widely available for clinicians to evaluate
gross changes in LVEF, cardiac hypertrophy, and valve dysfunction of any patient that
presents in the clinic with HD signs and symptoms. There are many forms of
echocardiography used in clinic, each with their own advantages and optimal target
quantifications (Table 1.1).
Transthoracic Echo is the most common form of Echo used in the clinic for its wide
availability and basic cardiac evaluation. Transthoracic Echo uses an ultrasound system
transducer to evaluate cardiac structure and function. It can evaluate gross structural
abnormalities, valvular disease and any abnormal blood flow through the heart46. Doppler
Echo is a specialized technique (still using a transducer) that can acquire myocardial
velocities and can obtain quantitative information about myocardial motion during the
cardiac cycle. Colour M-mode Doppler can also provide spatiotemporal distribution of the
velocities across a vertical line for more accurate assessment47. Doppler Echo has shown
promise in the evaluation of blood flow and cardiac structure in valvular stenosis, valvular
regurgitation, blood flow, intracardiac pressures, and intracardiac shunts48. This technique
is limited due to underestimating the severity of aortic stenosis if the sound beam is not
positioned precisely and may not provide accurate diagnosis post-surgery if velocities are
abnormally high.
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Stress Echo is 2D Echo with stress-induced changes in blood flow to determine severity of
coronary artery disease such as in ischemic heart disease and any abnormalities in cardiac
blood flow49. Stress Echo uses a stressing agent, either through physical exertion/ exercise
or a chemical agent (such as dobutamine) to show the function of the heart under these
conditions. Echo measurements will be gathered prior to the stress agent and then once
again after full stress to the heart is induced. This will allow for clinicians to evaluate the
change in blood flow and potential coronary artery disease or ischemic regions in the
heart50. There are some limitations with this technique that have not yet been fully
evaluated including tissue characterization of the myocardial structure, myocardial
perfusion with contrast, and regional wall motion quantification with new technologies.
New advancements have focused on targeting these limitations to match the data acquired
with PET perfusion imaging50.
One emerging technique that is changing the use of Echo is 3D Echo which measures the
geometry and size/ volume of the LV along with valve assessment and functional
parameters of the heart. Researchers have evaluated various reconstruction techniques
where sequential 2D sliced through the heart have been reconstructed into 3D images to
assess better measurements of the heart. Real-time 3D Echo has also been developed to
incorporate these reconstructions in real time to more efficiently generate quantitative
data50. 3D Echo is proposed to generate LV wall thickness and volume measurements
comparable to that of cardiac magnetic resonance imaging (cMRI)51. New advancements
and improvements with clinical studies will help to broaden the applicability of this
modality in a variety of cardiovascular diseases. The main limitations with this technique
are the user dependence, the extra expense of the probe and software, and the lack of
availability in clinical settings.
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Table 1.1 Types of Echocardiography Used in Clinic.

MEASUREMENTS

TRANSTHORACIC

Most common form of echo; measures basic cardiac

ECHOCARDIOGRAPHY

structure and function

DOPPLER

Used to measure blood flow in the chambers and valves;

ECHOCARDIOGRAPHY

Can detect abnormal blood flow indicating problems with
valves or walls

STRESS

Measures stress induced changes to blood flow and

ECHOCARDIOGRAPHY

determine severity of CAD; stress agent can be physical
exertion or chemically induced

3D ECHOCARDIOGRAPHY

Helpful for identifying problems with heart valves,
replacement valves, and the LV; new additional ways to
use 3-D echo are being developed

Therefore, echocardiography provides a wide variety of initial measurements for LV size
and overall blood flow. After a patient is initially screened with Echo, they may go on to
be scanned with cardiac magnetic resonance imaging (cMRI) or cardiac computed
tomography (CT) for accurate diagnosis of HF.
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1.2.3

Cardiac CT and MRI

Computed tomography (CT) is a technique that allows high-resolution detection of
structure and anatomy, thereby enhancing the diagnosis of gross structural changes. CT
involves the use of narrow x-ray beams aimed at the target which are quickly rotated to
create a combination of cross-sectional planes to generate a 3D image of the specific target
of interest52. CT provides excellent spatial resolution (0.5-0.625 mm) to evaluate 3D
morphological changes in the heart including dimensions and overall heart function.
Temporal resolution of CT is limited and poses a challenge with the beating heart53. To
acquire optimal images using CT, images should be captured between heart beats when
movement is lowest. A contrast agent, iodine, can be used to help visualize the difference
between adipose and soft muscle tissue as non-contrast CT cannot distinguish between
these tissue types. Contrast CT can evaluate the extent of cardiac lesions, myocardial
perfusion, and tissue viability54. One important consideration with CT imaging is its use
with implant devices. CT can be used to image the heart even with implanted devices
present although devices near the heart may show an irregular artifact. Although CT
imaging uses small doses of radiation, there is no evidence that the radiation disrupts the
implanted devices55.
CT perfusion (CTP) has been shown to improve the specificity and overall accuracy of
cardiac CT to detect cardiac blood flow. In CTP, the iodine contrast agent is injected
followed by rest and stress scans to evaluate the artery plaque/lesion presence and blood
flow56. Scans are performed immediately after contrast injection as either static single
image scans, or a dynamic set of sequential scans to better visualize perfusion over time57.
Rest scans are performed with low resting heart rates, <65 beats per minute, where lesions
can be detected in the heart. Stress scans are initiated with vasodilator stress agents
including adenosine, dipyridamole, or regadenoson followed immediately by a CT scan to
enhance defects in perfusion58. Rest and stress scans are compared for changes in perfusion
which can provide specific information on cardiac defects: 1) hypoperfusion with the same
intensity in both stress and rest images indicate regional necrosis; 2) hypoperfusion in stress
but normal in rest indicate ischemia; 3) hypoperfusion in stress which decreases in rest
show peri-necrosis ischemia; 4) normal perfusion in both rest and stress58. Myocardial
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blood flow using CTP has been evaluated in porcine hearts before and after a myocardial
infarction where decreased perfusion was present specifically in the infarcted region and
not in the remote myocardium59. CTP imaging is advantageous for cases of suspected
coronary artery disease where both blood flow and cardiac anatomy can be examined in
one set of images60. Further research is needed to evaluate the potential clinical advantages
in patient care, treatment costs, and patient outcomes when compared to the current gold
standard cardiac PET perfusion imaging.
Cardiac magnetic resonance imaging (cMRI) is an emerging technique that allows for
highly reproducible assessment of cardiac dimensions, function, flow, and perfusion. cMRI
can recover early structural changes in the heart that comprise many different
cardiomyopathies61. MRI uses strong magnetic fields to orient protons in the body, then a
radiofrequency is applied to detect the location of these protons and can differentiate based
on the type of tissue present. MRI provides spatial resolution of 1-2 mm, with temporal
resolution of 20-50 milliseconds, and excellent soft-tissue contrast53. Due to enhanced
resolution of cMRI, sequences have been developed to determine cardiac function, edema,
iron deposition, and perfusion62. In addition, a gadolinium contrast agent can be used to
visualize the morphological changes in the heart and determine cardiomyocyte viability
with fibrosis deposition, typically after cardiac ischemia. However, this contrast agent is
only able to discern concentrated fibrotic areas and not diffuse regions of fibrosis which is
common in some ischemic cardiomyopathies63. Therefore, T1 mapping (anatomical
images) can be gathered before and after contrast images to accurately determine total
fibrotic deposition in the heart. One of the main limitations with cMRI is that patients with
magnetic devices or implants near the heart cannot be imaged. Magnetic devices are
attracted to the high-powered magnets resulting in damage to the patient and the machine.
Additionally, implants near the heart can cause image artifacts and skew images. cMRI
provides comprehensive evaluation of HD and is the current gold standard in evaluating
ventricular volumes, wall motion and dimensions, and systolic and diastolic function. With
the many techniques that encompass cMRI, it detects physical cardiac changes in many
forms of HD including: myocardial infarction, dilated and hypertrophic cardiomyopathy,
myocarditis, sarcoidosis, and pulmonary hypertension64. Overall, cMRI is a robust tool to
comprehensively evaluate HD through cardiac anatomy, function, and wall motion.
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Hyperpolarized MRI is an emerging technique using
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C to track changes in cardiac

metabolism. Hyperpolarized MRI uses a combination of low temperatures and high
magnetic fields to allow for high polarization (nearly all electrons are aligned in the same
direction).
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C uses this technique to enhance MRI signals65. Natural

extremely low in the body (~1.1%) and therefore the use of
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13

C abundance is

C-tracers have been

developed to temporarily enhance the abundance and cause an increase in signal where
these tracers are located in the tissue65. The most commonly used tracer is
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C-pyruvate

where it can measure cellular metabolism through many metabolic processes from energy
production to the formation of lactate, alanine and CO266. A shift in myocardial energy
metabolism from primarily fatty acid metabolism to more glucose metabolism is expected
to contribute to the development of HF67.
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C-pyruvate can be measured through the

activity of the pyruvate dehydrogenase complex where increases in its activity show a
preference for glucose metabolism. 13C-pyruvate flux through this complex is reduced in
the hyperthyroid heart, diabetic heart, and dilated cardiomyopathy while the flux increased
in hypertrophic cardiomyopathy65. This technology in the heart has only recently been
explored and the clinical translatability in heart disease requires further evaluation.
When deciding which imaging tool to use between cMRI or CT, it is important to evaluate
each case individually to determine the best one for the patient. cMRI is the gold-standard
cardiac imaging technique, however not all patients can safely be imaged (i.e. any patient
with metal implants) along with longer scan times as multiple sequences may be used. In
evaluation of HD, it is imperative to use accurate and reproducible imaging methods with
high temporal, spatial, and contrast resolution68. cMRI fulfills all these components in the
evaluation of LV function. Recently, new techniques in CT have been developed that
approach the function of cMRI by enhancing the temporal resolution. One study evaluated
a new dual-source CT technique where temporal resolution (83 milliseconds) results in
minimal differences when compared

to cMRI69. Another study used dual-energy

equilibrium contrast-enhanced CT which uses two different x-ray potentials
simultaneously to detect both blood and myocardium together in addition to iodine contrast
agents measuring fibrosis70. The emergence of new cardiac CT imaging techniques can
allow for more options when evaluating patients who need diagnostic imaging. Even with
many CT techniques being developed to target each aspect of myocardial imaging, cMRI
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still remains the gold standard for HD diagnosis. It is important to note that these modalities
are used primarily for diagnosis of gross structural changes once HD is already established,
and not for the prediction of the onset of HD, prior to overt symptoms. It is imperative to
discern changes to the myocardium to be able to facilitate targeted interventions to prevent
the progression to HF. One clinical molecular imaging modality that can be used to
elucidate the biochemical changes early in HD pathogenesis is positron emission
tomography (PET).

1.2.4

Cardiac PET Imaging

Positron Emission Tomography (PET) is a powerful imaging technique that detects
molecular and biochemical changes in the body. PET encompasses quantitative noninvasive in vivo imaging using positron-emitting radioisotopes (such as 11C, 13N, 15O, 18F,
68

Ga,

82

Rb) incorporated into biological compounds/ molecules targeted to a specific

biological process. Positrons are positively-charged electrons that travel short distances
and interact with an electron, causing an annihilation producing two 511 keV gamma rays
moving 180° from each other. PET ring detector arrays can detect these gamma rays and
determine the original location of the positron which results in sequential high-quality
corrected images71. PET systems have good temporal resolution and spatial resolution of
4-7 mm which is decreased slightly by movement during image acquisition. Using tracer
kinetic modelling with motion and respiratory correction results in high-precision
quantitative imaging of targeted biological processes72. The main limitation of this
technology lies in the limited availability of both PET scanners and a cyclotron facility
used to generate the radionuclide compounds for tracers. PET compounds can be useful
with drug development, disease diagnosis and monitoring of treatment response based on
a specific target. Sensitivity with PET imaging is exceptional as low concentrations of
radionucleotide tracers (10-11 – 10-12 M) are needed to generate precise images73. Many
tracers have been developed to target overall perfusion and known biological pathways of
metabolic processes including fatty acid transport, oxygen consumption, and glucose.
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Single photon emission tomography (SPECT) imaging uses radiopharmaceuticals injected
into the body where gamma-rays are emitted and detected by collimated radiation
detectors. The most common radiopharmaceutical used with SPECT is 99technetium (99Tc)
99

as it has a relatively short half-life of 6 hours.

Tc-sestamibi (99Tc-MIBI) is a common

perfusion tracer that enters cardiomyocytes through passive diffusion and accumulates in
the mitochondria. Increased uptake of 99Tc-MIBI demonstrate areas of adequate blood flow
while decreased uptake show a loss in perfusion 74. Evaluation of

99

Tc-MIBI in patients

with confirmed coronary artery disease showed a diagnostic sensitivity of 90% to evaluate
myocardial blood flow and tissue viability75.

99

Tc-MIBI has shown a demonstrated

prognostic value of future acute MI or cardiac death with abnormalities in perfusion
imaging76,77. Therefore,

99

Tc-MIBI may be a useful diagnostic and predictive tool for

patients with suspected blood flow abnormalities.
PET imaging shows promise over other radionucleotide imaging techniques, such as single
photon emission computer tomography (SPECT), with its superior sensitivity compared to
echocardiography/ cMRI, standardized correction of attenuation, and quantitative
measurements of tracer uptake78. Therefore, PET has begun to be recognized as a useful
tool to evaluate biochemical changes throughout the body, including in the heart. In clinical
imaging of HD, PET is used primarily to evaluate cardiac perfusion/ tissue viability
(ischemia), inflammation, and neuronal activity71. Using PET to identify changes in these
processes remains an important diagnostic and prognostic tool for evaluation of many
forms of HD and HF in patients. Myocardial perfusion tracers (13N-ammonia, 15O-water,
82

Rubidium) detect reduced blood flow within the heart and vasculature to determine

subclinical coronary stenosis and the severity of both coronary artery disease and ischemia.
Inflammation is common in many forms of HD where PET tracers (18Ffluorodeoxyglucose) can measure significant increases of regional inflammation associated
with diseases such as endocarditis, sarcoidosis, atherosclerosis, and acute tissue injuries
including myocardial ischemia. Neuronal imaging (11C-meta-hydroxyephedrine) assesses
the severity of HF and post-transplant reinnervation along with arrhythmias in the heart79.
Therefore, PET is an exciting in vivo molecular imaging technique that allows for diagnosis
of biochemical processes altered in the severity and type of HD and HF.
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1.2.5

Cardiac Perfusion PET Tracers

Myocardial perfusion is an important assessment of coronary artery disease and cardiac
ischemia where there is a marked regional reduction in blood flow. PET imaging has
emerged as the gold standard for non-invasive myocardial perfusion measurement. The
commonly used PET tracers are

13

N-NH3,

15

OH2, and

82

Rb, which all have their own

strengths and weaknesses (outlined in table 1.2)80. All tracers have relatively short halflives, ranging from 75 seconds to 10 minutes. Although all of these tracers detect perfusion,
their mechanisms of action differ.

13

N-NH3 passively enters the cardiomyocytes and is

incorporated into glutamine through the glutamate synthesis pathway, thereby getting
metabolically trapped in the cell. When cardiomyocytes are damaged and the cellular
membranes are weakened, 13N-NH3 cannot enter the cells to access myocardial blood flow.
Similarly,

82

Rb is a potassium analog and enters cardiomyocytes through the

sodium/potassium ATP transporter in the cell membrane where it accumulates and gets
retained. In cells that are dead or damaged, 82Rb is not taken up and does not accumulate
therefore no signal is generated. In contrast, 15OH2 is a metabolically inert tracer that freely
diffuses across the cell membrane and creates an equilibrium between blood and tissue
without significant accumulation in the myocardium. This tends to result in lower count
density and overall lower quality images for quantification with this tracer80,81.

Table 1.2 Common Cardiac Perfusion Tracer for PET Imaging80.
13N-NH
3

15OH
2

82RB

GENERATION

Cyclotron

Cyclotron

Generator

HALF-LIFE

~10 min

~125 sec

~75 sec

MECHANISM

Trapped in cell

Freely diffuse into cell

Trapped in cell
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All these tracers have been evaluated in the forms of HD that are characterized by
decreased cardiac perfusion in the myocardium and vasculature. In particular, decreased
perfusion reported by 13N-NH3 PET is a strong predictor of adverse cardiac outcomes in
HD82. Lee et al. was able to show that quantitative 13N-NH3 imaging of myocardial blood
flow improved detection of coronary artery stenosis and suggested that this in vivo imaging
method be used to accurately determine disease severity prior to invasive coronary
angiography surgery83.

13

N-NH3 has also been used to detect tissue viability in cardiac

ischemia with rest/ stress induced imaging to discern ischemic myocardium from viable
tissue84. 82Rb has similarly been used in studies evaluating cardiac perfusion where reduced
blood flow was an indicator of short-term cardiac events85,86. Zampella et al. was able to
show that 82Rb can detect the extent of calcification and blockage in coronary artery disease
patients86.

15

OH2 has also assessed the extent of coronary artery disease87,88 and detect

blood flow in ischemic patients89. Taken together, these tracers have been shown to noninvasively correctly identify and diagnose reduced regional blood flow and disease severity
in various forms of HD.

1.2.6

Inflammation in the Heart with 18F-FDG PET

Inflammation is commonly associated with HD and HF, and excessive proinflammatory
processes may be a predictor of future adverse cardiac events. Inflammation is a common
process in the body used to remove dead and damaged cells followed by specific repair
mechanisms. Initially after cardiac injury, or reduced cardiac perfusion, an immune
response is activated where inflammatory cells including neutrophils, monocytes, and
macrophages target the area of interest. This process removes the dead and damaged cells
from the area. The immune reaction induces pro-inflammatory cytokine activation
including tumor necrosis factor-alpha (TNF-α), interlukin-6 (IL-6), and interlukin-1 (IL1)90. After the pro-inflammatory phase subsides, the anti-inflammatory phase initiates
fibroblasts and matrix metalloproteins to deposit fibrotic (scar) tissue in place of the dead/
damaged cells. However, fibrosis deposition may also occur in the presence of chronically
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active pro-inflammatory markers where both the pro- and anti-inflammatory phases are
active simultaneously91. When these pro-inflammatory markers are significantly elevated
for prolonged periods of time, they can be a sign of chronic inflammation and can
contribute to the progression of HF92. A commonly used tracer for inflammation and tissue
viability is 18F-fluorodeoxyglucose (18F-FDG). 18F-FDG is a glucose analog that is taken
up by viable cardiomyocytes through glucose transporters and promptly gets trapped in the
cell as

18

F-glucose-6-phosphate via hexokinase. Proinflammatory macrophages have a

significant overexpression of glucose transporters which results in increased
uptake93. One important thing to note when using

18

18

F-FDG

F-FDG in studies of cardiac

inflammation is that normal myocardial glucose uptake should be suppressed to minimize
normal tissue uptake. This is usually done with an Intralipid™ infusion in animal studies.
Human subjects are required to fast or consume a high fat meal prior to imaging to reduce
the extent of myocardial glucose uptake and increase the lipid metabolism in the normal
myocardium94. One example of imaging cardiac inflammation is the case of cardiac
sarcoidosis, an inflammatory disease where granulomas (white blood cells) form in the
heart muscle and disrupt normal function. 18F-FDG has been shown to accurately detect it
in its early stages where perfusion defects may not yet be present95. In patients with
suspected unstable angina,

18

F-FDG was able to detect angina more sensitively than

myocardial perfusion imaging (85.7% vs 52.4% respectively). Therefore, increases in 18FFDG in angina may indicate angina as an inflammatory condition where 18F-FDG clearly
demonstrates the accuracy and sensitivity of non-invasive PET imaging96. 18F-FDG PET
can also assess the severity of inflammation associated with coronary artery disease (CAD)
and atherosclerosis97,98. Upon plaque build-up from low-density lipoprotein in the arteries,
monocytes, leukocytes, and T-cells are recruited to the plaque area, where monocytes
mature into macrophages, the target for

18

F-FDG99. Therefore,

18

F-FDG is a specific

clinically relevant tracer to examine the extent of inflammation associated with HD.
18

F-FDG is the current clinical gold standard for determination of viable tissue in patients

after myocardial infarction and in cardiac dysfunction with accurate assessment of scar
presence75,100. In addition, 18F-FDG can be used to measure the efficacy of treatments by
comparing scans before and after treatment. One study used 18F-FDG to evaluate alcohol
septal ablation treatment in patients with hypertropic obstructive cardiomyopathy where
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clear reduction of tracer uptake, and associated inflammation, was seen after treatment101.
Ultimately 18F-FDG is an important non-invasive imaging tool to detect inflammatory heart
disease and assess disease severity.

1.2.7

Neuronal Cardiac PET Imaging

Cardiac neuronal imaging is an important tool to evaluate arrythmias associated with HF.
In congestive heart failure there are abnormalities in the autonomic nervous system with
altered sympathetic traffic (blood pressure) to peripheral vascular areas; however, how this
process functions remains largely unknown.

11

C-meta-hydroxyephedrine (11C-HED) is a

norepinephrine (NE) analogue that targets the NE transporter on nerve endings in the
sympathetic nervous system, therefore determining NE transporter activity and density102.
In HF and in arrythmias there are NE transporter abnormalities that can be revealed by 11CHED PET. Patients with congestive HF had reduced retention of 11C-HED globally in the
heart which corresponded to blunted vascular sympathetic responses103. Diastolic
dysfunction was shown to be associated with impaired sympathetic innervation in the heart
using 11C-HED in patients with HF and preserved ejection fraction104. 11C-HED imaging
may also be used as an alternative for myocardial blood flow imaging in ischemic
cardiomyopathy105. Additionally, cardiac transplant patients can be imaged with 11C-HED
to determine the extent of sympathetic reinnervation of the newly-implanted heart106. One
study evaluated sympathetic activity in patients at different time points after transplant
surgery, and healthy controls. In patients with recent surgery there was a 70% reduction in
11

C-HED uptake, which improved to a 59% reduction after 2 years. The authors found that

after cardiac transplantation, the sympathetic activity in the heart improved from 30% to
41% activity107. Regional and localized 11C-HED retention in the heart can show disease
severity and dysfunction in arrhythmias108. Overall, 11C-HED can evaluate impairments in
cardiac conductivity that are associated with HF and cardiac arrhythmias.
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1.2.8

Emerging Cardiac PET Tracers

In addition to these known tracers for cardiac PET imaging, many new tracers are being
developed to specifically target aspects of cardiac pathology in HD. One new perfusion
tracer that is not yet clinically available is 18F-flurpiridaz, a pyridazinone derivative, which
gets metabolically trapped in the cardiomyocytes through the mitochondrial membrane
complex-1 and reports cardiac blood flow.

18

F-flurpiridaz was able to accurately detect

reduction in myocardial blood flow in patients with coronary artery disease (sensitivity
71.9%).

18

F-flurpiridaz was superior to SPECT perfusion imaging in image quality,

diagnostic certainty, and radiation exposure in human clinical trials109,110. Another tracer,
11

C-acetate, can indirectly estimate myocardial blood flow and oxygen metabolism where

11

C-acetate accumulation in cardiomyocytes refers to low oxygen consumption and blood

flow111. In a rat model of congestive heart failure,

11

C-acetate demonstrated decreased

myocardial oxygen consumption with significant correlation to myocardial blood flow,
therefore, 11C-acetate can be used as an estimate of cardiac perfusion112. Another target for
perfusion imaging is the mitochondrial membrane potential which is higher in healthy
cardiomyocytes and loss of this signal is associated with cell death. Ammonium and
phosphonium cations accumulate in mitochondria and these compounds are targets for
potential 18F imaging agents. Many

18

F derivatives of tetraphenylphosphonium salt have

been developed and tested for detection of cardiac perfusion in animal models78. In cardiac
amyloidosis, many tracers have been developed to target amyloid depositions including
11

C-Pittsburgh B (PIB),

18

Florbetapir, and

and severity113,114. In addition,

18

18

Flutemetamol in detecting disease presence

F-sodium fluoride (18F-NaF) detects calcification and

plaque formation in coronary artery disease and can determine plaque vulnerability along
with future cardiac events115. An alternative to 18F-FDG for inflammation imaging is 68GDOTATATE which targets the somatostatin receptor type 2 that is overexpressed in
inflammatory macrophages. 68G-DOTATATE can accurately detect inflammation after a
myocardial infarction with minimal background uptake116 and can determine
atherosclerotic disease severity by assessing high versus low risk lesions in the
vasculature117.

68

G-pentixafor, targeted to the chemokine receptor CXCR4, can also be

used to image inflammation associated with atherosclerosis118. With cardiac neuronal
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imaging, new

18

F-labelled tracers are being developed to target the sympathetic nervous

system in the cardiomyocytes. These tracers target the norepinephrine transporter uptake1 and accumulate in vesicles within the cells. These tracers have similar function to 11CHED although the longer half-life of 18F aids in the versatility in imaging119. In addition to
the tracers described above, there are many other new tracers being developed to target
specific molecular pathways of HD. These tracers have the potential to be used in an array
of imaging profiles to help with diagnosis and targeted treatments of HD.

1.2.9

Simultaneous PET/CT and PET/MR Imaging

To better diagnose and predict adverse cardiac events, simultaneous imaging with PET and
CT or MRI can be used to determine both molecular and functional abnormalities in HD.
The main limitations with PET imaging alone are the low spatial resolution and lack of
anatomical reference. Initially, sequential imaging sessions (PET followed by CT or MRI)
were used with co-registration software to integrate the two sets of images. This posed a
challenge due to the difference in scanner profiles, patient positioning and organ movement
between scans120. To overcome these challenges, hybrid systems for both PET/CT and
PET/MRI were developed to optimize scan overlay, to lower costs due to multiple scans,
and to lower the burden on the patient. Simultaneous imaging poses significant advantages
over sequential imaging as the scan duration is minimized and the patients do not have to
move, allowing for improved co-registration of the PET images to anatomical imaging of
MRI or CT. With PET/CT, an established x-ray (CT) based attenuation correction is used
to quantify PET data. PET/MRI is more challenging due to the limited reliability of
developed attenuation corrections for PET121. The advantages of using PET/CT are the
high spatial resolution, shorter study times, can be used with patients with metal implants,
and availability. Its disadvantages include extra radiation exposure, possible renal toxicity
with large volume of iodine contrast agent (contrast induced nephropathy), limited use in
patients with arrhythmias, and functional data acquired retrospectively. In contrast,
PET/MRI poses many advantages including temporal resolution, superior soft-tissue
contrast, and evaluation of both cardiac anatomy and function. The disadvantages include

26

inability to scan patients with certain implanted devices, possible renal failure with
gadolinium contrast agent (nephrogenic systemic fibrosis), cost, and difficulties with scan
duration with patients who have claustrophobia122. Overall, PET/MRI can provide more
detailed anatomical information with less radiation over PET/CT, but availability is limited
in the clinic and patient comfort level should be evaluated.
When performing simultaneous imaging, one study evaluated information provided by
PET when using either PET/MRI or PET/CT using the same patient cohort for both
modalities. They found the same PET image results regardless of the imaging modality123.
Therefore, when using simultaneous imaging modalities, the use of CT or MRI should be
evaluated based on the choice of diagnostic parameters for the type of HF. In a patient
sarcoidosis study with PET/MRI and PET/CT, overall 18F-FDG PET uptake using tissue to
blood ratio (TBR) was comparable between imaging methods, although MRI data provided
more detailed information in regional fibrotic deposition and edema124. Combined PET and
MRI supplied complimentary information on disease pathology with both LV and RV
abnormalities in cardiac sarcoidosis125. In myocarditis, cardiac MRI is widely used for
diagnosis and 18F-FDG PET can add more information on the inflammation associated with
myocarditis. PET/CT does not provide optimal anatomical information in this disease due
to the lack of soft tissue contrast126. In patients with myocardial infarction and plaque
formation, 18F-NaF PET/MRI and PET/CT were compared to find vulnerable plaques and
scar tissue specifically in the myocardium where PET/MRI enabled structural myocardial
information that CT was not able to provide. Overall PET/CT data was able to determine
scar tissue and plaque presence and these results were comparable with PET/MRI results
although anatomy was easier to identify with MRI127. Taken together, hybrid imaging with
PET and either CT or MRI provides an exceptional amount of information that can improve
diagnostic and prognostic accuracy. The choice of PET/CT versus PET/MRI relies on each
individual patient and equipment availability.
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1.3 Heart Failure and Heart Disease Biomarkers
In addition to clinical examination and imaging, circulating cardiac biomarkers are used to
evaluate heart disease. There is a need to develop methods to accurately predict which
individuals will proceed to HF, particularly in the early stages when risk factors are present
without any measurable deterioration in heart function. Circulating biomarkers can help
augment the information provided by imaging and clinical examination.
Circulating cardiac biomarkers are quantifiable biochemical indicators of alterations in
cardiac function. Ideally, these biomarkers can be used to determine early molecular
changes in the heart that precede the functional changes, as measured by imaging and
clinical examination. Elucidating profiles for biomarkers of HD will help to guide therapies
and help disease management. An ideal cardiac biomarker would be:
•

Quantifiable; able to be accurately and repeatably quantified with quick
turnaround times

•

Specific; a marker native to cardiac tissue

•

Sensitive; shows changes that are scaled to disease severity

•

Stable; changes do not degrade prior to detection

The most common clinical biomarkers used to detect damage in the heart are natriuretic
peptides and cardiac troponins which measure cardiomyocyte stress and cardiac damage,
respectively.

1.3.1

Biomarkers of Cardiomyocyte Stress

Cardiomyocyte stress occurs with extensive pressure and volume overload in the heart.
This causes atrial and ventricular diastolic stretching which stimulates natriuresis and
vasodilation, and LV relaxation128. Natriuretic peptide-B (BNP) is the gold standard
biomarker for the diagnosis and prognosis of HF129, and is produced by primarily
ventricular myocytes under conditions of stress. BNP is initially produced as the precursor
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molecule pre-pro-BNP and cleaved to generate proBNP. The enzyme corin then cleaves
proBNP to the active hormone BNP and the inactive form NT-proBNP (the N-terminal of
pro-BNP)130. Both BNP and NT-proBNP are released into the blood stream from
predominantly the left ventricle upon increased wall stress and neurohormonal activation.
Physiologically, BNP promotes diuresis (sodium and water excretion), vasodilation, and
attenuate the renin-angiotensin-aldosterone secretion (RAAS). In addition to BNP secreted
from the ventricular myocytes, atrial natriuretic peptide (ANP) is produced primarily in the
atrial myocytes and is secreted with hypertension and wall stress. The hormones ANP and
BNP are eliminated from the body via two methods: receptor internalization, or proteolytic
degradation in the excretion organs including kidneys and lungs130. The active form BNP
has been evaluated in healthy individuals where circulating levels are extremely low. In
one study, Tsutamoto et al. measured the circulating BNP levels in 85 patients with chronic
HF where levels increased in proportion to disease severity. The plasma levels were 5-fold
higher in patients who did not survive compared to survivors131. Other studies have also
evaluated the measurement of plasma BNP in HF severity and found BNP to be an
independent predictor of mortality132. BNP is also secreted under conditions of severe
aortic regurgitation, mitral regurgitation, and aortic stenosis133. Another study compared
BNP and NT-ANP to echocardiograms where BNP correctly identified HF with a positive
predictive value of 84% while NT-ANP’s positive predictive value was only 78%.
Therefore, BNP is an accurate diagnostic marker of HF134. BNP and NT-proBNP have the
same cardiac actions which are released upon cardiac stress, although the half-life of NTproBNP is 5- to 10- fold higher (60-120 min) than BNP (23 min). The threshold values for
HF diagnosis with BNP are: <100pg/ml – no HF; 100-400pg/ml – potential HF; >400pg/ml
– HF; however, the diagnostic values for NT-proBNP differ significantly based on age:
<300pg/ml – no HF; >450pg/ml – HF for patients under 50 years of age; >900pg/ml – HF
for ages 50-75; >1800pg/ml – HF for ages over 75135. Therefore, due to the longer
circulating half-life and age specificity of diagnostic thresholds, NT-proBNP is more
commonly measured in a clinical setting.
Although BNP and NT-proBNP are commonly used to diagnose clinical HF, it is important
to note that BNP levels are increased or decreased with other comorbidities, most notably
renal failure and sepsis, along with age, sex and obesity. BNP, along with all natriuretic
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peptides, is elevated with renal failure even when no adverse cardiac events are present136.
BNP is also elevated in sepsis and other non-cardiac disease states including atrial
fibrillation, pulmonary embolism and amyloidosis137. BNP levels were significantly lower
in obese patients which may be a contributing factor to the higher susceptibility of these
individuals to adverse cardiac events138. BNP also increases with age139 and is higher in
women compared men140. Different assay systems also have different thresholds and
ranges which make having a universal threshold difficult140. With the multitude of variables
present for the measurement of BNP, it is suggested that both BNP and NT-proBNP may
not be the most suitable for detection of HF in the entire population.
Suppression of tumorigenicity 2 (ST2) is another measure of mechanical stress in
cardiomyocytes129. The ligand for the ST2 receptor is interleukin 33 (IL-33) which has
anti-hypertrophic and anti-fibrotic benefits in the myocardium, partly due to inhibition of
the pro-apoptotic pathway141. The soluble form of ST2 (sST2) is secreted from the
myocardium and detectable in the circulation under conditions of cardiomyocyte stress.
sST2 acts as a decoy receptor for IL-33 to suppress the natural IL-33 pathways which
ultimately leads to increases in cardiac apoptosis and fibrosis. Therefore, increases in sST2
indicate increased fibrosis, inflammation, and remodeling, reflecting many hallmarks of
several cardiovascular diseases142. sST2 levels also appear to increase in acute HF, but
unlike BNP, these values were not an independent predictor of mortality143. However,
when measured with BNP, the prognostic accuracy for HF was greatly improved141.
Therefore, it is evident that creating a panel of biomarkers to more accurately detect and
predict HD is needed.

1.3.2

Biomarkers of Cardiac Damage

Cardiac troponins (cTn) are the leading candidate biomarkers in predicting myocardial
damage. It is well established that cardiac troponins T and I levels are significantly elevated
in myocardial injury, mainly ischemia144. In healthy cardiomyocytes, troponins are
essential for regulation of muscle contraction through modulation of calcium-mediated
actin and myosin interaction145. Cardiac troponin T, I, and C form the cTn complex where
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troponin T (cTnT) and I (cTnI) are specific for mediating contractile function144. When the
cardiomyocyte membrane is disrupted via ischemic (most common) or non-ischemic
causes, the cTn complex disaggregates and enters the bloodstream, and therefore, increased
levels of cTnI and cTnT correlate with the extent of cellular injury. Studies have observed
increases of cTnT and cTnI in many forms of heart disease including coronary heart
disease, heart failure, and atherosclerosis146,147. It is important to note that cTns are an acute
marker of cardiac damage where their half lives in the blood range from 90-120 min with
prolonged elevation (3-4 days) indicating severe and irreversible damage to the heart148.
cTn measurements provided complimentary information to cardiac perfusion imaging to
enhance diagnostic accuracy149. Some studies have also shown elevations of cTns in other
disease states including stroke, pulmonary embolism, sepsis, perimyocarditis and
tachycardia150,151. Therefore, measurement of cTn is usually evaluated along with clinical
examination and imaging to form an accurate diagnosis of cardiac injury.
In addition to troponins, heart-type fatty acid-binding protein (H-FABP) is another measure
of cardiac damage. H-FABP is a cytoplasmic protein that transports long-chain fatty acids
into the cardiomyocyte and is rapidly released into the bloodstream upon cardiomyocyte
membrane damage129. Serum H-FABP levels were measured in chronic HF when patients
were both admitted and released from the hospital where prolonged elevation at the time
of release were associated with significantly higher future cardiac event rates152. When
circulating levels of H-FABP were measured concurrently with cTn, testing sensitivity was
improved in the first 4 hours after admission. However, at later timepoints H-FABP
increased the false-positive rate of patients with acute MI153. Another study also evaluated
H-FABP and cTn in acute coronary artery syndrome where early testing of H-FABP
showed increased levels associated with cardiac events in all patients. In contrast to the last
group, this group found H-FABP to have a greater predictive capacity for cardiac events
within 6 months of initial admission154. Due to such differing findings with this biomarker
at later stages, further analysis of the predicative value of H-FABP is needed. These studies
have shown the importance of using an array of biomarkers in HD for improved prediction
of adverse cardiac events and progression to HF.
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1.3.3

Inflammatory Biomarkers

Inflammation is a key process that contributes to the progression of many forms of HD.
Initially, acute inflammation is a necessary step in the process of healing. However, when
the inflammation fails to resolve and becomes prolonged, further tissue damage may occur.
Many cardiac biomarkers have been discovered to link to the overall cardiac inflammation
in HF. Early studies focused on interleukin-6 (IL-6), tumour necrosis factor alpha (TNFα), C-reactive protein (CRP) and toll-like receptor 4 (TLR4) with their role in HF
progression via adverse effects on vascular endothelium, cardiomyocyte apoptosis,
induction of hypertrophy, and left ventricular dilatation155.
Interleukin-6 (IL-6) is a common inflammatory cytokine that is secreted in response to
infections and tissue injuries. It is produced by various cell types and exerts many
biological responses through the IL-6 receptor. IL-6 has been reported to play a large role
in the process of ischemic HD and HF156. In patients with chronic HF, plasma levels of IL6 increased with diseased severity and could provide prognostic information independent
of left ventricular ejection fraction157. In a clinical trial from patients with acute coronary
syndrome, increased IL-6 levels associated with adverse cardiac outcomes158 and increased
risk of major cardiac events including possible HF159. Plasma levels of IL-6 are also
elevated after trauma from acute myocardial infarction where prolonged elevation
correlates with residual ischemia in the heart160. In addition to cardiac ischemia, IL-6 levels
increase in dilated or hypertrophic cardiomyopathy and are associated with a higher risk of
congestive HF161. In contrast to the findings that IL-6 further increases cardiac damage,
some studies have shown that IL-6 may play a role in cardio-protection after ischemia/
reperfusion signalling162 and may even aid in tissue repair163. Therefore, IL-6 can be
proposed to play a dual role in cardiovascular inflammation. Short term signalling of IL-6
after ischemia can protect the heart from further damage while long term IL-6 elevation
plays a role in the development and prediction of future cardiovascular diseases.
Tumour necrosis-alpha (TNF-α) is an inflammatory protein produced primarily by
macrophages and released into circulation to elicit an immune response. TNF-α binds to 2
possible receptors, TNFR1 and TNFR2, with each producing divergent responses in HF.
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TNFR1 functions through pathological pathways while activation of TNFR2 shows
protective effects in the heart. In a mouse model of MI, knockout of TNFR1 indicated
attenuated ventricular dysfunction and improved post-MI survival while knockout of
TNFR2 exacerbated ventricular dysfunction and cardiac remodeling164. Therefore, TNF-α
is expected to play a protective role in the heart via the TNFR2-mediated pathway. In the
circulation, TNF-α levels have been found to increase in patients with heart disease and
heart failure156. In patients with coronary artery disease (CAD), TNF-α increased according
to disease severity165. When both TNF-α and IL-6 were measured in CAD, there was
significant predictors of CAD severity while measured together they are an indicator of
chronic inflammatory burden and increased atherosclerotic risk166. This pattern was also
present in patients with LV diastolic dysfunction independent of other cardiac
parameters167. In mechanistic studies utilizing transgenic mice, overexpression of cardiac
TNF-α resulted in LV wall thinning and increased cardiomyocyte apoptosis via loss of
cytoprotective factor Bcl-2 and activation of cell death pathways168. In isolated perfused
rat hearts, TNF-α not only decreased heart rate and contractile force, but activated protein
kinase C (PKC) which promotes the development of cardiac dysfunction169. High levels of
TNF-α can also disrupt contractility through increases of intracellular calcium in
cardiomyocytes170.
The presence of C-reactive protein (CRP) in HF patients was first discovered back in 1956
and since then there has been extensive work on the relationship between CRP and the
inflammatory process in HF130. In the 1990s a more sensitive test was developed for CRP,
namely high-sensitivity CRP (hs-CRP), as testing for this marker of cardiac inflammation
became more prevalent171. hs-CRP is synthesized in the liver, and with increased vascular
inflammatory cytokines in the circulation, hs-CRP is released into the bloodstream which
can then be detected in inflammatory HF and atherosclerosis172. hs-CRP has a long halflife of about 19 hours with its peak occurring at about 24-48 hours after initial inflammatory
response173. A large meta-analyses evaluating the circulating levels of hs-CRP showed it
to be a predictor of coronary heart disease and future coronary events174. Increased levels
of this marker are also associated with many risk factors of heart disease including physical
ability, smoking, cholesterol levels, body mass index (BMI), and blood pressure175.
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The toll-like receptor (TLR) superfamily plays a crucial role in the innate immune system.
Toll like receptor 4 (TLR4) is a membrane-bound receptor in cardiomyocytes and
endothelial cells that is upregulated in HF where its activation leads to further inflammatory
signalling. TLR4 can be activated by many ligands including endotoxins, heat shock
protein 60 (HSP60), reactive oxygen species (ROS) and high mobility group box 1
(HMGB1). Once TLR4 is activated, initiation of both My88-dependent and My88independent

pathways

activate

many

inflammatory

transcription

factors

and

proinflammatory cytokines, respectively176. Both pathways activate transcription of NFκB and activator protein-1 (AP-1) which regulate the expression of inflammatory cytokines
IL-6 and TNF-α. Compared to all other toll-like receptors TLR4 has the highest expression
in inflammatory HD including myocarditis, myocardial infarction, ischemia reperfusion
(I/R) injury, HF, valve diseases, hypertension, and atherosclerosis177. In HF, many
endogenous ligands of TLR4, such as HSP, ROS, and HMGB1, are elevated and mediate
myocardial inflammation176. Studies in mice showed that TLR4 expression was increased
in cardiomyocytes isolated after long-term myocardial infarction (MI)178, while mice with
TLR4 deficiency showed reduced infarct sizes after I/R injury179. Cardiac TLR4 expression
was also increased in patients with advanced HF180. Due to TLR4 overexpression in HD,
this pathway has become a target of inhibition to reduce pro-inflammatory responses.
Statins have been shown to inhibit TLR4 activity and reduce inflammation in the vascular
system181. Eritoran is a TLR4 antagonist and has been shown to attenuate I/R injury182.
Therefore, TLR4 may be a biomarker of myocardial inflammation in several types of HD
and vascular diseases.

1.3.4

Specificity of Cardiac Biomarkers

Most of the cardiac biomarkers described above are secreted into the blood and can
therefore be measured through a simple blood test. However, they can be associated with
other comorbidities that can confound results. Some biomarkers are not even produced by
the heart but are secreted by other tissues when cardiac injury or dysfunction occur.
Therefore, circulating biomarker levels may not reflect actual cardiac tissue levels which
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is a limitation to measuring circulation compared to tissue-specific biomarkers of HD.
There is a clear need for the identification and development of ways to non-invasively
detect tissue-localized biomarkers. In addition, there is evidence that no one single
biomarker can accurately determine HD prognosis. In a study by Jungbauer et al. it was
suggested that a panel of cardiac biomarkers should be used to more accurately diagnose
and predict cardiac outcomes for patients183. As HD is a complex syndrome with diverse
signs and symptoms, it is imperative to use a large panel of biomarkers to encompass all
possible characteristics and aid in better diagnoses. One novel biomarker of interest that
reflects cardiac tissue is the growth hormone secretagogue receptor (GHSR) and its
endogenous ligand ghrelin. This cardiac system could be an important addition to the
already established panel of biomarkers.

1.4 Ghrelin-GHSR as a Novel Biomarker
Upon cardiac biomarker discovery, a new hormone, ghrelin, and its receptor the growth
hormone secretagogue receptor (GHSR) have been identified as potential target localized
to cardiac tissue. The emerging discovery of this new biomarker has gained traction in HD
with the identification of changes in this ghrelin-GHSR system in HF.

1.4.1

GHSR and Ghrelin Discovery

Ghrelin is a peptide hormone that modulates systemic metabolism through activation of
orexigenic effects in the body184. Ghrelin is a 28-amino acid peptide that is encoded by the
preproghrelin gene first discovered in the X/A like cells in the gastric oxyntic cells in the
stomach185. It is first synthesized as a precursor, preproghrelin, which is cleaved to produce
both ghrelin and obestatin. Obestatin has been thought to play a role in food intake and
metabolism via the G protein-coupled receptor 39 (GPCR39) although these results have
yet to be substantiated186. Ghrelin, however, has been extensively studied for its production
and secretion in endocrine cells in the gastrointestinal mucosa. Ghrelin is present in cells
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in two forms, acylated and un-acylated ghrelin. In the endoplasmic reticulum membrane,
proghrelin is acylated on Ser-3 by ghrelin O-acyl transferase (GOAT) prior to its
processing to mature ghrelin. Only the acylated form of ghrelin is the natural ligand to
GHSR184. Although the un-acylated form of ghrelin (des-acyl ghrelin) does not bind
GHSR, it also modulates energy metabolism, likely through an unknown receptor187.
Structure-function studies have shown that the N-terminal 8 amino acids of ghrelin,
including the octanoylated group, constitutes the receptor binding domain.
The biologically active receptor for ghrelin is GHSR1a (here termed GHSR), a 366 amino
acid, seven transmembrane G-protein coupled receptor that contains an extracellular
binding region where active ghrelin binds specifically to transmembrane domains 3 and 6
of GHSR. The splice variant GHSR1b contains only 298 amino acids and is truncated to
only contain transmembrane sections 1-5188. GHSR1b has been shown to be expressed in
the same tissues as GHSR1a as well as adipose tissue, breast, skeletal muscle and
prostate188. GHSR1b is known to heterodimerize with other G-protein coupled receptors
and functions in signalling. GHSR1b may form a heterodimer with GHSR1a in neurons
and HEK293 cells where receptor internalization occurs with inhibition of GHSR1a
signalling189,190. Although GHSR1b has been shown to dimerize with GPCRs, its biological
function in the heart is not fully elucidated.
While ghrelin was originally discovered in rat and human stomach191, it is now known that
ghrelin and GHSR are expressed in many other organs; various brain regions; lung, liver,
kidney; the epsilon cells of pancreatic islets; and, most importantly, cardiovascular tissues.
The presence of GHSR has been demonstrated in human vascular tissues including the
aorta, coronary and pulmonary arteries, as well as in the myocardium, indicating that
GHSR is present throughout the heart192. Ghrelin has been thought to exert paracrine and
autocrine effects in the heart where binding of ghrelin to GHSR elicits many
cardioprotective responses193.
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1.4.2

GHSR Signalling in the Heart

Activation of GHSR in the heart has been identified through both classical G-protein
signaling and G-protein-independent pathways showing the complexity of GHSR
activation194. Ghrelin activation of GHSR initiates many downstream signalling processes
ranging from apoptosis and survival signaling, calcium regulation and contractility
signaling, cellular metabolism, and inflammation.
One of the main contributors to cardiac health is cardiomyocyte contractility and regulation
of calcium influx/efflux. Calcium (Ca2+) signalling in the cardiomyocyte begins with an
influx of calcium into the cell through the L-type calcium channel induced by excitation
contraction coupling of the cardiomyocyte membrane. At the same time, Ca2+ is released
from the sarcoplasmic reticulum (SR) through the ryanodine receptor 2 (RyR2). Increases
in cytoplasmic Ca2+ bind to protein kinase C (PKC) and initiate phosphorylation of
Ras/Raf, MEK1/2 and ERK1/2195. Intracellular Ca2+ induces cardiomyocyte contraction
through binding to troponin (Tn) C within the actin filament in the sarcomere of the cell.
Ca2+ is released from the Tn C and actin filament where a signal is sent to the cell to reduce
intracellular levels. Stimulation of G-protein coupled receptors (GPCRs) initiate a
signalling cascade starting with Gs activating cyclic adenosine monophosphate (cAMP),
protein kinase A (PKA) which phosphorylates phospholambin B (PLB) and inhibits
binding to sarcoplasmic reticulum calcium ATPase pump (SERCA2a) ultimately allowing
for Ca2+ uptake into the SR. Furthermore, stimulation of GPCRs activates Gαq,
phospholipase C β (PLCβ), inositol 3 phosphate (IP3) which binds to the IP3 receptor. This
receptor is minimally active in healthy cells and becomes overactive in damaged or stressed
cardiomyocytes196. Upon relaxation, Ca2+ is stored in the SR or removed from the cell
through the sodium-calcium exchanger (NCX) on the cell membrane. This process is
demonstrated in figure 1.1. The disruption or dysregulation of this process results in cardiac
dysfunction197.
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Figure 1.1 Calcium Regulation and Contractility Signaling in Cardiomyocytes.
Calcium (Ca2+) into the cell through the L-type voltage gated calcium channel. Ca2+
induces the PKC → MEK → ERK1/2 pathway and stimulates both the opening of the
ryonadine receptor 2 (RyR2) receptors to release stored Ca2+ and activation of GPCRs.
GPCRs activate Gs → cAMP → PKA → PLB to initiate influx into the sarcoplasmic
reticulum along with Gαq → PLCβ → IP3 and binding to IP3 receptor (IP3R). Ca2+ is
removed from the cytosol through storage in SR via SERCA2a and removed from the cell
through the sodium-calcium exchanger (NCX). To induce contraction, Ca2+ binds to the
troponin (Tn) C on the actin filament where myosin binds to contract the cell. Ca2+ and
myosin are released from the actin upon relaxation of the cardiomyocyte. Figure was
created in Biorender.

38

A number of studies using isolated cardiomyocytes have shown that the ghrelin-GHSR
system in the myocardium plays a role in the regulation of Ca2+ homeostasis, which is
associated with its action in cardioprotection and overall heart function. Treatment of
mouse ischemic cardiomyocytes with ghrelin resulted in protection from ischemia/
reperfusion injury, likely from regulation of intracellular Ca2+ levels194. When ghrelin was
administered to rat ventricular cardiomyocytes, a positive inotropic effect was seen through
increased intracellular Ca2+ transients and increased L-type Ca2+ channel current, likely
through GHSR-mediated signalling through PKC198. The same group evaluated the same
parameters of intracellular Ca2+ flux on mouse cardiomyocytes with ischemia/ reperfusion
(I/R) injury. Activation of GHSR with ghrelin produced a positive inotropic effect again
with prevention of Ca2+ transient reduction and SR calcium reduction199. Therefore, GHSR
is expected to protect the heart from I/R injury via the PLB pathway ultimately allowing
for maintenance and recovery to normal contractility after cardiac injury199. Overall, GHSR
is an important regulator of calcium signalling and ultimately contractility in the heart
where activation of this system functions as a cardioprotective mechanism for HD.
The inflammatory process plays an important role in the process of HD development.
Ghrelin activation of GHSR is known to inhibit pro-inflammatory pathways and activate
anti-inflammatory pathways to help protect the heart from further damage. Ghrelin has
been shown to act on both immune and endothelial cells to inhibit the leptin- and
endotoxin- induced production of pro-inflammatory cytokines, including interleukin 1-β
(IL-1β), interleukin-6 (IL-6), and tumour necrosis factor alpha (TNF-α)200,201. Further
studies evaluated the effect of ghrelin on the toll-like receptor 4 (TLR4)/ NF-κB
inflammatory pathway. In the rat heart, ghrelin administration lessened pro-inflammatory
signalling through the TLR4/ NF-κB pathway202. Additionally, in rats with induced
ischemia/reperfusion injury, the increased expression of TLR4, IL-1β, and Caspase-1 were
all reduced with the administration of ghrelin202. Endogenous ghrelin can also induce antiinflammation pathways; in ghrelin knockout mice with induced cardiac hypertrophy, the
cholinergic anti-inflammatory pathway was suppressed and plasma inflammatory markers
(IL-6, IL1-β) were high, compared with wild-type mice203. Ghrelin and GHSR also
contribute to the inhibition of inflammation via activation of the Akt-activated antiinflammatory pathway202. Therefore, activation of GHSR with ghrelin both inhibits pro-
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inflammatory pathways and activates anti-inflammatory pathways to reduce the cardiac
damage seen with excessive inflammatory response.
GHSR signalling suppresses apoptosis and promotes survival. One study investigated
GHSR signaling in rats with myocardial infarction (MI) and showed a decrease in both
apoptosis (metalloproteinase 2 and 9) and inflammation (IL-1β and TNF-α)204. GHSR
activation promotes pro-angiogenesis, pro-survival and proliferation through Akt and
AMP-activated protein kinase (AMPK) in rat cardiomyocytes205, and extracellular
signalling related kinase (ERK) phosphorylation in cardiomyocytes and endothelial
cells206. Ghrelin has been shown to improve the integrity and decrease shrinkage of rat
cardiomyocytes207. The ghrelin-GHSR system has been shown to inhibit apoptosis by
decreasing pro-apoptotic signalling. In the rat left ventricle, administration of ghrelin
decreased the pro-apoptotic factors Bax and Caspase-3 while increasing the anti-apoptotic
factors Bcl-2 and Bcl-xL and prevented mitochondrial swelling208. In angiotensin II- (Ang
II) and isoproterenol-induced HF in rats, activation of AMPK through ghrelin decreased
overall apoptosis with decreases in apoptotic factors caspase-3 and caspase-12

208,209

.

GHSR activation has shown to be a cardioprotective marker as it activates many
downstream signalling pathways for both decreasing apoptosis and promoting
cardiomyocyte survival via a cardioprotective mechanism.
Along with cellular survival, ghrelin acts through GHSR to regulate cellular metabolism,
notably glucose metabolism and oxidative stress. In dogs with HF, ghrelin administration
enhanced fatty acid oxidation and oxygen consumption and reduced glucose oxidation,
thereby partially correcting the metabolic deficiencies from HF210. Ghrelin also attenuates
the ER stress response to ischemia/reperfusion; in rat hearts with I/R, pre-administration
of ghrelin reduced the IR-induced overexpression of mRNA and proteins of the ER stress
(ERS) response, glucose-regulated protein78 (GRP78) and C/EBP homologous protein
(CHOP)211. This group further evaluated the mechanism of ERS activation and determined
that ghrelin activates GHSR through the calcium-calmodulin-dependent protein kinase
kinase (CAMKK) and AMP-activated protein kinase (AMPK) to ultimately protect the
heart from ERS-induced injury209. Additionally, ghrelin administration in the mouse heart
using adeno-associated virus vectors sustained autophagy and minimized dysfunctional
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mitochondria after MI212. Taken together, these studies demonstrate the multiple metabolic
pathways through which ghrelin activation of GHSR operates to protect against cardiac
damage and stress.
Fibrotic deposition is commonly associated with extensive damage and disruption to the
myocardium. Many studies have evaluated alterations in scar formation and size after
GHSR activation to protect the heart from further injury. Ghrelin has been shown to reduce
scar size and volume after MI in mice213, and ghrelin suppresses collagen I and III mRNA
levels in rat cardiomyocytes214. In an Ang II-induced model of HF, ghrelin attenuated
myocardial fibrosis and expression of fibrotic factors (collagen I, III, TGF-β1) through
upregulation of PPAR-γ and inhibition TGF-β1 signalling215. The mechanism by which
ghrelin inhibits fibrotic deposition was further evaluated in rat ventricular cardiomyocytes
where activin A (Act A) levels were significantly increased after a MI. Ghrelin
downregulated Act A back to basal levels, thus correcting this Act A imbalance during
ventricular remodelling216. Therefore, GHSR activation with ghrelin attenuates fibrosis
deposition and inhibits fibrotic protein formation to protect the heart from further damage.
The ghrelin-GHSR system is proposed to initiate a cardioprotective mechanism when the
myocardium is stressed or damaged. Therefore, studies evaluated cardiac function after
activation of this system using ghrelin administration. In healthy humans, ghrelin was
injected, and heart function was evaluated acutely after injection. Interestingly, ghrelin
dose-dependently enhanced LVEF217 and vasodilation determined through forearm blood
flow218. When ghrelin was repeatedly given to CHF patients, there was a drastic
improvement in LVEF along with LV mass and end-systolic volume, oxygen capacity and
muscle wasting219. In human studies, there has been clear evidence that the ghrelin-GHSR
system functions to improve cardiac function after myocardial damage. Therefore, these
studied have shown the clinical relevance of the ghrelin-GHSR system in HD models.
Overall, these data depict a complex biochemical signalling network upon activation of
myocardial GHSR. Cardio-protection via the ghrelin-GHSR system functions to regulate
calcium homeostasis and, in turn, contractility; reduce inflammation; inhibit apoptosis and
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cell death; regulate cellular metabolism; and reduce fibrosis deposition. These processes
are represented in a signalling cascade pathway shown in Figure 1.2.

Figure 1.2 Proposed Biochemical Signalling Cascade of ghrelin-GHSR in
Cardiomyocytes.
Ghrelin activation of cardiac GHSR initiates downstream signalling pathways for
contractility (cAMP → PKA → PLB → SERCA2a and calcium homeostasis); apoptosis/
hypertrophy (PKC → MEK → ERK1/2); cellular survival (PI3K → PDK1 → Akt); protein
synthesis and cellular growth (Akt → mTOR); inflammation (TLR4 → MyD88 → NFκB
→ IL-1β and TNF-α). Figure was created in Biorender.
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1.4.3

Argument for GHSR as a Biomarker in Heart Disease and
Heart Failure

The biology of the myocardial ghrelin-GHSR system has been extensively studied and now
the question remains, could this system act as a targeted biomarker for HD and a predictor
of HF? Activation of the ghrelin-GHSR system improves overall heart function potentially
acting through a cardioprotective mechanism to help mediate the negative effects of HD.
The ghrelin-GHSR system dynamics are known to change for different forms of heart
disease including diabetic cardiomyopathy, valvular disease, CHF, and MI.
Changes in the ghrelin-GHSR system within the heart may provide clues to the
development of HD and HF. The rodent MI model in which the left anterior descending
coronary artery is ligated, has revealed some interesting dynamics. Following surgery,
myocardial GHSR expression increased over time and ghrelin expression decreased220.
Additionally, ghrelin serum levels correlated negatively with LV end-diastolic pressure
and dimension indicating this ghrelin-GHSR system plays a role in LV function220. A rat
model of MI was used to evaluate the effects of ghrelin administration on heart function.
In rats that were ghrelin-treated post-MI, LV end-diastolic pressure and enlargement were
reduced compared to saline controls214 and overall mortality rates were reduced221 while
cardiac cachexia was reduced222. Similarly in a model of MI, isolated rat hearts were
administered ghrelin during reperfusion where coronary flow, heart rate, contractility, and
left ventricular end systolic and end-diastolic pressures were significantly improved223.
Similar results were seen in another model of cardiac injury induced by isoproterenol in
rats where GHSR and ghrelin mRNA expression increased with cardiac injury and were
decreased back to normal levels with ghrelin treatment224. Interestingly, in a model of
hypoxia/ reperfusion in isolated rat cardiomyocytes, GHSR expression was decreased
acutely while ghrelin injection increased the expression of GHSR back to normal
cardiomyocyte levels207. With Doxorubicin induced cardiotoxicity in mice, there was
remarkable mortality and cardiac dysfunction which was ameliorated with ghrelin
administration225. Our past work in a rodent model of diabetic cardiomyopathy (DCM)
showed significant decreases in GHSR expression in acute severe and chronic mild DCM
compared to control hearts. This is the first study showing GHSR expression changes in
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DCM and significant decreases in GHSR expression in a model of HD. Together these
results indicate significant regulation of cardiac function through the ghrelin-GHSR
system. Threshold levels for GHSR expression decrease and increase based on the type
and severity of heart disease.
Is the ghrelin-GHSR system a clinically meaningful indicator of HD or HF? A few studies
have evaluated the expression of both ghrelin and GHSR in human patients with heart
disease. In a study by Beiras-Fernandex et al., myocardial tissue from patients with CHF
was analyzed for expression of both GHSR and ghrelin and compared to control tissue.
The authors found tissue ghrelin levels significantly decreased and levels of GHSR
markedly increased in CHF226. This was the first study showing changes in both ghrelin
and GHSR in the myocardium of patients with HF with association to cardiac function
where these changes could reflect a compensatory mechanism. Another study evaluated
GHSR density in cardiac vasculature using a labelled ghrelin probe, [125I-His9]-ghrelin,
where GHSR density increased in atherosclerotic aorta, and coronary arteries and veins.
These changes in GHSR density in atherosclerosis vasculature represent a potential
therapeutic target in the treatment of cardiovascular disease227. Changes in GHSR are also
associated with LV mass. GHSR gene variant analysis revealed one variant that was
common in individuals with highly symptomatic LV hypertrophy. These data suggest that
GHSR variants differ based on susceptibility to LVH228.
Another indicator of cardiac damage is the circulating form of ghrelin where elevations can
lead to poor outcomes for patients with cardiac conditions. Chen Y et al., demonstrated a
decrease in plasma ghrelin levels in patients with CHF where survival analysis showed that
a higher plasma ghrelin level (>85pmol/l) lead to increased 2-year survival rate229.
Significant correlations were seen between circulating ghrelin levels and NT-proBNP
indicating ghrelin could be a predictor of readmission in HF similar to NT-proBNP.
Ghrelin also correlated to LVEF, another predictor of readmission, further suggesting
lower circulating ghrelin levels could lead to patient readmission and a biomarker of HD
and HF229. Another study in cardiac hypertrophy patients evaluated the relationship
between plasma ghrelin levels and ventricular wall thickness. Higher plasma ghrelin levels
correlated to increased wall thickness reflecting a possible compensatory mechanism to
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up-regulate ghrelin concentrations and act through the cardiac ghrelin-GHSR system230.
Plasma ghrelin levels were also correlated to atherosclerotic plaques in atherosclerosis
where ghrelin was positively associated with mean artery plaque thickness231. Taken all
together, these studies indicate that there are thresholds in serum ghrelin levels that are
associated with disease severity in HD and HF.
Overall, these data show a clear indication of the cardioprotective effects the ghrelin-GHSR
system has on the myocardium and overall cardiac function. The expression of GHSR and
ghrelin are altered depending on the type and severity of heart disease present while they
ultimately act to improve the biochemical signalling in cardiomyocytes and enhance
overall cardiac function. Therefore, the literature supports the use of GHSR as a cardiac
localized biomarker of HD and HF and its potential predictive value as serum ghrelin levels
and GHSR-associated biochemical signalling occurs early in the progression of cardiac
dysfunction.

1.4.4

Imaging Agents Targeting GHSR: Fluorescent Probes and
PET Tracers

With the relevance of the ghrelin-GHSR system to not only overall cardiac function but
the multitude of biochemical signalling pathways involved in HD progression, this system
is a promising target for evaluation of HD. Since ghrelin is produced and secreted from
many tissues across the body the use of circulating ghrelin as a biomarker of HD may be
confounded. Hence, GHSR may be an optimal target as it is localized to cardiac tissue and
GHSR expression levels change significantly in the disease process. Therefore, imaging
changes in myocardial GHSR may be an indicator of HD progression.
The detection of GHSR and its associated signalling pathways in tissue has been
problematic as antibodies targeting G-protein coupled receptors (GPCRs) are not
specific232. To overcome this problem, transgenic mouse models of green fluorescent
protein (GFP) tagged to GHSR were developed to specifically localize GHSR in vitro. In
a mouse model of GHSR-GFP, GHSR was regionally localized in the anterior pituitary
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with positive GFP fluorescent analysis233,234. Although this model accurately identifies
GHSR positive cells, there is still the challenge of targeting GHSR in cells that are not
transfected with a fluorescent reporter gene. To tackle this issue, fluorescent analogues
have been developed targeting GHSR in any histological tissue. One study by Liu M et al.,
developed a fluorescent analogue of full-length human ghrelin where Alexa Fluor 568 was
chemically bound to the C-terminal end of ghrelin. This analogue was found to bind GHSR
in vitro with an IC50 of 11nM (comparable to native ghrelin at 3.3nM)235. Another study
evaluated an endogenous GHSR antagonist, liver-expressed antimicrobial peptide 2
(LEAP2). This group developed a fluorescent LEAP2 analogue termed F-LEAP2 where
the fluorescent moiety (F) was conjugated to the N-terminal end and specific binding to
GHSR was observed in cells of mouse brain regions with a binding affinity of 3.9nM236.
More recently, our team has developed fluorescent ghrelin analogues targeted to GHSR.
The first fluorescent analogue developed was a truncated 18-amino acid analog of ghrelin
tagged with fluorescein isothiocyanate (FITC). The analog was found to bind in mouse
cardiac tissue. However, the FITC tag posed a problem as tissue autofluorescence occurs
in this fluorescent wavelength in cardiomyocytes237. Therefore, we developed a far-red
analogue to target GHSR to circumvent the autofluorescence issue. A far-red analogue of
truncated ghrelin with a Cy5 fluorescent probe on the C-terminal end, Cy5-Ghrelin(1-19),
was developed and tested in P19-derived cardiomyocytes to target GHSR. This analogue
bound to GHSR specifically with a binding affinity of 26nM in cardiomyocytes with
specificity validated in mouse cardiac tissue238. Since then we have developed a second
generation of fluorescent peptides targeting GHSR239. These peptides have enhanced
stability and affinity using a “stapling” method to bridge the peptide, ultimately preserving
the cyclic α-helical structure essential for binding. Promising candidates from this array
include Sulfo-Cy5-Ghrelin(1-20), Sulfo-Cy5-cyclo-12-Ghrelin(1-20), and Sulfo-Cy5cyclo-8-ghrelin(1-20) with binding affinities of 11nM, 1.0nM, and 6.2nM respectively239.
With these new developments in fluorescent ghrelin-derived probes, there are many
compounds available to specifically target GHSR in situ in cardiac cells and tissues.
Additional to in situ imaging analogues, in vivo imaging agents have been developed to
target GHSR in the body. Initial PET and SPECT imaging agents involved radio-labelling
native ghrelin targeting GHSR through in situ studies. Studies have demonstrated that the
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structure of ghrelin could be highly modified and the n-octanoylated group manipulated
while preserving strong affinity to the receptor. This allowed for enhanced stability of the
imaging agent to be used for in vivo studies240. The next stage in GHSR probe development
was in 2009 where Rosita et al. reported new manipulation of ghrelin peptides including
significant truncation and alterations in the octynol side chain of active ghrelin. The lead
candidate for PET imaging was a fluorine-bearing 12 carbon aliphatic side chain of the
ghrelin(1-14) compound with binding affinity of 28nM while the lead candidate for SPECT
imaging was ghrelin(1-14) modified with a rhenium metal complex side chain with binding
affinity of 35nM. These analogs show possibilities for future studies with
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F PET and

99m

Tc SPECT imaging to noninvasively detect GHSR in vivo241. Additional SPECT

imaging agents was reported by Koźmiński and Gniazdowska where 99mTc conjugated to
CN-Lys-ghrelin was evaluated in situ in human prostate cells and in vivo in mice. Two
promising candidates,

99m

Tc(CO)3Ls,o(CN-Lys-GHR) and

99m

Tc(NS3)(CN-Lys-GHR),

showed strong binding affinities to GHSR (54nM and 45nM respectively) with good
stability and minimal tracer degradation in the human serum over time. Although these
lead compounds showed promise in vivo, there was minimal uptake in the mouse heart242.
Charron et al. developed a [68Ga]-ghrelin analogue, [Dpr3(octanoyl),Lys19(68GaDOTA)]ghrelin(1-19), with a strong affinity to GHSR (5.9 nM) and strong serum stability.
This analogue was tested in a xenograft mouse model where the tracer accumulated in the
xenograft with excessive uptake in the kidney and minimal uptake in the heart243. Due to
the limited uptake in the heart with these imaging agents, the labelled ghrelin-peptide may
not be optimal for imaging in vivo changes in cardiac GHSR density.
To overcome these issues, development of small molecule ligands of GHSR for in vivo
imaging have been evaluated for increased affinity and serum stability. A study by Chollet
et al. compared the binding of a 68Ga-NODAGA-ghrelin agonist peptide tracer to a 68GaNODAGA-ghrelin small molecule inverse agonist tracer (binds to GHSR with opposite
physiological responses). In vivo imaging experiments in rats showed increased stability in
blood, reasonable clearance in kidneys and liver with both the peptide and small molecule,
but higher uptake in the heart with the small molecule inverse agonist compared to the
peptide tracer. The small molecule inverse agonist had unspecific diffusion and posed a
challenge in understanding GHSR signalling244. Another study by Potter et al. evaluated a
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(S)-stereoisomer of N-methyl piperidine-substituted quinazolinone small molecule
derivative of ghrelin was developed to target GHSR with a binding affinity of 22nM. In
vivo mouse studies demonstrated slight uptake in the heart, however blocking studies
showed decreased tracer specificity (38%) and further enhancement of GHSR small
molecules should be evaluated245. These initial results in ghrelin imaging agents have led
to many developments in probes targeting GHSR in vivo. PET imaging probes have been
developed and optimized by our research team. In a study by Charron et al., this group
developed an array of ghrelin-derived peptides and small molecules labelled with
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F-

fluorine where the lead small molecule analogue, [Inp1,Dpr3(6-fluoro-2-naphthoate),1Nal4,Thr8]ghrelin(1−8), had a significantly stronger affinity (0.11nM) to GHSR compared
to native ghrelin (3.3nM). This analogue incorporated a 6-fluoro-2-pentafluorophenyl
naphthoate (PFPN) group to incorporate 18F and enhance in vivo stability246. In addition to
these developed tracers, work by Abbas et al. evaluated a promising peptidomimetic
candidate, [1-Nal4, Lys5(4-[18F]-FB)]G-7039, for in vivo PET imaging with binding
affinity of 69nM. In healthy wild-type mice and mice lacking GHSR, there was no change
in tracer uptake in the heart indicating mouse models may not be optimal for imaging
GHSR in vivo247. Therefore, PET tracer development is an ongoing process to target GHSR
in vivo in the heart.
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1.5 Rationale and Aims of the Study
With discovery and identification of the cardiac ghrelin-GHSR system there has been
significant evidence of cardioprotective signalling through its activation. GHSR density in
cardiac tissue may decrease and increase throughout the progression of HD. GHSR is
elevated in end stage heart failure while circulating ghrelin may be a predictor of adverse
cardiac events. GHSR activation after cardiac damage may increase pro-survival
signalling, boost contractility and maintain calcium regulation, decrease harmful
inflammatory effects, and enhance overall cardiac function. Many studies have evaluated
the specific biochemical signalling pathways associated with GHSR activation although
identification of GHSR density in situ and in vivo remain difficult. Conventional antibodies
targeting GHSR lack specificity with in situ histological analysis and thus new targeted
fluorescent imaging agents have been developed for GHSR binding and in vivo PET
imaging agents have been optimized for GHSR detection. In this context, our team has
developed and characterized imaging agents targeted to cardiac GHSR. These targeted
imaging agents aid in revealing the dynamics of the ghrelin-GHSR system with associated
biochemical signalling in HD and HF both in situ with quantitative fluorescence
microscopy and in vivo with PET imaging. Elucidating the role of the ghrelin-GHSR
system in the pathophysiological process of HD and HF may aid in clinical diagnosis and
targeted therapies.

The hypothesis of my thesis is:
GHSR is a biomarker for the underlying biological mechanisms involved in heart disease
and heart failure.

The specific aims of my thesis are:
1) To identify GHSR as a scalable biomarker in human heart failure and heart
disease using quantitative fluorescence microscopy
2) To develop and characterize a targeted PET imaging agent for cardiac GHSR
in a large animal model of myocardial infarction
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2.1 Introduction
The peptide hormone ghrelin is well-known as a potent orexigenic hormone. It stimulates
food intake by activating hypothalamic neurons that regulate normal feeding behaviour1.
It is the natural ligand of the growth hormone secretagogue receptor (GHSR), a seven
transmembrane, G protein-coupled receptor, which, in addition to the hypothalamus, is
expressed in other brain regions as well as several endocrine organs, such as the anterior
pituitary, pancreatic islets, the intestine, thyroid, and adipose tissue. In addition, ghrelin
and GHSR are both expressed in cardiomyocytes where they function through a system
that is independent of their role in regulating energy expenditure2. Activation of GHSR in
cardiomyocytes promotes excitation-contraction coupling by increasing Ca2+ flux through
both voltage-dependent Ca2+ channels3 and the sarcoplasmic reticulum Ca2+-ATPase pump
(SERCA2a)4–6, and promotes cardiomyocyte growth and survival through extracellular
signaling related kinase 1/2 (ERK1/2)4,5, and phosphatidylinositol-3-kinase / Akt
(PI3K/AKT)5,7. We6, and others3, have recently shown that levels of GHSR are decreased
in rodent models of diabetic cardiomyopathy, thus indicating that the dynamics of ghrelin
and GHSR change even with mild impairments in left ventricular function.
In contrast, levels of ghrelin and GHSR are dramatically increased throughout the heart in
patients with severe heart failure8, indicating that myocardial GHSR is altered differently
in heart failure compared with mild cardiomyopathy. The clinical syndrome of heart failure
(HF) is most commonly associated with significant impairment of left ventricular (LV)
contractility, leading to elevated intra-cardiac diastolic pressures and extravasation of fluid
into the lung parenchyma and other tissues. The early detection and treatment of HF are
limited by two issues: a) the specific series of molecular mechanisms leading to impaired
contractility remain elusive in patients with idiopathic cardiomyopathies, and b) the
responses to guideline-directed medical therapies remain highly variable, such that many
patients continue to deteriorate, leading to either the need for cardiac transplantation or
ultimately death. Clinically, there is a critical need to prospectively identify groups of
patients who will ultimately be at higher risk, particularly in the early stages of left
ventricular dysfunction, when the clinical status and ventricular function are not by
themselves consistent reliable predictors of disease progression and clinical outcomes.
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Circulating biomarkers, such as natriuretic peptide type-B (BNP), particularly the Nterminal form (NT-proBNP), and troponins T and I9–11, provide some prediction of the
progression of HF, by indicating changes within the cardiomyocyte that lead to stress,
injury and apoptosis. However, they are produced whenever heart tissue is damaged by any
direct or indirect injury to the myocardium, and there may be discordance between tissue
and circulating levels of these biomarkers. Therefore, there is a need to identify biomarkers
that are localized to the myocardium that reflect the cellular and molecular processes within
the heart that underlie the progression of HF.
In this study, we evaluated the role of tissue ghrelin-GHSR levels as a localized biomarker
of cardiac dysfunction in a cohort of patients who underwent cardiac transplantation. We
examined samples from the diseased explanted heart and biopsies from the same
individual’s engrafted heart followed through to one-year post-transplantation. In addition,
we aimed to determine the relationship between ghrelin-GHSR and BNP to biochemical
signaling molecules in cardiac dysfunction. Given the importance of intracellular Ca2+
homeostasis in atrial and ventricular contractility and the role of phospho-ERK 1/2 in
cardiomyocyte growth, we hypothesized that changes in the ghrelin-GHSR system in
myocardial tissue could potentially reflect derangements in cardiomyocyte contractility
and initiation of cardiac hypertrophic reprogramming that characterize the progression of
heart failure.
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2.2 Methods
2.2.1

Patient Cohort

Tissue samples were harvested from 10 patients who underwent cardiac transplantation at
the London Health Sciences Center (LHSC) between 2011 and 2013. The protocol for
sample dissections was approved by Western University’s Health Sciences Research Ethics
Board. Samples, roughly 0.5cm to 1.5cm in length, were collected from the right atrium
(RA) and left ventricle (LV) of the explanted/diseased heart (DH) from each cardiac
transplant patient. Endomyocardial biopsies, roughly 0.1 to 0.3cm in length, from the right
ventricle (RV) of the newly grafted heart were also taken at various time-points posttransplantation (PTx), generally weekly for the first 4 weeks, monthly for months 2-6 and
then at 1 year PTx. Not all patients had biopsies at all time points listed post transplantation
and therefore there are missing data points at some time points stated. Patient
demographics, cardiac function (LVEF), and medications pre- and post-transplantation are
shown in Tables 2 and 3, respectively. All patient samples and patient data were kept
anonymous and all marker analyses was done prior to receiving clinical data.
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Table 2.1 Cardiac Transplant Recipient Patient Demographics

Recipient Condition

Number of Patients with Condition (n of 10)

Male gender

6

Mean recipient age (years)

54

Coronary artery disease

5

Hypertension

1

High pulmonary artery pressure

10

Diabetes

0

Assist Device Pre-Transplant

3

LVEF <30% Pre-Transplant

10

LVEF

>50%

1

month

Post-

8

LVEF >50% ≥ 6 months Post-

10

Transplant

Transplant
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Table 2.2 Patient Medications Pre- and Post-Cardiac Transplant

Medications

Pre-transplant

Post-transplant 1
month (n of 10)

Post-transplant 6
months (n of 10)

Post-transplant
1 year (n of 10)

(n of 10)
ACE Inhibitor *

8

2

2

8

Anti-arrhythmic

5

2

0

0

ARB

0

0

0

0

Anti-platelet

5

7

7

8

Coumadin

7

1

0

0

Beta blocker

10

1

0

0

Calcium channel
blocker

10

2

4

3

Digoxin

8

0

0

0

Diuretics

10

7

2

2

Statins

5

5

6

6

Nitrates

0

0

0

0

Nitroglycerin

0

0

0

0

Anti-diabetics

0

0

0

0

Inotropic support
(Milrinone/
Dobutamine)

1

0

0

0

Tacrolimus

0

9

10

10

Mycophenolate
mofetil

0

9

9

9

Prednisone

0

7

9

6

*ACE: Angiotensin Converting Enzyme; ARB: Angiotensin receptor blocker
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2.2.2

Immunofluorescence Microscopy

Samples from both the explanted (diseased) and grafted hearts were frozen and embedded
in optimal cutting temperature compound (OCT), and subsequently sectioned at 7 μm
thickness, as previously described4,12. Immunohistochemistry using primary and
fluorophore-conjugated secondary antibodies was conducted as previously described4,12.
In brief, tissue sections were incubated with primary polyclonal or monoclonal
antibodies13–22 (Table 1) for 1h at room temperature in a humidified chamber. These
antibodies were used to identify ghrelin (1:100), BNP (1:1000), pERK1/2 (1:250);
SERCA2a (1:300), and collagen I (1:500). Samples were rinsed twice in phosphate
buffered solution (PBS) and incubated for 2h at room temperature with secondary
antibodies (1:500) (Table 1). To detect GHSR, we used the far-red ghrelin peptide analog,
Ghrelin(1-18, Lys18(Cy5), as we have previously done to quantify GHSR in situ4. This
analog binds with high specificity to GHSR in mouse cardiac tissue samples6. Following
incubation with secondary antibodies, this fluorescent peptide analog was added to tissue
sections for 30 min. Sections were washed with PBS, incubated 8 min with DAPI nuclear
stain (1:1000), and mounted with ProLong Gold antifade (Life Technologies) to prevent
the tissues from photobleaching. Images were captured with a Nikon Eclipse TE2000-S
fluorescent microscope. Five random fields of view were acquired for each of 4 tissue
sections at 20X magnification (Nikon NIS Elements v. BR 4.50.00) and used for further
image analysis. Higher-resolution images were captured using a Nikon A1R confocal
microscope at 60x magnification.
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Table 2.3 Antibody Table – Information on Antibodies Used.

Antigen

Catalog #

Dilution

Host

Reference #

Ghrelin

sc-10359

1:100

Goat

13

Serca2A

ab3625

1:300

Rabbit

14

pERK1/2

sc-377400

1:250

Mouse

15

BNP

ab19645

1:1000

Rabbit

16

Collagen I

ab34710

1:500

Rabbit

17

DAPI

62247

1:1000

-

18

Alexafluor 488

A11055

1:500

Donkey anti-goat

19

Alexafluor 594

A21207

1:500

Donkey anti-rabbit

20

Alexafluor 594

A21203

1:500

Donkey anti-mouse

21

Alexafluor 488

A21206

1:500

Donkey anti-rabbit

22
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2.2.3

Fibrosis Imaging

In order to assess fibrosis, heart tissue sections were stained with Masson’s Trichrome stain
by the core Pathology laboratory at LHSC. Sections were acquired using bright field
microscopy at 10X, 20X or 40X magnifications with a Zeiss Axioskop EL-Einsatz
microscope and Northern Eclipse software. Fluorescence microscopy was also used to
acquire collagen I images as described above.

2.2.4

Data Analysis

Images of GHSR, ghrelin, BNP, SERCA2a and pERK were analyzed with FIJI v. 1.49v, a
distribution of ImageJ software (National Institutes of Health, Bethesda). Fluorescence
intensities of each section were quantified using a custom FIJI script that integrates raw
density images that represent protein expression levels, as we have previously
reported4,6,12,23,24. Briefly, thresholding was conducted for each image to determine the
fluorescence intensity (positive pixel count above threshold minus the background).
Fibrosis was analyzed using an online script which quantified the percentage of fibrotic
tissue in each sample by distinguishing fibrotic tissue from non-fibrotic tissue25. Statistical
analyses were performed using GraphPad Prism version 7.02 or IBM SPSS statistics 25,
as follows: unpaired student t test, a one-way ANOVA with analysis of variance using
Tukey post-hoc test to compare differences between diseased hearts and biopsies of the
grafted hearts; Pearson correlation and logistic linear regression for correlations between
markers: and Spearman bivariate correlation for relationships between LVEF and the
following markers: GHSR, ghrelin, BNP, pERK1/2 and SERCA2a, all with significance
set at p<0.05.
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2.3 Results
2.3.1

Cardiac Transplant Patient Cohort

Six of the 10 patients who underwent cardiac transplantation were male, with an overall
mean age of 54 years (Table 2.1). Five had significant coronary artery disease pretransplant, and none had diabetes. All patients had elevated pulmonary artery pressures
pre-transplant, along with severely reduced left ventricular ejection fraction (LVEF <30%)
by echocardiographic assessment. Serial echocardiographic assessment of LV function
following cardiac transplant showed LV improvement to an LVEF > 50% in 8 of patients
by 1 month PTx. By 6 months PTx, all patients had normal LV function (Table 2.1).
Although most patients were receiving HF medications, i.e., angiotensin converting
enzyme (ACE) inhibitors/beta blockers/diuretics, prior to transplantation, only a small
number continued to receive these medications following surgery. Table 2.2 contains a
complete listing of medications pre- and post-Tx.

2.3.2

GHSR and Ghrelin Expression in Cardiomyocytes

In any given cardiac transplant patient, the expression of GHSR and ghrelin in both LV
and RA appeared to be elevated in the explanted heart in comparison to their expression
PTx in the grafted heart tissue biopsies over time (Figure 2.1 A-C). By logistic regression
analysis of all patient specimens, both pre-and post-transplant, the level of GHSR
expression demonstrated a strong and highly significant positive linear regression with the
level of ghrelin expression (r = 0.7817, p<0.0001). To examine associations of ghrelin and
GHSR with cardiac dysfunction, data were divided into 2 groups of LVEF < 30% (pretransplant) and LVEF > 50% (post-transplant), as there were no mid-range values of LVEF.
In the pre-transplant hearts with LVEF < 30%, expression of GHSR and ghrelin clustered
towards the higher end of the regression line, while in grafted heart biopsies at 1 and 6
months (LVEF > 50%), expression of GHSR and ghrelin clustered towards the lower end
of the regression line (Figure 2.1 D). To more closely examine correlations between
ghrelin-GHSR and cardiac dysfunction, we used a Spearman bivariate correlation test, and
showed significant negative correlations between GHSR and LVEF (p=0.018) and ghrelin
and LVEF (p=0.004) (Figure 2.1 E).
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Figure 2.1 Ghrelin and GHSR expression in patients pre- and post- cardiac
transplant.
A) Representative fluorescent images of GHSR (red), ghrelin (green), and DAPI (white)
are shown in explanted heart tissue (left) and grafted heart biopsies (right) taken from the
same patient. B) and C) Quantified fluorescence intensity of GHSR (red) and ghrelin
(green) is shown from explanted heart tissue (LV and RA, black dots) and grafted heart
biopsies (Bi 1-10, coloured dots). D) Positive linear regression of GHSR and ghrelin
expression is shown in the entire cardiac transplant cohort with EF <30 in green and EF>50
in red with white dots representing tissue samples without related EF values. Each dot
represents one transplant patient sample. E) Negative correlation between LVEF and
GHSR (red) and ghrelin (green). LV: Left Ventricle; RA: Right atrium; Bi 1 – Bi 10:
Biopsy 1 – Biopsy 10; EF: ejection fraction.
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2.3.3

Metabolic Markers in Cardiac Tissue

The expression of metabolic markers in cardiac tissue that are associated with cardiac
dysfunction were measured by immunofluorescence microscopy. We measured the
following markers: a) SERCA2a, as an index of cardiomyocyte contractility, b) pERK1/2,
as a marker of cardiomyocyte growth/hypertrophy, and c) BNP, as a validated clinical tool
used to determine the presence and degree of HF. Representative images of SERCA2a,
pERK1/2 and BNP expression are shown in Figures 2.2A and 2.3A, respectively. The
expression of SERCA2a was significantly elevated in cardiac tissue from the RA of the
diseased heart (Figure 2.2 B) when compared to its expression in endomyocardial biopsies
taken at weeks 1, 2, and 3 PTx by 3.2, 2.4, and 2.7 fold, respectively. However, there was
no significant difference in SERCA2a expression in the RA after the first month PTx. There
were also no significant differences in the expression of SERCA2a in the LV tissue of the
diseased heart when compared to the PTx endomyocardial biopsies. pERK1/2 expression
was significantly increased in the cardiac tissue of the diseased heart taken from the RA by
1.8-3.1-fold and LV by 1.7-2.9-fold when compared to the grafted heart tissue biopsies
taken at any time-point PTx (Figure 2.2 C). The degree of BNP expression (Figure 2.3B)
showed similar trends as for GHSR and ghrelin. Logistic regression analyses were
performed to determine the association between SERCA2a, pERK1/2, GHSR and ghrelin
levels (Figure 2.2D-H). Highly significant and strong positive linear regressions were
found between pERK1/2 and SERCA2a (r = 0.6867, p<0.0001), pERK1/2 and ghrelin (r =
0.5719, p<0.0001), and SERCA2a and ghrelin (r = 0.7171, p<0.0001). By contrast, there
was a much weaker linear regressions between SERCA2a and GHSR (r = 0.2320,
p=0.0483), and there was no linear regression between pERK1/2 with GHSR. Logistic
regression analyses were performed between all metabolic markers and BNP to determine
any possible relationships (Figure 2.3 C-F). There was a positive linear regression between
ghrelin and BNP (r = 0.6782, p<0.0001), and SERCA2a and BNP (r = 0.4838, p<0.0001).
However, there were weak linear regressions between GHSR and BNP (r = 0.2423,
p=0.0282), and pERK1/2 and BNP (r = 0.2745, p=0.0196). Spearman bivariate correlations
(correlation coefficients, CorC) were calculated as above and indicated highly significant
negative associations between LVEF and SERCA2a (p<0.001, CorC = -0.63), and pERK
(p < 0.001, CorC = -0.814), and between LVEF and BNP (p < 0.001, CorC = -0.773).
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Figure 2.2 Cardiac metabolic markers in patients pre- and post-cardiac transplant in
entire transplant patient cohort.
A) Representative fluorescent images of pERK1/2 (green) and SERCA2a (red) are shown
from explanted heart tissue (left) and grafted heart biopsies (right) samples taken from the
same patient. B and C) Quantified fluorescence intensity of pERK1/2 (green) and
SERCA2a (red) are shown for explanted heart tissue (LV and RA, black dots) and grafted
heart biopsies (Bi 1-10, coloured dots). D-H) Positive linear regression is seen in the entire
cardiac transplant cohort for pERK1/2 vs SERCA2a, pERK1/2 vs ghrelin, SERCA2a vs
ghrelin, pERK1/2 vs GHSR, and SERCA2a vs GHSR. Each dot represents one transplant
patient sample. LV: Left Ventricle; RA: Right atrium; Bi 1 – Bi 10: Biopsy 1 – Biopsy 10.
*p<0.05 from RA; ** p<0.01 from RA; *** p<0.001 from RA; **** p<0.0001 from RA;
# p<0.05 from LV; ## p<0.01 from LV.
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Figure 2.3 BNP expression in patients pre- and post-cardiac transplant.
A) Representative fluorescent images of BNP are shown from explanted heart tissue (left)
and grafted heart biopsies (right) taken from the same patient. B) Quantified fluorescence
intensity of BNP is shown in explanted heart tissue (LV and RA, black dots) and grafted
heart biopsies (Bi 1-10, coloured dots). C-F) Positive linear regression is shown in the
entire cardiac transplant cohort for ghrelin vs BNP, BNP vs GHSR, pERK1/2 vs BNP, and
SERCA2a vs BNP. Each dot represents one transplant patient sample. LV: Left Ventricle;
RA: Right atrium; Bi 1 – Bi 10: Biopsy 1 – Biopsy 10.
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2.3.4

Cardiac Fibrosis

Cardiac fibrosis was determined in all patient samples using Masson’s trichrome stain
which measured the presence of collagen I and III (in blue) and compared that to the nonfibrotic tissue (in red). Quantification of fibrosis is illustrated in Figure 2.4 A, and revealed
a high degree of variability both between and within patients from one time point to another
(Table 2.4). Representative images showing the high degree of variability between patients
taken from a single time-point are shown in Figure 2.4 B where significant fibrosis was
seen in one patient with large amounts of collagen I and II (blue) and minimal fibrosis was
seen in another patient at the same time-point To determine whether GHSR tissue levels
were contributed to by fibrosis, cardiac tissue was examined for colocalization between
collagen I and GHSR by fluorescence microscopy (Figure 2.5 A and B). These analyses
showed no colocalization between collagen I and GHSR in the human tissue samples
(Figure 2.5C and D).
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Figure 2.4 Cardiac fibrosis in patients pre- and post-cardiac transplant.
A) Quantified fibrotic data are shown for explanted heart tissue (LV and RA, black dots)
and grafted heart biopsies (Bi 1-10, coloured dots). B) Representative images of the fibrotic
variability between patients showing high levels of fibrosis (top) and low levels of fibrosis
(bottom) where blue is fibrotic tissue (collagen I and III) and red is healthy cardiac tissue.
Images of the RA, Bi 1, Bi 4, Bi 10 showing different patients at same time point pre- and
post-cardiac transplant. LV: Left Ventricle; RA: Right atrium; Bi 1 – Bi 10: Biopsy 1 –
Biopsy 10.
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Figure 2.5 Fibrosis and GHSR in human myocardial tissue.
Representative images from grafted heart biopsy 1 showing the same patient sample in all
images. A and B show no colocalization of GHSR (red) and collagen I (green) with DAPI
showing nuclei (blue). C and D show Masson’s trichrome staining of same patient sample
as in A and B where blue is fibrotic tissue (collagen I and III) and red is healthy tissue. A
and C show 10X magnification where B and D show 20X magnification.
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Table 2.4 Fibrosis Percentages of explanted hearts and healthy implanted heart
biopsies.
(RA and LV of explanted heart; Biopsy 1-10 of grafted heart). All values listed in
percentages (%).

LV

RA

Bi 1

Bi 2

Bi 3

Bi 4

Bi 5

Bi 6

Bi 7

Bi 8

Bi 9

Bi 10

Patient 1

26.1

10.6

1.3

2.9

5.4

1.5

15.8

2.2

1.3

-

-

-

Patient 2

24.6

6.0

19.1

3.8

3.8

5.7

-

-

-

-

-

-

Patient 3

-

7.0

3.9

11.4

22.2

0.9

-

-

-

3.6

2.2

-

Patient 4

2.6

32.5

1.2

0.3

-

3.9

4.6

-

-

13.1

-

-

Patient 5

53.6

-

2.4

7.3

3.9

1.3

-

-

-

-

-

-

Patient 6

3.7

7.8

2.4

38.0

1.3

-

-

-

4.1

5.9

2.3

11.7

Patient 7

5.5

-

39.4

2.9

2.7

3.1

17.4

3.5

1.8

6.1

6.4

0.3

Patient 8

7.6

1.6

10.7

1.1

6.9

3.6

0.9

1.3

2.8

0.3

6.6

3.6

Patient 9

-

21.9

8.9

6.1

3.5

-

1.2

2.3

-

17.3

-

-

Patient 10

11.5

11.9

3.8

8.3

13.8

0.9

30.9

2.2

3.2

-

-

-
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2.4 Discussion
This study is the first comprehensive and longitudinal study to examine tissue GHSR,
ghrelin and subsequent downstream biochemical signaling molecules involved in
cardiomyocyte contractility and growth, over time, in the same patients with two different
hearts. Our findings have demonstrated a relationship between cardiac function, as
measured by LVEF, and the expression of both ghrelin and GHSR, suggesting that the
cardiac ghrelin-GHSR system may represent a new cardiac-localized biomarker in HF. Our
findings further showed an association between some signaling proteins and their
relationship to LVEF. Our results demonstrate relationships between GHSR, ghrelin, and
biochemical signaling molecules in human cardiac tissues and their relationship to LV
function, therefore providing substantial new findings related to this myocardial ghrelinGHSR system.
Currently the “gold standard” cardiac biomarkers of heart failure are BNP and NT-proBNP,
which are markers of myocardial stress. Historically, past studies using BNP have focused
on characterizing HF with reduced EF as associated with and directly linked to elevated
circulating BNP levels11,26. More recent studies have also attempted to understand the
mechanisms leading to HF in the setting of preserved EF. To explore this and other
etiologies of HF, a variety of biomarkers including hormones (growth hormone)27,28,
extracellular matrix proteins (matrix metalloproteinase, galectin-3); oxidative stress
proteins (8-hydroxy-2,-deoxyguanosine, neopterin); and inflammatory molecules (creactive protein, pentraxin 3)29 have been identified and their association with the presence
and degree of heart failure investigated. Further, circulating biomarkers of HF continue to
be discovered through proteomic and gene sequencing of blood serum analyses30–32. Many
novel serum biomarkers are currently being identified33,34, and the ghrelin-GHSR system
may provide a complementary cardiac tissue-localized indicator of LV function in HF.
Certainly, biomarkers that are intimately involved in the different pathological processes
in HF would help to both enhance diagnosis and might have the potential to optimize
targeted therapies29,35. We propose that the ghrelin-GHSR system represents the first
cardiac-localized indicator of HF.
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A prior study has also shown that levels of myocardial GHSR are elevated in chronic heart
failure in humans8. In contrast to our findings, where both GHSR and ghrelin were
elevated, that study also reported a decrease in ghrelin expression in chronic heart failure.
The difference in the degree of ghrelin expression between these two studies may be due
to the different tissues being compared. Beiras-Fernandez et al8 compared tissue obtained
from HF patients to those obtained from young adult subjects with no previous history of
heart disease. In contrast, our study compared levels of GHSR and ghrelin at end stage HF
with serial biopsies from the engrafted heart under the effects of immunosuppressive
therapy taken up to a year after transplant surgery. Furthermore, there were significant
relationships between LVEF and tissue ghrelin and GHSR levels in two hearts from the
same patient. Similar to Beiras-Fernandez et al, our sample size is relatively small, and
may provide challenges in making broad generalizations on increases or decreases in the
cardiac ghrelin-GHSR system. Now that we have established that higher levels of GHSR
and ghrelin associate with LVEF in the very low range, these results set the stage for a
larger study examining changes in cardiac GHSR and ghrelin in patients with a range of
LVEF values that reflect the evolution of heart failure.
Strong positive linear regressions between GHSR and ghrelin were present in the entire
patient cohort as shown in Fig 2.1D indicating the potential regulation of this ghrelinGHSR system in human HF. Additionally, we examined linear regressions between GHSR
and ghrelin in both the end-stage HF and engrafted heart biopsies separately (Supplemental
Fig 2.S1) where there are still highly significant positive linear regressions in both these
individual cohorts. This may provide information about the engrafted heart as this ghrelinGHSR system is still increased up to 1 year after cardiac transplantation. Other cardiac
markers, such as BNP, are known to be chronically elevated after transplantation which
demonstrates ongoing active cardiac structural remodeling, vascular injury, and
inflammation in the engrafted heart36. The correlation of the ghrelin-GHSR system in
engrafted heart biopsies may provide more information on the biochemical processes that
are activated in the engrafted heart after cardiac transplantation.
Ghrelin is produced in a variety of cardiovascular cell types, including endothelial cells,
inflammatory cells and cardiomyocytes37. Ghrelin down-regulates pro-inflammatory and
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up-regulates anti-inflammatory signalling pathways in attenuating cardiac hypertrophy38,
post-infarct cardiac remodeling39, and sepsis40. Although we did not study inflammatory
signalling pathways, it is possible that the higher levels of ghrelin-GHSR in the diseased
heart may indicate up-regulation in response to the inflammatory environment of heart
failure. The post-transplant immunosuppressive regimen may also affect myocardial
ghrelin levels and ghrelin-GHSR signalling, particularly through anti-inflammatory
pathways.
Circulating ghrelin may also be a potential single biomarker of HF, and from a prognostic
perspective, a level of 85 pmol/l or higher was predictive of increased survival 41. However,
circulating ghrelin levels are also elevated in the fasting state, and are decreased in both
the elderly population and with patients who have a higher BMI42, therefore skewing this
prognostic cut-off level. While we did not obtain blood samples for measurement of
circulating ghrelin, our data in cardiac tissue samples provide the first direct measure of
the ghrelin-GHSR system being elevated in the human myocardium. These data further
strengthen the case for the use of ghrelin-GHSR as a novel cardiac-localized biomarker of
HF. However, how tissue levels of ghrelin-GHSR change with age or BMI in humans is
not known.
As mentioned above, circulating BNP and NT-pro BNP are the currently used clinical
biomarkers of HF, as levels rise with decreasing LVEF43–45. Our results indicate that levels
of BNP in human cardiac tissue trend towards an increase when LVEF is in the very low
range and was more strongly correlated with LVEF than was ghrelin, suggesting that tissue
levels of BNP could also be a sensitive biomarker for severe HF. Interestingly, in our study,
levels of both GHSR and ghrelin were also associated with LVEF, indicating that the
ghrelin-GHSR system may also be a good cardiac biomarker of LV function. As discussed
below, ghrelin showed stronger correlations with biochemical signalling molecules,
indicating that tissue ghrelin is more closely associated than is BNP with the biochemical
mechanisms that underlie the development of HF.
To better understand the potential mechanisms underlying HF, we examined the
downstream signaling pathways that link the ghrelin-GHSR system to cardiomyocyte
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contractility and growth. The significant elevation of pERK1/2 levels we observed in endstage HF is consistent with the reported elevations in pERK1/2 in cardiac tissue in mouse
and rat models of HF46. Signalling through pERK1/2 is associated with pressure overloadinduced myocardial hypertrophy, and thus indicates maladaptive alterations under
conditions of persistent myocardial stress. Interestingly, ghrelin and GHSR gene variants
are also associated with LV hypertrophy47,48. Therefore, our data suggest a new upregulated
ghrelin-GHSR-pERK1/2 pathway that may mediate HF in humans through myocardial
hypertrophy.
The strong positive correlation between ghrelin and SERCA2A is in accordance with the
role of ghrelin in the improvement of Ca2+ dynamics in cardiomyocytes isolated from
rodents with ischemia-reperfusion myocardial injury49. In this study, activation of GHSR
by either ghrelin or hexarelin increased SERCA2a expression and activity through
increased phosphorylation of its regulatory binding protein, phospholamban, thus
replenishing Ca2+ stores in the sarcoplasmic reticulum. However, our results indicating that
SERCA2a levels are actually elevated in end-stage HF are in sharp contrast to the literature
documenting a decrease in SERCA2a expression and activity in the failing human
myocardium50. In contrast to the literature, we compared SERCA2a expression between
end-stage heart disease and engrafted hearts, and not to healthy controls. The relative
decrease in SERCA2a expression in biopsies taken at earlier time points may reflect a
subclinical immune response, as a recent study has suggested that decreases in tissue
SERCA2a correlate with graft rejection51.
Cardiac fibrosis due to a deposition of extracellular matrix proteins including fibroblasts
and collagen, occurs in all etiologies of heart disease and heart failure and is a marker of
increased heart failure severity52,53. Our results indicate increased collagen I and III
deposition in the diseased hearts, although there was significant variability both between
and within patients. The variability could be a consequence of sampling location; a high
presence of fibrosis in the apparently healthy implanted hearts likely indicates a
considerable degree of geographic heterogeneity within any given patient’s heart.
Traditionally biopsies are acquired from the RV, as what was done here, although a recent
study found LV biopsies to be not only possible with low risk via radial access, but
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preferable for determination of heart function through immunohistochemistry and
molecular analyses54. In our study, values of RV used a surrogate measure of LV
dysfunction as RV failure is commonly associated with LV dysfunction and these biopsies
were collected with preserved LV function (seen with preserved LVEF). Since there was
such a large degree of variability in the amount of fibrotic tissue in both pre-transplant
hearts and grafted heart tissue, there was a possibility that GHSR expression originated
within the fibrotic tissue, thus potentially skewing our results. However, we have shown
that GHSR was found only in non-fibrotic tissue; therefore, the variability in expression
likely lies in HF type and severity, and not in sampling location. Since the diseased heart
tends to have larger amounts of collagen deposition, the positive fluorescent signal is only
originating from a limited, non-fibrotic component of the whole tissue section. Therefore,
the measurement of GHSR which we used was affected by the extent of collagen deposition
within any given sample, with samples with higher degrees of fibrosis having an artificially
depressed measurement of “myocardial” levels.
The present study characterized changes in myocardial GHSR and ghrelin before and after
cardiac transplantation. The engrafted hearts were subjected to immunosuppressive
therapy, and we did not measure the degree of inflammation or subclinical indicators of
rejection in these biopsies. However, that four of these patients were followed up to a year
after transplant, with normal EFs, and no dramatic changes in GHSR, ghrelin, SERCA2a,
pERK1/2 and fibrosis from the first through to the last biopsy, suggests a normally
functioning and stable engrafted heart during this time period. Our next step is to
characterize the ghrelin-GHSR system in cardiac tissue obtained from human donors with
no history of heart disease.
Overall, we have identified the ghrelin-GHSR system as a cardiac-localized biomarker of
cardiac dysfunction in human heart failure. This system was demonstrated to have a higher
sensitivity to the downstream signaling molecules linked to cardiomyocyte contractility
and hypertrophy when compared to BNP, the gold standard biomarker of HF used
clinically. Cardiac fibrosis was highly variable both within and between patients and GHSR
was not expressed in fibrotic tissue. We are currently examining the expression and
relationship of ghrelin-GHSR signaling that contribute to defective cardiomyocyte
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programming in other types of heart disease in humans, as well as in healthy human hearts.
Our ongoing work will help to identify the role of myocardial ghrelin-GHSR as a
biomarker that may be used to determine the progression of HF at earlier stages.

2.5 Supplemental Figures

Supplemental Figure 2.S1 Ghrelin and GHSR Correlation in End-Stage HF and
Engrafted Heart Biopsies.
Positive linear regression of GHSR and ghrelin expression is shown separated out into
end-stage HF and in engrafted heart biopsies where string significance of p=0.0001 is
seen in both these cohorts. Each dot represents individual patient values.
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3.1 Introduction
Ghrelin is a peptide hormone that has well-known orexigenic effects on the body. Ghrelin
is an endogenous 28 amino acid peptide that is a natural ligand of the growth hormone
secretagogue receptor (GHSR) 1a, a seven transmembrane G-protein coupled receptor.
More recently, ghrelin has been studied for its effects and role in cardiac energetics through
activation of myocardial GHSR. Specifically within cardiomyocytes, the binding of ghrelin
to GHSR activates downstream signalling pathways that lead to cardioprotective effects,
such as maintenance of contractility1,2, suppression of inflammation3,4, and promotion of
growth and survival5. Cardiac GHSR activation promotes excitation-contraction coupling,
increasing Ca2+ flux through the sarcoplasmic reticulum ATPase pump (SERCA2a) and
the voltage gated Ca2+ channels, which produces a positive inotropic effect and protects
against ischemia/reperfusion injury in cardiomyocytes2. Ghrelin also regulates
inflammation in the heart through the protein kinase B (Akt) pathway, decreasing
expression of the pro-inflammatory markers6 IL1-β, TNF-α, and IL-6, and upregulating the
tumour necrosis factor α/ nuclear factor kappa-light-chain-enhancer of activated B cells
(NFκB) pathways3. Ghrelin has been shown to protect the heart through the toll like
receptor 4 pathway (TLR4)4. Apoptosis is decreased upon GHSR activation through
extracellular signal-related kinases 1/2 (ERK1/2) and Akt serine kinases5,6 and inhibition
of caspase-3 and 97. Fibrosis deposition is also minimized in the heart after ghrelin
administration8,9. Therefore, the ghrelin-GHSR system within the myocardium plays a
critical role in the maintenance of cardiomyocyte function and survival.
The discovery of the myocardial ghrelin-GHSR system and its role in cardiomyocyte
function and health has prompted studies on its dynamics in heart failure and
cardiomyopathy. We and others have shown that myocardial GHSR is elevated in heart
failure (HF)10,11. Additionally, we showed that the cardiac ghrelin-GHSR system was
abnormally up-regulated in end-stage HF compared to endomyocardial biopsies from
engrafted hearts11, thus suggesting that tissue levels of ghrelin and GSHR could be
indicators of the health of transplanted hearts. In contrast, one study has reported decreased
GHSR in tissue from patients with dilated cardiomyopathy, which negatively correlated
with LVEF12. We13 and others14 have shown that tissue GHSR also decreased in mouse

106

models of diabetic cardiomyopathy, suggesting that the dynamics of the myocardial
ghrelin-GHSR system may differ in earlier stages of myocardial decompensation as
compared with end-stage heart failure.
Some potential causes of heart failure include coronary artery disease (an accumulation of
cholesterol (plaques) in the vessel walls) or aortic stenosis (progressive restriction of the
opening of the aortic valve)15, and there has been some clinical

investigation into

correlations with serum ghrelin levels and the effects of ghrelin administration on heart
function in these conditions. In humans with coronary artery disease and with diabetesassociated coronary atherosclerosis, serum levels of ghrelin decreased significantly
compared to healthy controls16,17. Another study also showed an inverse relationship
between serum ghrelin and coronary artery disease (CAD) detected by angiography that
was independent of other cardiovascular risk factors16, suggesting that a reduction in
ghrelin-GHSR signalling may be correlated with progressively more severe CAD. Ghrelin
administration in rats with aortic stenosis reduced calcification buildup in the myocardium
in a dose-dependent manner18, and attenuated aortic calcium deposition both in vivo and in
vitro19. Therefore, investigating the dynamics of the ghrelin-GHSR system and signaling
within cardiomyocytes may provide further insight into the potential use of ghrelin as a
therapy for myocardial dysfunction (heart failure).
In this study, towards the goal of determining the potential of ghrelin-GHSR as a biomarker
of heart disease, we examined their levels in a cohort of patients who underwent elective
cardiac valve replacement surgery and compared their expression levels to control heart
tissues. We also determined the correlation of ghrelin-GHSR with an array of biomarkers
including natriuretic peptide type-B (BNP), sarcoplasmic reticulum ATPase (SERCA2a),
and toll-like receptor 4 (TLR4). With these data, we hope to obtain further insights into the
distinct molecular signalling patterns associated with the progression of heart disease.
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3.2 Methods
3.2.1

Patient Cohort

Tissue samples were harvested from 25 patients who underwent aortic valve replacement
surgery for aortic stenosis at the London Health Sciences Center (LHSC) between 2013
and 2014. Twenty-four of these patients had aortic stenosis and one had mitral valve
impairment. Of these 25 patients, 11 concurrently had coronary artery disease and received
coronary artery bypass grafts. Sixteen patients were male and nine were female, with an
overall average age of 66 years. Twenty-three patients had normal ejection fractions
(>45%) prior to surgery, and two patients had reduced ejection fractions (35-40%). The
protocol for obtaining tissue samples was approved by Western University’s Health
Sciences Research Ethics Board. Tissue samples, roughly 0.2cm to 0.5cm in length, were
collected from the left atrium (LA) and left ventricular (LV) myocardium from each
patient. The left atrial samples were obtained from the posterior left atrial wall just on the
left atrial side of the inter-atrial septum (close to the right atrium but technically the left
atrium). The left ventricular samples were taken from the posterior left ventricular wall,
just below the mitral valve. Patient demographics, cardiac function (LVEF), and
medications are shown in Tables 3.1 and 3.2. All patient samples and patient data were
kept anonymous and all biomarker analyses were completed prior to receiving clinical data.
In order to provide a reference non-diseased control, paraffin-embedded and sectioned
samples of cardiac tissue (n=10) were obtained from the tissue archives of the Department
of Pathology, London Health Sciences Centre. These tissue samples had been obtained
from the LV of patients who had died from non-cardiac causes at the time of post-mortem,
24-48 h after the patient was pronounced dead. Of these 10 patients, 5 were male and 5
were female. The average age of all ten patients was approximately 59 years. Analysis of
these tissues was compared to the analysis derived from the surgery patients for overall
marker fluorescence intensity and differences in biomarker relationships.
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Table 3.1 Cardiac Surgery Patient Demographics.

Patient Condition

Number of Males with

Number of Females with

Condition (n of 16)

Condition (n of 9)

Age range (years)

49 – 84

45 – 77

Mean age (years)

69

60

Coronary artery disease

9

2

Moderate – Severe Aortic

14

8

Hypertension

8

2

High pulmonary artery

10

7

Diabetes

2

1

LVEF <45%

2

0

LVEF >45%

14

9

Stenosis

pressure
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Table 3.2 Patient Medications Post-Heart Surgery.

Patient Medication

Number of Males with Use

Number of Females with

(n of 16)

Use (n of 9)

ACE Inhibitor

1

2

Anti-arrhythmic

1

2

Angiotensin receptor

6

1

Coumadin

4

2

Beta blocker

5

5

Calcium channel blocker

2

3

Diuretics

8

3

Statins

11

3

blocker (ARB)
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3.2.2

Quantitative Fluorescence Microscopy

Samples were fixed, frozen and embedded in optimal cutting temperature compound
(OCT), and subsequently sectioned at 6-7 μm thickness, as previously described20,21.
Immunohistochemistry using primary and fluorophore-conjugated secondary antibodies
was conducted as previously described20,21. In brief, tissue sections were incubated with
blocking buffer in 10% serum for 30 minutes at room temperature followed by incubation
with primary polyclonal or monoclonal antibodies (Table 3.3) for 1h at room temperature
in a humidified chamber. These antibodies were used to identify ghrelin (1:100) [Santa
Cruz Biotechnology], BNP (1:1000) [Abcam], SERCA2a (1:300) [Abcam], and TLR4
(1:250) [Abcam]. Samples were rinsed twice in phosphate buffered saline (PBS) and
incubated for 2h at room temperature with secondary antibodies (1:500) (Table 3.3). To
detect GHSR, we used the far-red ghrelin peptide analog, [Dpr3(n-octanoyl),Lys19(sulfoCy5)]ghrelin(1-19), referred to as Cy5-ghrelin(1-19), as we have previously done to
quantify GHSR in situ21. This analog binds with high specificity to GHSR in mouse and
human cardiac tissue samples11,13. After incubation with secondary antibodies, Cy5ghrelin(1-19) was added to tissue sections for 30 min. Sections were washed twice with
PBS, incubated 8 min with DAPI nuclear stain (1:1000), and mounted with ProLong
Diamond antifade (Life Technologies) to prevent the tissues from photobleaching. N
numbers for each biochemical marker were different due to the limited amount of tissue
available at the time of staining.
For control cardiac tissue, all sections were deparaffinized with decreasing concentrations
of alcohol solutions (95%-70%). Samples were then stained as previously stated for the
following biomarkers: ghrelin (1:100) [Santa Cruz Biotechnology], BNP (1:1000)
[Abcam], SERCA2a (1:300) [Abcam], and TLR4 (1:250) [Abcam] and GHSR (1:100)
using Cy5-ghrelin(1-19).
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Table 3.3 Antibody Table – Information on Antibodies Used.

Antigen

Catalog Number

Dilution

Host

Ghrelin

sc-10359

1:100

Goat

BNP

ab19645

1:1000

Rabbit

SERCA2a

ab3265

1:300

Rabbit

TLR4

ab22048

1:250

Mouse

DAPI

62247

1:1000

Alexa Fluor 488

A11055

1:1000

Donkey anti-goat

Alexa Fluor 594

A21207

1:1000

Donkey ant-rabbit

Alexa Fluor 488

A21206

1:1000

Donkey anti-rabbit

Alexa Fluor 594

A21203

1:1000

Donkey anti-mouse

-
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3.2.3

Background Subtraction for Fluorescence Microscopy
Imaging

To ensure specificity of the fluorescent signal for GHSR, background subtraction was
performed, as GHSR has a diffuse staining pattern. To calculate the background signal,
tissue sections were first incubated with 100µM hexarelin, a GHSR ligand22 known to
competitively displace Cy5-ghrelin(1-19)21, for 1 hour at room temperature prior to
incubation with 10µM Cy5-ghrelin(1-19) as described above. Tissues were then stained
for DAPI (1:1000), washed and mounted with ProLong Diamond antifade as described
above. For control tissue samples, background fluorescence intensity values were
calculated in 5 separate control samples, and the average value of these intensities was
subtracted from the total fluorescence intensities of GHSR in each of the 10 original tissue
samples. For diseased tissue samples, background values were calculated from 5 fields of
view in one slide from each patient, and the average value of this slide was calculated as
the background fluorescence. These values were subtracted from the total fluorescence
intensities of non-blocked tissue from that patient to obtain specific Cy5-ghrelin(1-19)
signal in the diseased tissue.

3.2.4

Image Acquisition and Analysis

High resolution images of both the diseased and control tissues were captured with a Nikon
A1R Confocal Microscope at 60x magnification using an oil immersion lens. Five random
fields of view were acquired for each of 2 tissue sections per patient sample with the
exposure time, gain and high/ow look up tables set the same for all tissue sections.
Therefore, each patient sample (reported as data points in all graphs) reflects an average of
2 technical replicates.
Images of GHSR, ghrelin, BNP, SERCA2a, and TLR4 were analyzed with FIJI 1.49v, a
distribution of ImageJ software (National Institutes of Health, Bethesda). Algorithms built
into ImageJ were used to quantify different staining patterns in the tissue. Punctate staining
patterns were quantified using the RenyiEntropy algorithm, an entropy-based approach that
distinguishes the positive punctate signals within the cells from the background. The
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integrated density represents the mean intensity of the positive signal above a certain
threshold in scaled units divided by the area in pixels. The integrated density threshold was
set such that the entropies of distributions above and below the set threshold are
maximized. Therefore, this algorithm only captured the high intensity punctate staining
patterns and did not calculate any background staining of these images. A representation
of what the algorithm identified as positive versus background is shown in Supplemental
Figure 3.S1.
For diffuse staining patterns, the Li algorithm was used to quantify the specific
fluorescence signal after background subtraction as described above. All images for diffuse
staining were quantified using the built-in ImageJ Li algorithm with the integrated density
(stated above) determined for each tissue.

3.2.5

Fibrosis Imaging

To assess fibrosis, heart tissue sections were stained with Masson’s Trichrome stain by the
core Pathology Laboratory at LHSC. Sections of both the diseased and control tissue were
acquired using bright field microscopy at 10X and 20X magnifications with a Zeiss
Axioskop EL-Einsatz microscope and Northern Eclipse software as described
previously11,13. Images were acquired for the entire tissue section and quantification was
performed on the entire tissue.
Fibrosis was analyzed using an online script in the program ImageJ Fiji which quantified
the percentage of fibrotic tissue in each sample by distinguishing fibrotic tissue (blue) from
non-fibrotic tissue (red), as previously described23. Briefly, this script divides the RBG
image into each of its channels which thresholds the image for positive pixels in either the
red or blue channels. All tissue sections were set at the same threshold for both the fibrotic
and non-fibrotic tissue. The fibrosis was then quantified based on the fibrotic tissue
compared to the total area of tissue to determine the average percentage of fibrosis in each
of the diseased or control tissue samples.
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3.2.6

Data Analysis

Data from biomarkers (GHSR, ghrelin, BNP, SERCA2a, and TLR4) were disaggregated
by cardiac region using a post-hoc analysis. Statistical analyses were performed using
GraphPad Prism version 8. Unpaired student t-tests were used to compare overall
biomarker expression differences between the diseased and control tissue. Within the
diseased tissue cohort, a one-way analysis of variance (ANOVA) with analysis of variance
using Tukey post-hoc test was used to determine regional differences. Linear regression
was used to determine correlations between the following biomarkers: GHSR, ghrelin,
BNP, SERCA2a and TLR4. Linear regression analysis was used to compare biomarker
fluorescence intensities based on the following categories: entire patient cohort and
regional differences (left atrium and left ventricle). Pearson correlation was used to
determine colocalization between ghrelin and BNP in both diseased (LA and LV) and
control tissue. All statistical analyses were completed with significance set at p<0.05.

3.3 Results
3.3.1

Cardiac Surgery Patient Cohort

Of the twenty-five patients who underwent cardiac surgery, 16 were male and 9 were
female with mean ages of 69 and 60 respectively (Table 3.1). The patients had a range of
moderate to severe aortic stenosis while 11 also had coronary artery disease. In the patients
with coronary artery disease, there were no linear regressions between any markers
evaluated in this study (GHSR and ghrelin – r=0.3942 p=0.1826; GHSR and BNP –
r=0.0596 p=0.8467; ghrelin and BNP – r=0.1769 p=0.8850; SERCA2a and GHSR –
r=0.4132 p=0.2354; SERCA2a and ghrelin – r=0.5175 p=0.1256; SERCA2a and BNP –
r=0.4315 p=0.2131). Sixteen patients had elevated estimated pulmonary artery pressures,
based on their pre-operative echocardiograms and only two patients had a reduced ejection
fraction prior to surgery (30-40%). After cardiac surgery, 10 patients were on beta blockers,
11 were on diuretics and 14 were on statins (Table 3.2).
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3.3.2

Correlations Between GHSR and Ghrelin in Diseased
Cardiac Tissue

Fluorescence intensities of both GHSR and ghrelin were variable in any given cardiac
tissue sample in both the diseased and control cohort (Fig 3.1A & C). Overall GHSR
expression was not significantly different between the diseased and control groups (Fig
3.1B) while tissue ghrelin was significantly lower (p<0.0001) in the diseased cohort in both
the LA and the LV (Fig 3.2 D). Linear regression analysis of GHSR vs. ghrelin showed a
positive relationship in the overall cardiac surgery cohort (r = 0.3995; p=0.0318) (Fig 3.2
C). Regionally, this linear regression persisted only in the left atrium (r = 0.4859;
p=0.0299) and not in the left ventricle (r = 0.01730; p=0.7562) (Fig 3.2D). There was no
significant linear regression between GHSR and ghrelin in the control tissues (r = 0.1105;
p=0.3480) (Fig 3.2B).
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Figure 3.1 Representative confocal fluorescence images of all biomarkers.
(A) [Dpr3(n-octanoyl),Lys19(sulfo-Cy5)]ghrelin(1-19): red, (C) ghrelin: green, (E) BNP:
magenta, (G) SERCA2a: green, (I) toll-like receptor 4 [TLR4]; red) in the control tissue
left ventricle (LV; left column) and diseased tissue LV (middle column) and LVA (right
column). All images indicate DAPI nuclear stain in blue. Graphs represent quantification
of fluorescent images as means  95% CI of integrated densities for each biomarker with
each dot representing one patient sample. There were no significant differences in
fluorescence intensities of (B) Cy5-ghrelin(1-19) [control LV n=10, LV n=9, LA=20], (F)
BNP [control LV n=10, LV n=9, LA=20], (H) SERCA2a [control LV n=10, LV n=9,
LA=17] or (J) TLR4 [control LV n=10, LV n=8, LA=12]. There was a significant decrease
in the fluorescence intensities detecting (D) ghrelin (p<0.0001) [control LV n=10, LV n=9,
LA=20] in the diseased cohort compared to the control tissues.
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Figure 3.2 GHSR and ghrelin fluorescence intensity in human cardiac tissue.
(A) Representative confocal images of [Dpr3(n-octanoyl),Lys19(sulfo-Cy5)]ghrelin(1-19)
(red), and ghrelin (green) in diseased control left ventricle (LV, top), diseased LV (middle)
and diseased LA (bottom). DAPI (blue) indicates nuclear localization in cardiomyocytes.
Graphs indicate quantification of integrated densities using linear regression between Cy5ghrelin(1-19) and ghrelin. In control tissue, there was no linear regression between Cy5ghrelin(1-19) and ghrelin (p=ns) [n=10] (B). Linear regression between Cy5-ghrelin(1-19)
and ghrelin (r = 0.3995; p=0.0318) in the entire patient cohort [n=29] where each dot
represents one patient sample (C). Regional analysis showed a significant linear regression
of Cy5-ghrelin(1-19) and ghrelin in the LA (r = 0.4859; p=0.0299) [n=20] but not the LV
(p=ns) [n=9] (D). LA, Left Atrium; LV, Left Ventricle.
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3.3.3

Relationship of BNP to GHSR and Ghrelin in Diseased
Cardiac Tissue

Fluorescence images indicated the localization of BNP within the diseased and control
heart tissue (Figure 3.1E). Analysis of these images indicated no significant difference in
immunofluorescence (p=ns) in the disease cohort compared to the control tissues (Fig
3.1F). Linear regression analysis indicated a strong and significant positive relationship
between BNP and GHSR (r = 0.5633; p=0.0034); this relationship was strong within the
LA (r = 0.6751; p=0.0029) but not the LV (r = 0.0127; p=0.9784) (Fig 3.3 C – D). There
was also a significant positive relationship between BNP and ghrelin in the entire cohort (r
= 0.5008; p=0.0108). This relationship, however, differed by region: LV (r = 0.9152;
p=0.0014), LA (r = 0.394 p=0.1177) (Fig 3.3 E – F). Again, no relationship was seen
between BNP and GHSR or ghrelin in the control cardiac tissue (r = 0.2465; p=0.4923 and
r = 0.1236; p=0.7337 respectively).
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Figure 3.3 BNP correlation to ghrelin-GHSR.
Representative

fluorescent

confocal

images

of[Dpr3(n-octanoyl),Lys19(sulfo-

Cy5)]ghrelin(1-19) (red), ghrelin (green) and BNP (magenta) in human cardiac tissue in
the LA and LV (A & B). Nuclei were visualized with DAPI (blue). Graphs show linear
regression analysis of quantified integrated densities with each dot representing an
individual patient sample. There was significant linear regression of Cy5-ghrelin(1-19) vs
BNP (r = 0.5633; p=0.0034) in the entire patient cohort [n=25] (C). When data were
disaggregated by region, a significant linear regression was found in the LA (r = 0.6751;
p=0.0029) [n=17] but not the LV (p=ns) [n=8] (D). Ghrelin and BNP were correlated in
the entire patient cohort (r = 0.5008; p=0.0108) [n=25] (E). Linear regression analysis
between ghrelin and BNP indicate linear regressions in the LV (r = 0.9152; p=0.0014)
[n=17] but not the LA (p=ns) [n=9] (F). LA, Left Atrium; LV, Left Ventricle.
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3.3.4

Intracellular Colocalization of Ghrelin and BNP in
Cardiomyocytes

Ghrelin and BNP appeared to be spatially localized to the same intracellular compartment
within cardiomyocytes. In the control tissue, ghrelin and BNP appeared as larger ordered
punctate areas mainly surrounding the nucleus (Fig 3.4A) while in the diseased tissue these
colocalized areas of ghrelin and BNP were smaller and scattered more diffusely throughout
the cell, and are not focused primarily around the nucleus (Fig 3.4B – C). The Pearson
Correlation Coefficient was strong for both diseased LA (PCC=0.76) and LV (PCC=0.83)
and control (PCC=0.86) while there was a significantly higher correlation in the control
tissues compared to the LA (p=0.00169) diseased tissue but not LV (p=0.2923) (Fig 3.4D).
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Figure 3.4 Intracellular colocalization of ghrelin and BNP in control LV.
(A) and diseased tissue LV (B) and LA (C). (A-C) Representative confocal fluorescent
images of ghrelin (green) and BNP (red) in healthy and diseased tissue shows linear
regression of ghrelin and BNP in the merged images. DAPI (blue) indicates nuclear
staining. White arrows indicate areas of punctate staining and colocalization in the merged
images. (D) Pearson Coefficient Correlation (PCC) values indicate a stronger correlation
in the healthy tissue [n=10] compared to the diseased tissue in the left atrium (p=0.0040)
[n=29] but not the left ventricle (p=ns) [n=29]. Values are means ± SD.
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3.3.5

The Relationship of the Cardiac Contractility Biomarker
SERCA2a to Ghrelin and GHSR in the diseased Heart

Quantitative fluorescence microscopy was used to measure SERCA2a in the control and
diseased cohorts with representative images shown in Fig 3.1G. No differences in overall
expression were seen between the diseased and control cohorts (Fig 3.1H). Linear
regression analysis showed that SERCA2a had a positive relationship to GHSR, ghrelin
and BNP (Fig 3.5C – E) but only in the LV (r = 0.7893, p=0.0348; r = 0.7315, p=0.0392; r
= 0.8401, p=0.0180 respectively) and not the LA. Quantification of overall expression of
toll-like receptor 4 (TLR4) showed no differences between the diseased and control cohorts
(Fig 3.1J). No relationships were present in the control group between SERCA2a and any
other biomarker [GHSR (r = 0.0936; p=0.7970), ghrelin (r = 0.0089; p=0.9385), BNP (r =
0.2492; p=0.4875)].
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Figure 3.5 SERCA2a correlation to ghrelin-GHSR and BNP
(A) Representative fluorescent confocal images of Cy5-ghrelin(1-19) (red), ghrelin
(green), BNP (magenta), and SERCA2a (green) in cardiac tissue of the LA (A in top
panels) and the LV (B middle panels). DAPI (blue) nuclear stain in all images. Graphs
indicate fluorescence intensities represented by integrated densities where each dot
represents one patient sample. A significant linear regression is present in only the LV
between SERCA2a and (C) Cy5-ghrelin(1-19) (r = 0.7893; p=0.0348) [LA n=15, LV n=8],
(D) ghrelin (r = 0.7315; p=0.0392) [LA n=15, LV n=8], and (E) BNP (r = 0.8401;
p=0.0180) [LA n=14, LV n=7]. LA, Left Atrium; LV, Left Ventricle.
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3.3.6

Cardiac Fibrosis

Masson’s trichrome staining was used to determine the extent of fibrosis in all cardiac
tissue samples. There were highly variable amounts of fibrotic deposition (blue) in samples
of diseased tissue compared to the non-fibrotic tissue (red) in any given cardiac surgery
patient sample but not in the control tissue (Fig 3.6A – C). Quantification of fibrotic tissue
showed a significantly higher amount of collagen deposition in diseased tissues of the LA
(p=0.0034) but not of the LV (p=0.0509) compared to the control tissues (Fig 3.6D).

Figure 3.6 Fibrosis deposition in healthy and diseased tissue.
Representative images of fibrotic (blue) and non-fibrotic tissue (red) in control tissue LV
(A) and diseased tissues of the LV (B) and the LA (C) show variability in fibrotic
deposition in the diseased tissue while not in the control tissue. (D) Graph shows mean ±
95% CI of percentage fibrotic tissue with significantly less fibrotic deposition in the control
tissue [n=10] compared to the left atrium (p=0.0034) [n=17] but not the left ventricle (p=ns)
[n=11].
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3.4 Discussion
In this study, we used our fluorescent ghrelin analog, Cy5-ghrelin(1-19), to examine the
expression of myocardial GHSR in relation to that of ghrelin and other known markers of
downstream signaling pathways in tissue obtained from patients with valvular heart/
coronary artery disease but without reduced LVEF. We also measured these markers in
control, non-diseased, cardiac tissue. In patients with valvular heart disease (±coronary
artery disease), there were positive correlations between GHSR and ghrelin which were
regionally constrained to the left atrium. Similarly, there were regionally divergent
correlations between GHSR and BNP (the gold standard marker of HF) and ghrelin and
BNP. The positive correlations with the contractility marker SERCA2a were specific to the
left ventricle. In contrast, no correlations between GHSR and ghrelin, or any other
biochemical marker were observed in the control tissue. Additionally, we found that both
ghrelin and BNP localized to the same intracellular compartment within cardiomyocytes,
and this colocalization was slightly disrupted in the left atrium in the heart disease (HD)
cohort. Therefore, there was an emergence of region-specific patterns in the myocardial
ghrelin-GHSR signalling system in patients with valvular disease despite the absence of
measurable changes in heart function.
We have previously shown that GHSR and ghrelin are positively correlated in tissue
samples from patients with end-stage heart failure and are correlated negatively with
LVEF11. Results from other studies also indicate changes in the dynamics of the ghrelinGHSR system in end-stage heart failure10 and dilated cardiomyopathy12, suggesting this
cardioprotective ghrelin-GHSR system is abnormally up-regulated when there is injury or
stress to the heart11. Our present results also show a positive correlation between ghrelin
and GHSR in patients with heart disease, but this time in the absence of a decrease in
LVEF. As this correlation was not observed in tissue samples from the control group, we
suggest that changes in the myocardial ghrelin-GHSR system occur early in the progression
of heart disease, (in this study, in hearts subject to increased LV systolic pressures
secondary to aortic stenosis) prior to measurable changes in heart function, as defined by
the global LVEF.
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Post-hoc disaggregation of data by region showed that the positive correlation between
ghrelin and GHSR was maintained in the left atrium (LA) but not the left ventricle (LV).
Interpretation of these data is very limited as we did not collect data on the LA pressures
which are commonly elevated in valvular diseases due to stretching of the atrial wall. We
did, however, observe a very slight but significant negative correlation between GHSR in
the left atrium and LV diastolic pressure (r = 0.6887, p = 0.0402). Left ventricular diastolic
pressure is elevated in valve disease which is associated with increased LA pressure24. In
one study by Schwarz et al., in patients with aortic valve disease, there was an elevation in
end-diastolic left ventricular pressure and mean left atrial pressure along with significant
correlations with myocardial cell diameter25. Therefore, in our study of patients with aortic
stenosis, it is expected that with the increased LV diastolic pressure, left atrial pressures
are also increased. The increased LA pressures may be related to the strong correlation
between ghrelin and GHSR. The positive ghrelin-GHSR correlation in the LA but not the
LV may also represent a compensatory up-regulation under conditions of mild stress and
trauma of the LA without any measurable changes in the heart function as measured by the
LVEF. An up-regulation may be increased through GHSR signalling in the LA, which
promotes cardiomyocyte survival (through Akt and phosphorylated extracellular signalrelated kinase)5, contractility (through SERCA2a)26, and inhibits signalling through proinflammatory proteins and apoptosis6,27. More robust data will be required to establish a
concrete relationship between alterations in the ghrelin-GHSR system and onset of LA
dysfunction.
In addition to the myocardium, ghrelin and GHSR are also present in the endothelial cells
of the aorta, coronary arteries, and pulmonary arteries and veins28. Ghrelin is known to
have vasoconstrictive effects in the coronary arteries and dose-dependently increases
coronary perfusion pressure in a calcium-dependent manner thereby enhancing arteriole
contractility29. The density of GHSR is increased in the atherosclerotic coronary artery and
the saphenous vein compared to the corresponding non-diseased artery and vein30,
indicating that up-regulation of ghrelin-GHSR signalling may occur within the diseased
vasculature. In the same study, no differences in GHSR density were observed in the LA
or the LV between the ischemic heart disease or dilated cardiomyopathy to the control
tissues30. Our findings also showed no changes in myocardial GHSR as measured by Cy5-
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ghrelin(1-19), and a relatively weak correlation with ghrelin, suggesting that more dramatic
changes in GHSR may occur at the site of vascular tissue injury or dysfunction.
The secretion of both natriuretic peptide type-B (BNP) and its N-terminal form (NTproBNP), the current “gold standard” clinical heart failure (HF) biomarkers, are increased
under conditions of cardiomyocyte stress and pressure overload. Circulating BNP levels
are also increased in patients with aortic stenosis and mitral regurgitation, and can be used
as a potential indication for valve replacement in patients with normal ejection fraction31.
However, myocardial BNP mRNA does not change in patients who had aortic valve
stenosis32. In our current study in patients with valvular disease, we also did not find a
change in the tissue expression of BNP in either the LA or the LV. If tissue levels of BNP
do not change, but levels of circulating BNP increase in valvular disease, it may suggest
that the rate of post-translational processing of pro-BNP, rather than transcription or
translation, increases in cardiomyocytes.
Interestingly, we found that BNP and ghrelin correlated in the left ventricle, and
furthermore, strongly co-localized to the same intracellular compartment within ventricular
cardiomyocytes. In healthy individuals, BNP is predominantly localized in the atrium; in
heart failure, BNP appears to localize primarily in the ventricles33. In aortic stenosis, the
endocrine profile of aortic valves, which includes natriuretic peptides, their receptors and
processing enzymes, is altered 32; taken together with our results, we suggest that a regional
shift in myocardial endocrine programming may be part of the progression of heart disease
to heart failure. This regional shift may extend to other genetic programs as well; in dogs
exposed to prolonged rapid ventricular pacing, there were drastic changes in genes
expressing apoptosis, cell structure and mobility, and inflammation in the left atrium, while
genes involved in metabolism and Ca2+ signalling changed only in the left ventricle34,35.
Therefore, there are clear regional differences in the genetic programs that underlie
cardiomyocyte function in heart disease. Further studies will determine the intracellular
dynamics of ghrelin and BNP during the progression of heart disease.
We also evaluated GHSR signalling pathways involving contractility and inflammation.
We were particularly interested in correlations with SERCA2a, a common marker of
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contractility, as it has been shown to be activated through the GHSR signalling pathway,
reducing intracellular Ca2+ levels and improving LVEF after myocardial infarction2.
Additionally, we have previously found strong relationships between ghrelin and
SERCA2a in both a mouse model of cardiomyopathy13 and human heart failure11. In the
present study, we observed a positive correlation between SERCA2a and ghrelin-GHSR
only in the left ventricle, which may indicate the importance of contractility signalling in
the left ventricle, as it is the predominant chamber for contractile force. Activation of
GHSR is known to regulate calcium handling and cardiomyocyte relaxation. This positive
correlation in the LV may indicate the promotion of contractile function in the heart
through GHSR by enhancing SERCA2a function. GHSR activation causes Gαq11 to
activate the protein kinase A/calmodulin-dependent phosphokinases pathway through
phosphorylation of phospholamban (PLB) from SERCA2a on the sarcoplasmic reticulum
(SR) membrane thereby eliminating the inhibitory effect of PLB on SERCA2a uptake26.
Removal of this inhibition increases the calcium flux in the SR thereby decreasing
intracellular calcium and promoting contractility2,26. Additionally, SERCA2a and BNP
were also correlated only in the left ventricle. Through binding natriuretic peptide receptorA, BNP activates cyclic guanosine mono phosphate (cGMP) signalling, which is coupled
to L-type calcium channels and intracellular calcium levels through SERCA2a in
ventricular cardiomyocytes36. As LVEF was unchanged in most of the patients, it is likely
that alterations in the relationships between SERCA2a, ghrelin-GHSR, and BNP within
left ventricular cardiomyocytes occurs prior to any overt functional changes as detected by
echocardiography.
Toll-like receptor 4 (TLR4) is a marker of inflammation elevated in the myocardium in
end stage heart failure37,38, and ghrelin has been shown to attenuate the pro-inflammatory
effects of TLR4 in HF4,39. In this study, we did not find any significant correlations between
TLR4 and GHSR or ghrelin or other biomarkers, which may indicate the TLR4-mediated
pro-inflammatory system is not co-regulated with the ghrelin-GHSR system at this point
in valvular heart disease.
Another measure of cardiac damage is the presence of fibrosis (collagen and fibroblast
deposition) in the myocardium, which increases with HD severity40,41. Our results indicate
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a significant increase in the fibrotic deposition in only the left atrium of HD patients when
compared to the control heart tissues. The apparent lack of left ventricular fibrosis is
consistent with the preserved LVEF of this cohort42. This accumulation of fibrosis present
in the left atrium may be associated to the downstream signalling pathway changes seen in
ghrelin-GHSR in this cohort as increased fibrosis deposition is common in the heart during
the later stages of heart failure and is a sign of cardiomyocyte damage. However, these
results are a bit difficult to interpret due to the large degree of variability in fibrosis in the
patient cohort. This result is not surprising due to the heterogenous nature of fibrosis
deposition in the myocardium and the subsequent difficulty in obtaining representative
biopsy specimens43.
There are a few limitations to our study to note. Our study was conducted with a small
sample size that limited effective disaggregation of the data by region. It is important to
note that the control and diseased tissues were embedded differently (paraffin wax vs fixed
frozen respectively), although all samples were stained with the same protocols for each
marker tested. Quantification of both paraffin and frozen healthy heart tissue is shown in
Supplemental Figure 3.S2 where there was no difference in the quantification between
either tissue storage method. In addition, control LV tissue was obtained up to 1-3 days
post-mortem which could allow for potential protein degradation between time of death
and when the tissue samples were put in fixative during autopsy. Finally, we did not obtain
blood samples from the patients, which would have provided useful insight into the
relationship between myocardial and circulating levels of ghrelin and BNP.
To conclude, we have identified changes in the myocardial ghrelin-GHSR system in human
valvular heart disease as compared to control cardiac tissues. The correlation between
ghrelin and BNP and the colocalization in the myocardium of these peptides may suggest
a regional shift in myocardial endocrine programming of cardiac cells in valvular heart
disease. We have shown that the contractility marker SERCA2a was selectively correlated
in the left ventricle, potentially as a cardioprotective mechanism prior to decreased LVEF.
Our ongoing work will help to characterize GHSR-associated biochemical changes present
in early stages of heart disease.
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3.5 Supplemental Figures

Supplemental Figure 3.S1 Punctate staining with RenyiEntropy algorithm.
Top panel shows representative fluorescent staining of healthy, diseased left atrium (LA)
and diseased left ventricle (LV) tissue. Bottom panels show what the RenyiEntrophy
algorithm considers positive staining (green) and what is background staining (black) for
all types of tissues.
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Supplemental Figure 3.S2 Comparison between paraffin embedded control human
tissue and frozen healthy heart biopsy samples.
Marker comparison between GHSR (A), Ghrelin (B), and BNP (C) indicated no significant
difference in quantification between methods of tissue storage.
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Chapter 3

4

Hybrid PET-MRI for Spatio-Temporal Tracking of
Alterations in GHSR before and after Myocardial
Infarction using a Novel 18F-labelled Ghrelin Analogue
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4.1 Introduction
Detection of heart disease (HD) is limited by the current clinically used imaging modalities
and circulating cardiac biomarkers. Echocardiography is commonly used to evaluate heart
structure and function1,2 while cardiac magnetic resonance imaging (cMRI) evaluates the
heart anatomy, edema, and fibrosis deposition3. These modalities can provide information
on structural and functional changes when the disease has advanced to a level to become
clinically manifest, by which time, prevention and therapy are difficult. Circulating
biomarkers may be used as an adjunct to imaging to determine the state of cardiac distress
via a blood test. The gold standard biomarkers are natriuretic peptide type-B (BNP)4,5,
secreted from the myocardium upon pressure and volume overload in cardiac tissue, and
troponin T and I6, released into the circulation when the myocardium is damaged.
However, limitations of the use of these circulating biomarkers include normal variations
due to age, sex, and weight; their association with other comorbidities; and their short half
lives in the blood. Therefore, there is a need for the use of in vivo molecular imaging
techniques to detect HD earlier, when structural changes are not yet prominent, perhaps
even prior to clinical symptoms, using a biomarker localized and specific to the cardiac
tissue.
One particular marker of interest is the growth hormone secretagogue receptor (GHSR)
and its ligand ghrelin. Ghrelin and GHSR form an independent system in the myocardium,
and GHSR signalling is associated with cardioprotection through anti-apoptosis7, antiinflammation8,9, contractility10,11 and cell growth12. Their expression levels and associated
downstream signalling events are altered in both HD (initial or acute structural and
functional changes in cardiac output), and HF (severe function and structural damage to
the heart). Myocardial tissue expression of GHSR in patients is elevated in end stage heart
failure

13

and cardiac transplantation14. In patients with valvular disease there was a

decrease in myocardial ghrelin expression with minimal changes in GHSR expression15. In
rat myocardium after myocardial infarction (MI) the expression of GHSR increased over
time as an expected compensatory mechanism for the heart16. Therefore, GHSR may be a
potential molecular imaging target for detecting molecular changes in the HD process.
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Positron emission tomography (PET) imaging is a highly sensitive imaging modality that
can be potentially be used to image changes in GHSR in vivo. Radiolabelled PET tracers
based on the structure of ghrelin have been developed to target GHSR in tissues17. More
recently,

18

F-labelled peptidomimetic and small molecule GHSR agonists have been

developed18,19 with the overall purpose of imaging the dynamics of GHSR expression as a
clinically relevant means of detecting disease.
In this study, we characterized a new 18F-tracer targeting GHSR for its ability to evaluate
regional dynamics of GHSR over time in a canine model of moderately extensive anterior
MI. Using simultaneous multi-tracer PET/MRI, we were able to determine the relationships
between GHSR, perfusion and heart function before and after myocardial infarction. Our
18

F-tracer was found to bind sensitively and specifically in the left ventricle of the heart,

independent of perfusion tracer distributions and global cardiac function.

4.2 Methods
4.2.1

Production of 18F and Synthesis of 18F-LCE470

The [18F-]anion was produced by the PET cyclotron (St. Joseph’s Health Care London
Ontario, Canada) as a result of the 18O(p,n)18F reaction involving proton bombardment of
[18O]H2O. A Waters Sep-Pak® Accell™ PlusLight (46 mg) QMA Carbonate cartridge was
pre-activated by slowly treating with EtOH (10 ml) and Milli-Q® water (10 ml) and then
flushing with air. The radioactive [18F-] anion was then trapped by drawing up the [18O]H2O
solution containing it through the Sep-Pak.
To potassium carbonate (3.0 mg) and Kryptofix 222 (10.0 mg) was added water (200 μl)
and MeCN (800 μl) and the resulting solution used to elute the Sep-Pak® containing
[18F]fluoride into a glass vial. The mixture was dried azeotropically (120 °C). The drying
step was repeated twice more after the drop-wise addition of anhydrous MeCN (1 ml). The
precursor with tosylate (2.0 mg in 0.5 mL of MeCN) was added to the aforementioned
mixture, and the mixture was heated at 100oC for 10 min under sealed conditions. 0.5ml of
water containing 0.1% TFA as added. The radiolabelled compound LCE470 was purified
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by semi-prep HPLC using 40-80% MeCN in Water (0.1% TFA, flow rate: 4.5ml/min,
15min run, 2min wash).

Radioligand

[18F] LCE470

Radiochemical Yield (%)

42±10

Radiochemical Purity (%)
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Figure 4.1 Stacked HPLC chromatograms.
(λ = 254 nm) (bottom line) and radio chromatograms (top line) for LCE470 and [18F]
LCE470
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4.2.2

Animal Use and Surgical Preparation

All animals used in this study were treated in accordance with ethical guidelines of the
Canadian Council on Animal Care (CCAC). Animal protocol #2017-006 was approved by
the Animal Use Subcommittee at Western University for the experiments described herein.
Four bred-for-research female hounds (19-22kg) were obtained at 10-11 months of age.
Anesthesia for surgery was induced using Propofol and maintained with 1.5 – 2.0%
isoflurane. The heart was exposed through a left thoracotomy where the mid portion of the
left anterior descending coronary artery (LAD) was isolated and occluded for two hours by
a snare ligature, a type of ligature to allow for release externally, to induce a myocardial
infarction (MI). After the 2-hour occlusion, the ligature was released causing reperfusion
in the infarcted area. After MI surgery all animals were allowed to recover for 24 hours
before next imaging session and simultaneous PET/MR imaging was performed at multiple
time-points over a period of 1.5 years along with one timepoint one week prior to surgery
to establish a baseline. All dogs were administered an oral iron chelator (to reduce iron
deposition from blood and hemorrhaging in the heart) twice daily for 30 days after MI
starting on the day of surgery.

4.2.3

Positron Emission Tomography/ Magnetic Resonance
Imaging

Hounds were anesthetized as described above (induced with Propofol and maintained at
1.5 – 2.0% isoflurane) and placed onto the bed of a 3T Biograph mMR (Siemens Medical
Solutions, Erlangen, Germany). A hind leg catheter was inserted prior to imaging to allow
for injection of tracers and contrast agents. All hounds were imaged with simultaneous
PET/MRI for either 18F-LCE470 or 13N-NH3 at specified time points pre-post and surgery
(illustrated in Fig 4.2). Due to technical difficulties, not all tracers were imaged on all days.
Technical difficulties include: data corruption of either the PET or cMRI sequences, tracers
failed to generate at specific timepoints in the study, or early sacrifice for one animal at 6
months.
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Figure 4.2 PET/MR Imaging Schematic.
Injection of

13

N-NH3 tracer followed by 30 min scan and 50 min after injection the

18

F-

LCE470 tracer was injected and scanned for 60 min. Simultaneous MRI sequences
acquired include: MR attenuation correction (MRAC), TrueFISP cine images to determine
heart function and T1 images and 3D T1 weighted images to determine anatomy of the
heart. Gadolinium DTPA contrast was injected during the 18F-LCE470 scan to determine
scar location and volume.
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4.2.3.1

Imaging Perfusion with 13N-NH3

The PET-MR imaging protocol is illustrated in Figure 4.2. Hounds were imaged at the
following time points post-surgery: Day 21 (n=3), Week 16 (n=4), Month 11(n=3). A 30minute dynamic list-mode PET acquisition was initiated simultaneously with a bolus
injection of 6.5 – 7 MBq/kg of

13

N-NH3 (produced in-house at the Lawson Cyclotron

Facility). PET data was reconstructed using a 3D Ordered Subset Expectation
Maximization reconstruction (3 iterations, 21 subsets, 172 x 172 x 127 matrix size, zoom
of 2, and 4 mm Gaussian filter) in the following segments: 12 frames x 10 seconds, 2 frames
x 30 seconds, 1 frame x 60 seconds, 1 frame x 360 seconds. An MR-based attenuation
correction was used from a two-point Dixon MRI sequence that was segmented into water,
fat, lung, and air with constant attenuation coefficients for each tissue listed. PET voxel
size was 2.09 x 2.09 x 2.03mm.

4.2.3.2

Imaging GHSR with the Novel PET tracer 18F-LCE470

Fifty minutes following

13

N-NH3 imaging, hounds were imaged with

18

F-LCE470 at the

following time points: baseline (n=3), day 3 (n=4), Day 21 (n=3), Week 16 (n=4), Month
11(n=3). A 60-minute dynamic list mode PET acquisition was started simultaneously with
injection of 6.5 – 7 MBq/kg of

18

F-LCE470 in the hind leg catheter. PET data was

reconstructed using OSEM as above in the following segments for a dynamic scan: 12
frames x 10 seconds, 6 frames x 30 seconds, 5 frames x 60 seconds, 10 frames x 300
seconds. PET data was also reconstructed using the last 15 minutes to generate a static scan
for additional analysis. An MR-based attenuation correction was used as stated above. PET
voxel size was 2.09 x 2.09 x 2.03mm.

4.2.3.3

Cardiac MR Imaging

MR imaging was initiated at the beginning of the first PET scan (13N-NH3 or 18F-LCE470)
and continued throughout the full imaging session. MR sequences included short axis cine
stacks of the left ventricle synchronized to the Echo signal (true fast imaging with steady-
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state free precession (TrueFISP), slice thickness of 6 mm, 356 x 216 voxels with voxel size
of 1.09 x 1.09 mm, 10-12 second acquisition time, based in heart rate) with each slice
acquired during a breath hold where the ventilator was manually turned off for 10 seconds
to allow for image acquisition. To determine the scar formation in the left ventricle,
gadolinium diethylenetriamine penta-acetic acid (Gd-DTPA) contrast agent was injected
(44 mmol/kg, Gadovist, Bayer) as a bolus at the 30-min time point of the 18F-LCE470 scan.
A 3D T1 weighted image was used with LGE to create scar images (Echo triggered
inversion recovery sequence with respiratory gating, 256 x 200 x 112 voxels, voxel size
0.625 x 0.625 x 0.99 mm, 4-minute acquisition time, based on heart and respiratory rate).
T1 maps (Echo triggered modified Lock-Locker inversion recovery sequence, slice
thickness 6 mm, 256 x 144 voxels, voxel size 1.09 x 1.09, 12 second acquisition time,
based on heart rate) were generated in a single breath hold to acquire 2- and 4- chamber
views (Siemens Work In Progress).

4.2.3.4

TBR Analysis

Static acquisitions were used for the assessment of tracer uptake via calculation of
standardized uptake values (SUV) and tissue to blood ratios (TBR) of both

18

F-LCE470

and 13N-NH3, using the online software 3D Slicer 4.8.1 (https://www.slicer.org/). To obtain
the TBR for each tracer, the PET and gadolinium-enhanced T1 MR images were uploaded
and regions of interest (ROIs) were manually drawn onto the MR images. The regions
specified were the infarct region, the left circumflex region, remote tissue of the septal
wall, and blood pool. The 2D ROIs were then transferred to the corresponding PET slices.
The SUVs were determined where the tissue activity (MBq/ml) was divided by the injected
dose (MBq) all multiplied by the body weight (g). To determine the TBR, the SUV of each
tissue region (infarct, remote, left circumflex) were divided by the SUV of the blood pool.
TBR was automatically calculated for each hound at each time point using the following
formula:
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(1):
𝑔
)
𝑚𝑙
𝑇𝐵𝑅:
𝑔
𝑆𝑈𝑉𝑏𝑙𝑜𝑜𝑑 𝑝𝑜𝑜𝑙 ( )
𝑚𝑙
𝑆𝑈𝑉𝑡𝑖𝑠𝑠𝑢𝑒 (

4.2.3.5

Compartmental Modelling of PET Data

Compartmental modelling of both tracers was done by uploading the dynamic list mode
scan data to the online software package Carimas 2.10.0.0 (Turku Pet Center, Hospital
District of Southwest Finland, https://turkupetcentre.fi/carimas/). For

18

F-LCE470, the

reconstructed dynamic data from the left ventricle was used to segment the area of the LV
automatically (Fig 4.3). Manual corrections were made based on tissue localization in each
axis (coronal short axis, vertical long axis, horizontal long axis) and slice.

Figure 4.3 Representative images of LV segmentation.
Manual corrections were performed to delineate LV tissue, right ventricle, base and apex
of the heart to orientate the program for analysis.
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An image-derived arterial input function was extracted from the time-activity curve
measured in the blood pool of the left ventricle. This input function, along with the tissue
time-activity curves, was used to solve for the kinetics of the tracer uptake in heart tissue
using a two-compartment Logan model that accounts for free and bound components of
18

F-LCE47020, as we expect a receptor-ligand reversible interaction based on the natural

ghrelin-GHSR system present in the heart. From the Logan analysis, we calculated the
distribution volume of 8F-LCE470, and a full tracer kinetic analysis can determine the
binding potential and receptor density.
The following equation (2) illustrates the formula of Logan analysis where Ctissue represents
the pixel-wise time activity curves of the target tissue tracer concentration measured by
PET, Cplamsa is the tracer concentration in plasma, DVt is the slope of the resulting line, V
is the y-intercept or initial concentration ratio at time 0 of the graph. The distribution
volume (DV), total distribution for 18F-LCE470 in the tissue, is calculated using a 2-tissue
reversible compartmental model shown in the equation (2 – 3) where Cplasma is the
concentration is tracer in the blood plasma, Cfree is the concentration of unbound tracer in
the tissue, and Cbound is the concentration of specifically bound tracer to the receptor. The
distribution volume using the kinetic rate constants in equation 3 is represented by equation
4 where BP is the binding potential and AF is the binding affinity of the ligand.
𝑡

2)

∫0 𝐶𝑡𝑖𝑠𝑠𝑢𝑒 (𝑠)𝑑𝑠
𝐶𝑡𝑖𝑠𝑠𝑢𝑒 (𝑡)

𝑡

= 𝐷𝑉𝑡

∫0 𝐶𝑝𝑙𝑎𝑠𝑚𝑎 (𝑠) 𝑑𝑠
𝐶𝑡𝑖𝑠𝑠𝑢𝑒 (𝑡)

+𝑉

3)
𝐾

𝐾

4) 𝐷𝑉 = (𝐾1 ) (1 + 𝐾3 ) + 𝑉𝑝 ; 𝐵𝑃 =
2

4

𝐾3
𝐾4

; 𝐵𝑃 = 𝑟𝑒𝑐𝑒𝑝𝑡𝑜𝑟 𝑑𝑒𝑛𝑠𝑖𝑡𝑦 ∗ 𝐴𝐹
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The Logan analysis generates a polar map of the left ventricle partitioned into 17 individual
segments where the outer part of polar map represents the base of the heart and the center
is the apex. These segments were manually grouped into three regions: infarct, left
circumflex tissue, and remote non-infarcted tissue. The distribution volume (ml plasma/ml
tissue) was determined for each of these three regions to calculate the overall tracer
distribution in the LV. The segments assigned to each of the three regions was variable for
each dog due to differences in infarct size. Within each individual dog, grouped segments
were maintained for all timepoints to maintain consistency for all regions. Fig 4.4 shows
the 17 segmented polar maps with the three delineated regions outlined for all dogs at day
3.

148

Figure 4.4 Polar map segmentation with manual grouping of segments into 3 regions.
Left circumflex region (in light blue), infarct region (in pink), and remote tissue (all other
segments not outlined). All dogs show variability in infarct size and left circumflex tissue.
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For more precise mapping of tracer movement over time of the dynamic scan, the three
regions (infarct, remote, left circumflex, blood pool) were manually delineated using
Matlab R2020a software with custom scripts, and separate time-activity curves were
generated for the blood pool in the left ventricle and the 3 tissue regions (Supplemental Fig
4.S1).

For

13

N-NH3 the 30-minute data was segmented automatically in the left ventricle and

manual correction was performed as stated for 18F-LCE470. Compartmental modelling for
13

N-NH3 used a 1-tissue compartment model (5) as demonstrated by Degrado et al21 where

a polar map was generated and the left ventricle was segmented into 17 individual segments
as was done for 18F-LCE470. The rate of tracer movement into the tissue is defined by K1
and is represented as the flow of tracer in the heart. The equation used to generate this
compartmental model is illustrated in the following equation (6). Ctissue is the concentration
in the myocardial tissue, Cplasma is the concentration in the blood plasma, FBV is the
fractional blood volume in tissue coming from blood plasma and ⊗ is the convolution
operator.

5)

6) 𝐶𝑡𝑖𝑠𝑠𝑢𝑒 (𝑡) = (𝐹𝐵𝑉) (𝐶𝑝𝑙𝑎𝑠𝑚𝑎 (𝑡)) + (1 − 𝐹𝐵𝑉)𝐾1 𝐶𝑝𝑙𝑎𝑠𝑚𝑎 (𝑡) ⊗ 𝑒 −𝐾2 𝑡

The K1 (ml/g*min)) and K2 (min-1) values were generated for each segment and segments
were grouped into 3 regions in the left ventricle as stated above. These grouped segments
were maintained for all timepoints and for each hound to maintain consistency for all
regions amongst time.
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4.2.3.6

Correlation of 18F-LCE470 and 13N-NH3 Uptake

In order to determine the relationship between

18

F-LCE470 uptake and myocardial

perfusion, linear regressions were performed between TBRs of 18F-LCE470 and 13N-NH3
and between

18

F-LCE470 distribution volumes and K1 values of

13

N-NH3. Values from

remote and left circumflex areas were selected for analysis; values from the infarct region
were not used as tracer uptake in this area was significantly decreased and would therefore
skew the regression analysis. Data from day 21, week 16 and month 11 were selected, as
these were the time points at which both tracers were injected.

4.2.3.7

MRI Data Analysis

A commercial cardiovascular image analysis software Circle CVI42 (Circle cardiovascular
Imaging Inc, Calgary) was used to calculate the following parameters of heart function:
left ventricular ejection fraction, stroke volume, end systolic and diastolic volume, and end
systolic and diastolic mass. Short axis TrueFISP image series were uploaded and automated
segmentation for systole and diastole were generated. Manual adjustments were made
when needed to correct for LV segmentation and to select slices in the series at systole and
diastole for calculating functional parameters. Slices in the series were excluded due to
poor image quality, if the aorta or left atrium were visible, or if they were past the apex.
Based on proper segmentation of the series, all cardiac function values were calculated
automatically in the online software.

4.2.3.8

Statistical Analyses of PET and MR Imaging Data

Statistical analysis was performed with GraphPad Prism Version 8.2.0 (GraphPad
Software, San Diego, California USA, www.graphpad.com). For TBR and compartmental
modelling analysis, a repeated measures analysis of variance (ANOVA) for both

18

F-

LCE470 and 13N-NH3 were used to determine regional differences at any given time point
pre- and post- myocardial infarction. Corrections for multiple comparisons were performed
using Tukey’s post-hoc test. Statistical analysis of functional MR data was calculated using
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an ANOVA with Tukey’s post-hoc test for multiple comparisons based on each imaging
time point. All statistical analyses were completed with significance set at p<0.05. PET
and MR Images were generated using 3D Slicer software where MR and PET images were
optimized with individual window/levelling for each individual dog at each time point.

4.2.4

Tissue Harvesting and Imaging Acquisition

At 1.5 years after MI, animals were sacrificed, and tissue was obtained for histological
analysis. Immediately after sacrifice the chest was opened and the entire heart was
removed. Myocardial tissue samples (roughly 1 cm3) were collected in duplicate from areas
within the left ventricle including center of infarct, remote (non-infarcted) tissue, and the
territory served by the left circumflex artery. Tissue was immediately snap frozen in liquid
nitrogen and kept at -80°C until use. Frozen tissue blocks were embedded in optical cutting
temperature medium (OCT) and left to freeze at -80°C overnight. Tissue was cryosectioned
at 5-6 µm and adhered to positively charged microscope slides. All tissue sections were
stored at -80°C until use. Tissue sections were subsequently fixed using ice cold acetone
for 15 minutes at room temperature (RT). All tissues were then stained for GHSR using
our

custom-made

far-red

ghrelin

analogue

(cyclo

12,16)-

[Dpr3(octanoyl),Lys20(SulfoCy5)] ghrelin(1-20)22, termed Cy5-cyclo-ghrelin(1-20), at a 20
µM concentration for 1 hour at RT. We have previously used [Dpr3(noctanoyl),Lys19(sulfo-Cy5)]ghrelin(1-19) to detect GHSR in human14 and mouse cardiac
tissue23. Cy5-cyclo-ghrelin (1-20) has a greatly improved affinity towards GHSR (1.0 nM).
Samples were then stained with 4’,6-diamidino-2-phenulindole (DAPI) at a concentration
of 300 nM for 6 minutes at RT followed by mounting with ProLong Diamond Antifade
(Life Technologies) to prevent photobleaching.
High resolution images were captured with a Nikon A1R Confocal Microscope at 60x
magnification using an oil immersion lens. For each tissue location in the heart (technical
replicate of 2), five random fields of view were captured with microscope parameters
(exposure time, gain and LUT) set the same for all tissue sections.
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In addition, we evaluated regional fibrosis deposition using Masson’s Trichrome and tissue
morphology using hematoxylin and eosin (H&E). Adjacent sections were stained with
Masson’s Trichrome and H&E by the Molecular Pathology Department at Robarts
Research Institute. Images of all cardiac tissue (infarct, edge of infarct, remote, left
circumflex) were acquired using bright field microscopy at 10X, 20X and 40X
magnifications with a Zeiss Axioskope EL-Einsatz microscope and Northern Eclipse
software as described previously14,15.
Blood plasma was obtained at all time points prior to imaging to evaluate circulating levels
of ghrelin. Samples of whole blood were added to tubes containing a complete mini
protease inhibitor (Sigma Aldrich) to inhibit degradation of active circulating biomarkers.
The blood was centrifuged at 3000rpm for 10 min at 4°C to separate red blood cells from
plasma. The plasma was kept at -80°C until end of the study for analysis. Levels of canine
ghrelin (CGTMAG-98K-02 - Millipore Sigma) were measured using multiplexed
immunoassay kits according to manufacturers’ instructions (R&D Systems, Minneapolis,
MN). A Bio-Plex 200 readout system was used (Bio-Rad), which utilizes Luminex®
xMAP fluorescent bead-based technology (Luminex Corporation, Austin, TX). Levels
were automatically calculated from standard curves using Bio-Plex Manager software (v.
6.1, Bio-Rad).

4.2.4.1

Tissue Image Analysis

Images of tissue GHSR were analyzed with FIJI v. 1.49v, a distribution of ImageJ software
(National Institutes of Health). An algorithm built into ImageJ, Percentile 24, was used to
quantify regional distribution of GHSR in cardiac tissue. The value assumes the threshold
of all foreground pixels is 0.5 and therefore quantifies the integrated density of the
positively stained tissue. The integrated density represents the mean intensity of the
positive signal above the threshold in scaled units divided by the area in pixels. Therefore,
this algorithm only captured foreground images and calculated the intensity values based
on a percentile value of 0.5.
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4.2.4.2

Correlation of 18F-LCE470 Uptake and Distribution Volume
to Tissue GHSR and Plasma Ghrelin

In order to determine the sensitivity of the GHSR-targeted PET tracer

18

F-LCE470 to

GHSR tissue levels, both TBR and distribution volumes obtained at the final imaging
session (18 months) were correlated with fluorescence intensities of Cy5-cyclo-ghrelin(120). Values from all tissue regions were pooled to obtain a robust sample size.
To determine the impact of circulating ghrelin on LCE470 tracer binding in the heart,
plasma ghrelin levels were compared to LCE470 distribution volume at all time points
from baseline to 12 months post MI. Linear regression of plasma ghrelin and 18F-LCE470
distribution volume were compared based on region (infarct, remote, circumflex).

4.2.4.3

Statistical Analyses

Statistical analysis was performed with GraphPad Prism Version 8.2.0 (GraphPad
Software, San Diego, California USA, www.graphpad.com). Unpaired student t-tests and
a one-way ANOVA analyses were used to compare overall GHSR expression in tissue
based on region in the left ventricle. Correlation analyses of tissue and PET values were
performed using linear regression analysis. All statistical analyses were completed with
significance set at p<0.05.
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4.3 Results
4.3.1

18

F-LCE470 Tracer Uptake in the Left Ventricle

Standardized uptake value ratios (TBR) for 18F-LCE470 were calculated at baseline, day
3, day 21, week 16 and month 11 post-MI overall for all dogs (n=4). TBR was significantly
elevated in the left circumflex region compared to both the remote (p=0.0348) and infarct
(p=0.0003) regions over time (Fig 4.5a). TBR in the infarct region was significantly
decreased over time compared to the remote tissue (p=0.0365). Representative PET/MR
images from one dog are shown in Fig 4.5b at all time points analyzed in TBR analysis.
The PET signal in the LV at baseline shows a uniform distribution of tracer binding. After
MI, the tracer uptake decreases in the infarct area compared to the remote and circumflex
regions and this pattern is present at acute and chronic time points.
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Figure 4.5 In vivo 18F-LCE470 in canine model of myocardial infarction (n=4).
A) Tissue to Blood Ratio (TBR) for tracer 18F-LCE470 over time in the left ventricle from
baseline to 330 days post-myocardial infarction. Values calculated from static scan at 4560 min post-injection where three regions were delineated: infarct, remote non-infarcted
tissue, left circumflex tissue. For overall canine TBR values there was a significant
difference between infarct and remote regions (*p=0.0365); remote and circumflex regions
(*p=0.0348); infarct and circumflex regions (***p=0.0003). B) Representative images of
the four-chamber view of the left ventricle from one dog depicting the PET, MRI, and
fused PET/MR images for all timepoints shown in the graph above. Arrows point to the 3
regions of interest including: Infarct (blue), Remote (green), Circumflex (red). After MI
there is minimal uptake of tracer in the infarct while remote and circumflex increase. This
pattern is present at both acute and chronic time points.
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The regional dynamics of GHSR is represented by the distribution volume of 18F-LCE470
and is presented at all time points for each individual dog to show regional patterns in tracer
uptake in the LV (Fig 4.6a). Similar to the TBR analysis, 18F-LCE470 distribution volume
in the area of infarct was significantly decreased compared to the left circumflex area at
any given time point post-MI in all dogs (p<0.001). There was a slight decrease in tracer
uptake in the infarct region in dogs 2 and 4 only. One pattern that emerged in dogs 1, 2 and
3 was a significant increase (p<0.05) in

18

F-LCE470 distribution volumes in the left

circumflex region compared to the remote tissue at week 16 and month 11 post-MI, a
difference that was not present at baseline. Interestingly, this pattern was also observed in
dogs 2 and 3 at acute time point day 3. Polar maps (Fig 4.6b) were generated for a visual
representation of how the LV volume was segmented for the calculation of distribution
volume in the different regions of the left ventricle. Distribution volume in polar maps
indicated a lower uptake in the center of infarct (shown in green) while there is increased
tracer binding in the remote area (yellow to orange colour) and left circumflex tissue
increased in uptake even further (dark orange to red colours).
Dynamic

18

F-LCE470 tracer uptake over time was evaluated based on region (infarct,

remote, left circumflex area, blood pool) at all time points including baseline, day 3, day
21, week 16, and month 11 (Supplemental Fig 4.S1). Tracer uptake in the infarct slightly
decreased after Mi compared to baseline while both remote and left circumflex regions
increased in tracer uptake after MI. Tracer in the blood showed quick washout with rapid
decreased uptake.
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Figure 4.6 Compartmental modelling of

18F-LCE470

in the left ventricle of canine

hearts (n=4).
A reversible receptor-ligand interaction (Logan analysis) was used for compartmental
modelling of this novel tracer. A) The distribution volume was calculated for all dogs
shown in each graph. The left ventricle was segmented into 3 regions for each timepoint:
infarct, remote non-infarcted region, left circumflex region. [Black – Baseline; Red – Day
3; Blue – Day 21; Green – Week 16; White – Month 11] Significant differences were seen
between all regions at most timepoints, particularly between infarct and remote and infarct
and circumflex while these differences were not seen at baseline. (*p<0.05; **p<0.01;
***p<0.001; ****p<0.0001) B) Representative polar maps of the left ventricle for one dog
at all time points imaged with the 18F-LCE470 tracer. All images are scaled the same with
maximum DV of 7.45 and minimum DV 0. Images depict the binding pattern of the tracer
in the left ventricle showing the lower uptake in the apex/infarct of the heart at the center
of the map (green colour), with moderate uptake in the remote tissue (yellow - orange
colour), and increased uptake in the left circumflex area at the right middle to bottom (red).
[LCX – left circumflex tissue; Rem – remote tissue; Inf – infarct]

158

4.3.2
13

Perfusion Throughout the Left Ventricle

N-NH3 was used to determine changes in regional perfusion in the LV using TBR at day

21, week 16 and month 11 post-MI overall for all dogs (n=4) (scans at baseline and day 3
post-MI were not obtained). As expected, TBR was significantly decreased in the area of
infarct (p<0.0001) at all time points compared to the remote and left circumflex regions;
however, there were no differences in TBR between the remote and left circumflex tissue
at any time point (Fig 4.7a). Representative PET/MR images from one dog are shown in
Fig 4.7b. The PET signal in the LV after MI shows decreased tracer uptake in the infarct
area compared to the remote and circumflex regions. This pattern is present at acute and
chronic time points.
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Figure 4.7 Analysis of perfusion imaging tracer in dogs (n=4).
Due to technical difficulties perfusion imaging was only initiated at day 21. A) Tissue to
Blood Ratio (TBR) for tracer 13N-NH3 over time in the left ventricle from day 21 to 330
days post-myocardial infarction. Values calculated from static scan of 9-15 min where
three regions were delineated: infarct, remote non-infarcted tissue, left circumflex tissue.
For overall canine TBR values there was a significant difference between infarct and
remote regions (****p<0.0001); infarct and circumflex regions (****p<0.0001); but no
significant difference between remote and circumflex regions. B) Representative images
of the for-chamber view of the left ventricle from one dog depicting the PET, MRI, and
fused PET/MR images for all timepoints shown in the graph above. Regions are delineated
by coloured arrows including infarct (blue), remote tissue (green), left circumflex tissue
(red). The PET images have decreased distribution of ammonia in the infarct region
compared to the remote and circumflex regions at all time points.
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The rate of 13N-NH3 uptake (K1) into the tissue was determined at all timepoints for each
individual dog to allow for visualization of perfusion patterns (Fig 4.8a). There were
significant differences in the rate of tracer perfusion pattern between the infarct and both
the remote (p<0.05) and left circumflex (p<0.05) tissues at week 16 and month 11 in dogs
2 and 3, and at day 21 and week 16 in dog 1. There were no significant differences in K1
in dog 4. There was also no difference in K1 between the remote and left circumflex regions
at any time points in any dog. A visual representation of the regional rate of tracer perfusion
pattern in the LV is shown in polar maps representative of one dog (Fig 4.8b). These polar
maps demonstrate the 3 regions evaluated (left circumflex region, remote tissue, infarct)
where there was a decreased perfusion pattern in infarct (green to yellow) and an increased
perfusion pattern in the remote and circumflex regions (orange to red). There appeared to
be no visual differences between perfusion patterns in the remote or circumflex regions.
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Figure 4.8 Compartmental Modelling of Perfusion Tracer

13N-NH

3

in the left

ventricle of canine hearts (n=4).
A 1-Tissue compartment model was used for this tracer in the canine heart. A) The K1
values were calculated for all dogs shown in each graph. The left ventricle was segmented
into 3 regions for each timepoint: infarct, remote non-infarcted region, left circumflex
region. [Blue – Day 21; Green – Week 16; White – Month 11] Significant differences were
seen at some time points between infarct and remote and infarct and circumflex while no
differences were seen between remote and circumflex at any timepoint. (*p<0.05;
**p<0.01; ***p<0.001; ****p<0.0001) B) Representative polar maps of the left ventricle
for one dog at all time points imaged with the 13N-NH3 tracer. All images were normalized
for maximum flow (0.625) to the minimum flow (0). Images depict the rate of tracer
movement in the left ventricle showing the lower perfusion in the apex/infarct of the heart
at the center of the map (green colour), with moderate perfusion in the remote tissue
(orange - red colour), and no differences in colour perfusion of the left circumflex area
right middle to bottom (orange - red). [LCX – left circumflex tissue; Rem – remote tissue;
Inf – infarct]

162

4.3.3

18

F-LCE470 Uptake Does Not Correlate with Perfusion in
Remote or Left Circumflex Regions

To assess whether the regional flux of

18

F-LCE470 could be accounted for by perfusion

alone, linear regression analysis was applied for TBR values of both tracers (Figure 4.9A),
and to the distribution volumes of 18F-LCE470 (representing GHSR density) and adjusted
K1 values for 13N-NH3 (representing the rate of perfusion (Figure 4.9B). Linear regressions
were separated by day of scanning and were limited to the time points at which 13N-NH3
scans were acquired (Day 21, Week 16 and Month 11 post-infarct), and to the remote and
left circumflex regions. There were no significant linear regressions at any time point
between TBR values of the tracers (Fig 4.9a). There were also no significant linear
regressions between GHSR density and the rate of perfusion at any time point (Fig 4.9b).
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Figure 4.9 Correlation of 18F-LCE470 and 13N-NH3.
Data derived from the remote and left circumflex tissues from all dogs were pooled. A)
Linear regression analysis of TBR values showed no correlation at any given time point.
B) Linear regression analysis showed no correlation between tracer patterns in the remote
and circumflex areas at any time point.

4.3.4

Specificity of 18F-LCE470 Binding in Cardiac Tissue

Tissue quantification of GHSR was determined with quantitative fluorescence microscopy
using the fluorescent ghrelin analogue Cy5-cyclo-ghrelin(1-20)22. Representative images
of the infarct, remote and left circumflex regions are shown in Fig 4.10a, and quantification
of fluorescence in each region for each individual dog (n=3) is shown in Fig 4.10b. In all
dogs, Cy5 fluorescence in the left circumflex region was significantly increased compared
to the infarct region (p<0.0001). Interestingly, there was a significant increase in
fluorescence in the left circumflex region compared to the remote region in two of three
dogs (p<0.001). Tissue specificity was demonstrated through a blocking study with
hexarelin (GHSR blocking agent) shown in Fig 4.11 where blocking showed a drastic
decrease in fluorescent signal in the canine myocardial tissue.
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Figure 4.10 Tissue Characterization of GHSR in Canine Heart.
A) Representative fluorescent images of GHSR in the canine heart with the novel imaging
agent Cy5-ghrelin stapled peptide. Tissue gathered from 3 regions of the heart at sacrifice:
infarct, remote non-infarcted tissue, left circumflex tissue with red stain showing diffuse
staining of GHSR in the heart and DAPI nuclear stain in blue. B) Quantification of
fluorescent images for each dog (n=3) at end point. Significant differences seen between
infarct and remote, remote and circumflex. (***p<0.001; ****p<0.0001)
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Figure 4.11 Cy5-cyclo-ghrelin(1-20) specificity in canine tissue.
Tissue shown without blocking agent on left and with blocking agent (hexarelin) on right.
Blocked tissue showed decrease in fluorescence signal in the LCX region. LCX: left
circumflex tissue.

We then determined the sensitivity of the GHSR-targeted PET tracer 18F-LCE470 by linear
regression to Cy5-cyclo-ghrelin(1-20)22 fluorescence in the left ventricle by pooling data
from the infarct, remote and left circumflex regions (Fig 4.12). There was a significant
positive linear regression between tissue Cy5-cyclo-ghrelin(1-20) fluorescence and

18

F-

LCE470 TBR values (p=0.0070, r=0.8185). Tissue Cy5-cyclo-ghrelin(1-20) fluorescence
was also positively and significantly correlated to
0.0054, r=0.8318).

18

F-LCE470 distribution volume (p-
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Figure 4.12 Correlation of GHSR tissue analysis to 18F-LCE470 TBR and
distribution volume at end point.
A) Linear regression of tissue GHSR values and PET TBR for all dogs (n=3) at endpoint.
There was a significant linear regression between tissue and PET with r = 0.8185 and
p=0.0070. B) Tissue GHSR linear regression with 18F-LCE470 distribution volume (DV)
showing significant linear regression, r = 0.8318 and p=0.0054.
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4.3.5

Fibrotic Deposition and Circulating Ghrelin

Fibrotic deposition was determined regionally in the left ventricle using Masson’s
trichrome stain (Fig 4.13a). Qualitative images show a large amount of fibrosis (blue) in
the infarct while the remote and left circumflex areas were predominantly non-infarcted
areas (red). Hematoxylin and eosin (H&E) stain also qualitatively showed the distinct
changes in tissue morphology and type between in the infarct and both remote and left
circumflex areas. These images clearly show the extensive fibrotic deposition in the infarct.
Circulating ghrelin levels were evaluated at all time points and correlated to the LCE470
distribution volume tracer binding (Fig 4.13b). There were no significant linear regressions
in any region evaluated (infarct, remote, circumflex) where changes in circulating ghrelin
levels did not change with LCE470 tracer uptake.
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Figure 4.13 Representative qualitative images of fibrosis and hematoxylin and eosin
(H&E) are shown in each region.
A) Masson’s trichrome (MT) stained for fibrosis (blue) and non-fibrotic tissue (red) where
there were significant amounts of fibrosis in the infarct compared to the remote and
circumflex tissue regions (A top). H&E stain confirmed differences in tissue distribution
and type as seen in fibrosis (A bottom). B) Linear regression between LCE470 distribution
volume and circulating plasma ghrelin levels based on region (infarct, remote, circumflex).
There were no significant linear regressions in any region where circulating ghrelin did not
alter the binding of LCE470 regionally in the heart.
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4.3.6

Heart Function Before and After MI

Parameters of heart function were determined from the cardiac MRI sequence short axis
TrueFISP series (10-11 slices through the LV) and generates a 3D representation of the left
ventricle. The short axis TrueFISP sequences were acquired at all time points, from
baseline to 11 months post-infarct. Heart function parameters evaluated were left
ventricular ejection fraction, stroke volume, diastolic and systolic volume, and end
diastolic and end systolic mass. There were no significant differences in any measured
parameter at any given time point (Fig 4.14).

Figure 4.14 Heart Function Analysis (n=4).
Calculation of MR images of Echo triggered short axis TrueFISP image series was used to
calculate heart function parameters including left ventricular ejection fraction (LVEF) and
stroke volume. No significant differences were seen in overall heart function at any given
timepoint: baseline, day 3, day 21, week 16, or month 11.
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4.4 Discussion
In this study, we characterized a new PET tracer, 18F-labelled small molecule GHSR ligand
termed

18

F-LCE470 to examine GHSR density in the heart in vivo with simultaneous

PET/MR imaging in a canine model of MI. We used TBR to calculate tracer uptake and
quantitative PET to determine the distribution volume of 8F-LCE470, which is a measure
of GHSR in three regions of the LV: area of infarct, the territory of the left circumflex
artery, and remote myocardium, where we revealed a unique pattern of uptake of

18

F-

LCE470 in the left ventricle that persisted over time. This work is extremely novel as it
follows tracer distribution out for 18 months after MI including timepoints before and both
acutely and chronically after MI. The regional distribution of

18

F-LCE470 in the LCX

territory and remote myocardium differed from that of the perfusion tracer,

13

N-NH3,

suggesting potential specificity to binding GHSR. As well, both TBR and distribution
volume of 18F-LCE470 significantly correlated with levels of tissue GHSR as determined
by Cy5-cyclo-ghrelin(1-20)22 fluorescence in tissue obtained at the end of the study. Heart
function (global LVEF and stroke volume) as determined by cMRI did not change
significantly over the one-year period of the study, although regional changes may have
occurred but were not formally assessed in this study. Therefore, we have characterized the
specificity and sensitivity of 18F-LCE470 in detecting myocardial GHSR and shown that
regional GHSR distribution is altered after MI independently of changes in perfusion and
global LV function.
Specifically, for the entity of heart failure (HF) diagnosis, there is a need for the
development of new targets for in vivo imaging that are specific for cardiac tissue and can
directly detect molecular changes in disease pathophysiology. Such imaging may allow
early detection of altered disease patterns, and the fashioning of targeted interventions that
may improve patient outcomes. The current promising cardiac PET tracers have been
developed for the purpose of tracking the biological processes that underlie HD. In
particular 13N-ammonia (13N-NH3) is commonly used after a MI to determine the extent of
diminished cardiac perfusion and damaged myocardium21. 13N-NH3 freely diffuses across
the cell membrane and is utilized in glutamine synthesis via glutamate synthase. 13N-NH3
only enters viable cells and therefore regional perfusion patterns in the myocardium
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directly detects blood flow and tissue viability. Another common clinically used PET tracer
is a glucose analogue, 18F-fluorodeoxy glucose (18F-FDG) which primarily measures the
rate of glucose metabolism in cells. 18F-FDG enters cells through glucose transporters, gets
phosphorylated by hexokinase and is trapped in the cell. Changes in

18

F-FDG uptake are

primarily related to the upregulation or downregulation of glucose transporters on cellular
membranes. With an appropriate protocol that suppresses normal myocardial glucose
uptake,

18

F-FDG can be used to detect inflammation, mediated by primarily pro-

inflammatory macrophages25. Glucose transporters are upregulated in pro-inflammatory
macrophages; therefore, increased

18

F-FDG signal can be used to detect the extent of

inflammation in HD26,27. In addition,

18

F-FDG can measure changes in myocardial

substrate metabolism from predominantly fatty acid metabolism to glucose metabolism as
seen in congestive HF28.

11

C-meta-hydroxyephedrine (HED) is a norepinephrine (NE)

analogue that targets the NE receptor to evaluate regional changes in cardiac neuronal
activity which can help assess HF presence and reinnervation commonly present in
arrythmias29. In addition to these common cardiac PET tracers used in research, there have
been many recent discoveries in developing PET tracers targeting cardiac transporters,
receptors, and proteases that change in HD30,31. An emerging perfusion tracer is

18

F-

flurpiridaz, a pyridazinone derivative, which gets metabolically trapped in cardiomyocytes
through the mitochondrial membrane complex-1 and determines cardiac blood flow. 18Fflurpiridaz was able to accurately detect coronary artery disease using cardiac perfusion
PET imaging32,33. When detecting cardiac inflammation,

68

G-DOTATATE targets the

somatostatin receptor 2 that is overexpressed in inflammatory macrophages. It can
accurately detect inflammation after a myocardial infarction with minimal background
uptake34 and can determine atherosclerotic disease severity35. Lastly, there is emergence of
68

Ga labelled fatty acid analogues (68Ga–NOTA–undecanoic acid) that target fatty acid

transporters and can detect abnormalities of fatty-acid oxidation in myocardial disease36.
Therefore, there are several ongoing efforts at generating novel molecular imaging agents
that target a number of cardiac biomarkers of heart disease.
To optimize new targeted PET tracer development, there are many important factors to
consider. First, for improved plasma stability, small molecule ligands are preferable to
peptide analogues or natural ligands. Second, binding affinity that is improved from that
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of the natural ligand would be ideal for in vivo studies specifically. Finally, labelling with
a clinically used radioisotope, such as

18

F can allow for easy clinical translation. These

considerations have led our team to develop small molecule PET probes targeting GHSR,
specifically 18F-CE470, with strong binding affinities to the receptor (0.11nM). We have
developed an 18F-labelled ghrelin octapeptide analogue from N-terminal 8 amino acids of
native ghrelin, [Inp1,Dpr3(6-fluoro-2-naphthoate),1-Nal4,Thr8]ghrelin(1−8), termed

18

F-

LCE470, which had a significantly stronger affinity (0.11nM) to GHSR compared to native
ghrelin (3.3nM) with in vitro studies37. The next step for this analogue is to evaluate in vivo
binding. We also characterized the efficacy of

18

F-G-7039, a ghrelin peptidomimetic

(binding affinity 69nM), in healthy mice where minimal tracer uptake was present in the
heart18. Therefore, we concluded mouse models may not be optimal for imaging GHSR in
vivo. We also determined that small molecules (low molecular weight organic compound
with minimal resemblance to the ligand) are optimal for tracer binding compared to both
peptidomimetics (combination of amino acids to resemble ligand which have been
manipulated for better binding) and analogues (truncated versions of natural ligands).
We then evaluated our new PET tracer, 18F-LCE470, using both a semi-quantitative TBR
method to determine regional tracer uptake and quantitative kinetic modelling reflecting
GHSR distribution. It is important to note here that one limitation with our kinetic
modelling is the lack of plasma metabolite analysis that corrects the image-derived arterial
input function for metabolic degradation of the tracer over the image acquisition period.
Initial results in one dog showed that

18

F-LCE470 was fairly stable, with the parent

compound decreasing at a linear rate by approximately 40% 60 minute after injection
(Supplemental Fig 4.S2). While this result may indicate relative stability of 18F-LCE470 in
canine plasma over time, we need more robust data in canine plasma to accurately
determine the metabolite correction for this tracer and thus did not use metabolite
correction for this study38.
Typically, in humans, after a MI occurs, there are significant remodeling changes in the
left ventricle that result from both the acute and chronic phases of remodeling. This pattern
of remodeling also occurs in the canine heart after MI39. After the initial infarct, the acute
remodeling phase involves the myocardium surrounding the infarct, termed border
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myocardium, with infarct expansion and the initiation of adaptive biochemical processes
to preserve LVEF and stroke volume40. One such adaptive process is the upregulation of
the Gqα/Phospholipase C β (PLCβ) pathway which play a role in cardio-protection, cardiac
hypertrophy and fibrosis deposition41. This pathway is also known to be activated by
GHSR in cardiomyocytes in the regulation of calcium homeostasis and contractility10,42.
Therefore, the border myocardium may be essential in cardiac remodeling after injury. In
late stage remodeling, the LV is globally involved in progressive dilatation and scar
enlargement, along with distortion of shape and contractile function43. Importantly, in later
stages of remodeling, the border myocardium plays a large role in cardio-protection to
minimize the scar enlargement and reduce damage to heart structure and function44. In our
study, the border myocardium is represented by the left circumflex (LCX) tissue which
surrounds the edge of the infarct.
We evaluated uptake of

18

F-LCE470 in the LV semi-quantitatively through TBR values.

There were some significant regional changes in TBR of 18F-LCE470 post-MI compared
with pre-MI. The sustained post-MI decrease in

18

F-LCE470 uptake in the infarct area

compared to the remote and LCX tissue likely suggests a significant and sustained decrease
in GHSR expression over time after MI. Similarly, the slight decrease of

18

F-LCE470 in

the remote tissue could also be due to a slight decrease in receptor density, and the sustained
uptake in the LCX region suggests that GHSR expression is maintained in this region.
Interestingly, the decrease in 18F-LCE470 TBR specifically in the infarct region could also
be due to a lack of perfusion not allowing the tracer to enter this area. To better determine
the actual dynamics of GHSR distribution after MI, we used kinetic modelling to examine
changes in distribution volume.
Kinetic modelling revealed highly individual responses to MI regarding GHSR
distribution. One pattern that emerged was increased distribution volume in the LCX
border region compared to the remote and infarcted tissue, similar to the pattern of TBR.
These results suggest that one mechanism by which the border myocardium is
cardioprotective is through GHSR signalling. Activation of GHSR in the myocardium is
known to function through the Gαq/PLCβ pathway to regulate contractility through calcium
homeostasis11 along with decreasing inflammatory and fibrotic signalling45, reducing
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apoptosis12, and promoting cellular metabolism46. This pathway is likely upregulated to
compensate for the reduced contractile stress of this area acutely after MI47. Such a
mechanism may also operate to a lesser extent in the remote myocardium, as suggested by
the elevated distribution volumes compared to the area of infarct. In one study evaluating
the strain and stiffness of tissue from baseline to day 28 post MI, increased diastolic
stiffness was initially observed in the infarct and border myocardium at day 3 post MI but
not until day 14 post MI in remote tissue44. In addition apoptosis after MI is increased
extensively in border myocardium and to a lesser extent in remote tissue which is sustained
for 4 weeks48. This provides evidence that there is milder dysregulation of processes in the
remote tissue compared to border tissue. In a proteomic and histological analysis of
signalling in a porcine MI model, 4 weeks after I/R injury the border myocardium had
decreases in proteins for energy metabolism and mitochondrial dysfunction, while proteins
for endothelial growth and apoptosis increased. These results may provide a mechanism
for increased angiogenesis seen in LV remodeling after MI and for increased apoptosis in
the expansion of the infarct when the compensatory mechanisms fail48. Acutely after an
infarct necrosis of cardiomyocytes initiate an intense inflammatory and immune response
where monocytes, neutrophils, and leukocytes clear dead cells out of the infarcted area. An
anti-inflammatory response is then initiated at about 3-4 weeks post MI where fibroblasts
deposit extracellular matrix proteins and cross-linked collagen while granulation tissue
becomes apoptotic49. We have previously shown that GHSR is not expressed in fibrotic
deposition, specifically collagen I and III14. However, GHSR expression is present in
fibroblasts50,51 which may explain the lower 18F-LCE470 distribution in the infarct region
since as the scar matures, the density of cardiac fibroblasts is greatly reduced52. GHSR and
ghrelin are also expressed in macrophages53 which are chronically present in the infarct
and border myocardium at lower levels48, again attributing to part of the weakened

18

F-

LCE470 signal in the infarct. It is important to note that a lack of perfusion in the infarct
area can be physiology linked to the changes in receptor availability. The calculations
derived from kinetic modeling are not biased due to this as changes in perfusion are
reflected in the plasma-to-tissue influx and efflux. The binding potential of the tracer is not
dependent on these rate constants, rather to the tracer binding and disassociating to the
receptor. The concept of tracer binding to receptors independently of altered delivery
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(perfusion), have been validated in multiple PET studies. These overall changes in GHSR
binding and activation in the border myocardium to infarct region may prove optimal
targets for increasing angiogenesis and decreasing apoptosis/ scar expansion chronically.
To better evaluate if these changes in infarct and border myocardium are attributed to actual
changes in distribution volume or cardiac perfusion, we determined regional cardiac
perfusion post-MI. Perfusion in the LV was measured using 13N-NH321,54,55 which functions
through entering the cardiomyocytes by diffusion and incorporation into the glutamine
synthesis pathway56, and is thus metabolically trapped within the cardiomyocyte. This
pathway of uptake and retention does not operate if the cell membrane is damaged, and
therefore

13

N-NH3 detects only viable myocardium21,54. In our study, the pattern of 13N-

NH3 TBR indicated persistently lower perfusion in the area of infarct for the duration of
the study compared with the remote and LCX myocardium. Interpretation of this difference
is limited by the lack of perfusion data before MI and immediately after. However, it is
known that, in this particular model, perfusion of the infarct area significantly decreases
immediately after MI57,58. The MI biology changes dramatically acutely (up to 4 weeks
post-MI) versus chronically (4 weeks onwards). In the acute phase post-MI, the
inflammatory and immune response initiate the removal of dead tissue and begin formation
of new vasculature to restore blood flow to this area. Until this revascularization occurs,
blood flow to the infarcted area is highly limited49. Once fibrotic tissue is deposited and
angiogenesis is present in the infarct area, perfusion is restored while
remains minimal. Therefore, the decreased

13

13

N-NH3 binding

N-NH3 binding in infarct area shows a lack

of tracer access to infarcted area acutely, while chronically it represents scar formation.
When analyzing trends in perfusion imaging after MI, decreased perfusion with 13N-NH3
in patients with HD symptoms were predictive of adverse cardiac outcomes59,60. Therefore,
these acute immune and inflammatory processes may prove to be ideal therapeutic targets
for HD patients.
There is a notable divergence in the perfusion pattern of 13N-NH3 in the remote and LCX
areas when compared with uptake of 18F-LCE470, in that 13N-NH3 TBR was the same in
these two regions, whereas
uptake of

18

18

F-LCE470 TBR were different. These results suggest that

F-LCE470 is independent of perfusion in the remote myocardium. This is
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further supported by the lack of correlation of both TBRs and that of the distribution
volume of

18

F-LCE470 and K1 of

distribution volume of

18

13

N-NH3 in these two areas. Therefore, uptake and

F-LCE470 is likely due to binding to GHSR, and not due to

changes in perfusion. In lieu of a blocking study we compared the TBRs and distribution
volumes of

18

F-LCE470 to the kinetics of perfusion (blood flow) to determine tracer

specificity.
We acknowledge that the specificity of LCE towards cardiac GHSR would be further
confirmed through a blocking study, in which an excess of unlabeled ghrelin would be
administered before or during tracer injection. To date, there has been no GHSR
antagonists administered to humans. The most commonly used GHSR antagonists are [DLys-3]-GHRP-6 and YIL781 which have primarily been used in energy metabolism studies
in rodents61. However, there is evidence that increased concentrations of [D-Lys-3]-GHRP6 injected in rats show adverse cardiac events including elevated mean atrial pressure and
heart rate62. There has also not been any toxicity study performed for these antagonists in
canines and administering large doses is likely to cause significant adverse cardiac events,
similar to what was seen in rats. Therefore, with these important considerations, we did not
use a bocking study to determine tracer specificity.
To validate our in vivo findings, and to further demonstrate that

18

F-LCE470 yields a

readout of GHSR, we measured GHSR expression in all three LV regions using Cy5-cycloghrelin(1-20)22. Fluorescent signal intensity was significantly increased in tissue from the
LCX area compared to the infarct region, and in most dogs, the LCX tissue had higher
fluorescence intensity compared to the remote. These results indicate the relative
differences in the presence of GHSR in LCX, remote and infarct areas, and mirror the
distribution of 18F-LCE470 in each of these regions. In the chronic stages after MI, latestage remodeling occurs in both the remote and border myocardium which encompasses
decreased LV function and global apoptosis. As discussed above, activation of GHSR in
the border myocardium could contribute to enhanced cardioprotective signalling in the
failing cardiac muscle41,63. There is also a significant amount of fibrosis (collagen
deposition) in the infarct area, which may explain the low GHSR signal in this region, as
we have previously shown that GHSR is not expressed in the collagen deposition of fibrotic
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tissue14. GHSR is also known to have increased expression in HF13,14 and after MI16 which
reflects the pattern of GHSR expression present here in cardiac tissue at 18 months postMI. In addition, the lack of GHSR in infarct tissue provides further evidence that the
decreased 18F-LCE470 distribution in the infarct is due to a lack of GHSR uptake and not
solely due to decreased perfusion in that area.
In order to examine the sensitivity of

18

F-LCE470 in binding GHSR, we determined the

relationship between TBR and DV values obtained during the final imaging session and
tissue fluorescence intensities. The strong significant positive correlations between TBR
and fluorescence intensity, and between distribution volume and fluorescence intensity,
demonstrates high tracer sensitivity targeting GHSR density in the heart. One limitation to
note is that tissue was only collected upon sacrifice, and thus tissue GHSR expression could
only be compared to in vivo image analysis at 11 months. Other 18F PET tracers have been
validated for diagnostic accuracy using histological analysis with known positive and
negative samples64–66. The histological analysis in our study used a custom Cy5-cycloghrelin(1-20)22 to accurately determine GHSR presence in the tissue. This method is
superior as we measured GHSR protein in the tissue and we used a fluorescent analogue
instead of antibodies. Traditional GPCR antibodies have shown to have low specificity
whereas our fluorescent analogue demonstrated a high specificity to the receptor as shown
through significant decreases in fluorescence after added blocking agent (supplemental Fig
4.11). Nonetheless, the strong correlation between tissue fluorescence of GHSR and

18

F-

LCE470 uptake indicates the high specificity of 18F-LCE470 binding to GHSR in the LV.
Surprisingly, heart function as determined by MR did not significantly change over time
between baseline and both acute and chronic time points after MI. There was a slight but
not significant decrease in both LVEF and stroke volume observed at day 3 post-MI in the
overall cohort. Normally after a MI, heart function is significantly reduced at acute time
points and can either return to normal, pre-MI levels of heart function, or continue to
decrease and proceed to HF67. The main explanation for no significant functional changes
over time is due to the use of global function rather than regional function. Global heart
function can be an insensitive marker as hypercontractility in non-infarcted tissue will
compensate for the hypocontractility in the infarct. Another possibility for why we are not
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seeing significant changes could be due to the small cohort of dogs used in this study. In
addition, an iron chelator was given to these dogs twice a day from days 1-30 post MI. Iron
chelation has shown to reduce the amount of iron deposition in hemorrhages after acute
MI68 and reduce adverse remodeling such as ventricular enlargement and myocardial
hypertrophy69. The iron chelation agent used in this study could have had similar effects
on LVEF. Even with these variables present, we were still able to demonstrate clear
significant regional changes in both in vivo PET imaging with

18

F-LCE470 and tissue

GHSR fluorescence in the absence of any functional changes seen in the heart.
The main limitation to this study is the lack of metabolite-corrected arterial input function
for compartmental modelling of our new

18

F-LCE470 tracer. Metabolite corrections are

used to determine the rate of tracer decay over time70. Our initial results indicate that the
tracer appears to be relatively stable in the blood over the image acquisition time
(supplemental Fig 4.S2), and more studies need to be completed to show reproducibility.
Other forms of metabolite correction include a mathematical model of correction and
population-based correction. To use the mathematical model, an optimal model must be
selected based on the quality of data and reliability of results. In studies with unknown or
too many parameters, the fitting may be poor71. Metabolite correction based on population
can only be used with a large number of available samples and the population used to
correct must be diverse. This method is rarely possible due to the extensive testing and
validation required for each individual tracer71. Alternatively, a tissue reference region that
does not contain the receptor could be used to generate ratios of tracer uptake with
distribution volume for accurate analysis70. This option is difficult for our particular tracer,
since GHSR is present in both atrial and ventricular myocytes, and vascular endothelial
cells of the aorta, coronary, pulmonary, and arcuate arteries in human tissue72. If we assume
the binding patterns in canine cardiovascular tissue follow those of humans and rats, there
is no appropriate reference region in the heart. There is also evidence that GHSR expression
is present in lung tissue, thereby excluding them as a suitable reference region73. Therefore,
as of now, there is no accurate tissue reference region in the heart with this canine model.
To conclude, we have characterized a novel PET tracer,

18

F-LCE470, to sensitively and

specifically target GHSR in vivo. 18F-LCE470 had a unique, specific binding pattern in the
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canine heart after MI, which did not fully reflect changes in cardiac perfusion. Tissue
GHSR showed a strong correlation to 18F-LCE470 in vivo PET imaging, further supporting
the sensitivity of our tracer to GHSR density. While changes in 18F-LCE470 tracer uptake
were present in the LV, there were no significant changes to the overall heart function
indicating

18

F-LCE470 may reflect the molecular and biochemical changes that occur in

the absence of functional changes after MI. Our ongoing work will help to further
characterize the in vivo changes to the ghrelin-GHSR system throughout the progression
of HD.
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4.5 Supplemental Figures

Supplemental Figure 4.S1 Time-activity curves showing regional uptake of

18F-

LCE470 in infarct, remote, left circumflex area, and blood pool.
A) Baseline; B) Day 3; C) Day 21; D) Week 16; E) Month 11. Regional uptake decreased
slightly in the infarct after MI compared to baseline while both remote and left circumflex
tissues drastically increased after MI.
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18

F-LCE470 Metabolite Analysis
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Supplemental Figure 4.S2 Metabolite Analysis.
Preliminary metabolite analysis on one dog where parent tracer compound decreases 40%
by 60 minutes after injection. Metabolite analysis indicates the tracer degrades 40% over
60 minutes although more robust data needs to be collected for accurate correction.
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Chapter 4

5

Discussion, Future Studies, and Clinical Significance

5.1 Cardiac Ghrelin-GHSR System is a Scalable Marker for
Heart Disease
To optimize diagnosis for heart disease (HD) and prediction towards the development of
heart failure (HF), a better understanding of the underlying biological mechanisms through
the evolution of HF is needed. My work has revealed some dynamics of ghrelin and GHSR
in the human myocardium that may be a key factor in this understanding. GHSR expression
is abnormally elevated in end-stage heart failure1 and activation of this system elicits many
cardioprotective

mechanisms,

including

preservation

of

calcium

homeostasis/

contractiliy2, decreasing inflammatory and fibrotic signalling3, reducing apoptosis4, and
promoting cellular metabolism5. Because many of these effects occur before the onset of
structural changes that define HD, myocardial GHSR may be an optimal target for HD
diagnosis in its earlier stages. In Chapter 2, I used a novel far-red fluorescently labelled
ligand of GHSR to examine the dynamics of the ghrelin-GHSR system. It is important to
note that the expression of GHSR shown with this fluorescent ligand is not necessarily a
demonstration of biological activity in the myocardium. It is better demonstrated by an
increase in production of the receptor that is expressed both on the membrane and within
the cardiomyocytes. This is the first study that evaluated GHSR and ghrelin expression in
human cardiac tissue in patients before and up to 1 year after cardiac transplantation. I
demonstrated that both GHSR and ghrelin were slightly elevated in end-stage HF compared
to serial biopsies of the newly transplanted heart, and both ghrelin and GHSR were
correlated negatively with LVEF. Changes in the ghrelin-GHSR system were associated
with cardioprotective mechanisms as reflected by significant correlations to biochemical
markers of contractility and cell survival/ hypertrophy. My work suggested that ghrelinGHSR may be a more sensitive indicator of alterations in these signalling pathways of
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contractility and hypertrophy than BNP, the gold standard HF biomarker6. Additionally,
GHSR was not expressed in fibrotic tissue, specifically within areas of collagen deposition,
which can provide more information on the exact types of tissues express GHSR and the
biological composition of damaged tissue in this area. Therefore, ghrelin-GHSR can
provide significant information about HF biology.
To further understand the dynamics of how ghrelin-GHSR changes in the heart, this system
was measured in tissue obtained from patients with valvular heart disease with preserved
ejection fraction. These patients had not been diagnosed with HF, but had some significant
risk factors, such as valvular impairments, hypertension, coronary artery disease, and
medications including diuretics and ACE/ARB inhibitors. In Chapter 3, I evaluated the
expression and biology of the ghrelin-GHSR system using our fluorescently labelled
ghrelin ligand in control non-diseased cardiac tissue and in tissue obtained from different
regions of the heart from patients undergoing valve replacement surgery. A positive
correlation between ghrelin and GHSR was present in tissue from the left atrium but not
the left ventricle. In contrast, no correlations were present in the control tissue, which was
sampled from the left ventricle. Taken together with the correlations in end-stage HF, the
weak regional correlation of ghrelin and GHSR in the absence of measurable changes in
LVEF could indicate the scalability of this marker from control → HD → HF. Further
assessment of biochemical changes associated with GHSR activation in valvular disease
indicated a significant positive correlation with SERCA2a, a marker of Ca2+-dependent
contractility, only in the LV. That this relationship was also present in the absence of
measurable changes in LVEF suggests subclinical alterations in GHSR-associated
signalling in the LV. Therefore, I have demonstrated specific, regional changes in the
ghrelin-GHSR system and associated biochemical signalling pathways at different stages
in the progression of HD. The scalability of this system can help provide clues to
understanding to the underlying evolution of HD and the development of HF.
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5.2 Is the Ghrelin-GHSR System a Clinical Diagnostic
Biomarker?
Heart disease (HD) is a diverse clinical syndrome with no one specific path of progression.
This makes diagnosis extremely difficult in the evolution of HD as current biomarkers can
only detect at late stages. Here, we suggest the ghrelin-GHSR system as a potential new
cardiac-localized biomarker of cardiac dysfunction. My work has demonstrated a
significant relationship between ghrelin-GHSR and overall heart function indicating
increases in this system in late stages of HF. This system clearly shows its scalability with
disease severity progressing from no correlations in healthy tissue, to weak correlations in
HD with preserved ejection fraction, to strong correlations in end stage HF. This scalability
also translates with GHSR-associated biochemical signalling as there is no correlation of
GHSR with markers of signalling pathways in control tissue, weak correlations in the HD
cohort, and strong correlations in HF. That these specific alterations in GHSR-associated
signalling occur in both the presence and absence of reduced LVEF indicates subclinical
changes in contractile function may occur prior to overt derangements in cardiac function
and structure. This work is unique in its development and use of a novel fluorescent optical
imaging tool to specifically target expression of GHSR as conventional antibodies lack
specificity. This imaging tool was evaluated in human cardiac tissue, demonstrating the
clinical relevance of ghrelin-GHSR in cardiovascular disease and heart failure. The next
step was to develop a novel in vivo imaging tool to target and track changes in GHSR in
the heart. We then developed a targeted PET tracer for GHSR that can track changes in
tracer distribution in HD and HF.

5.3 In Vivo GHSR PET Tracer Optimization
In the past decade there have been developments for targeting GHSR in vivo with PET
imaging. The first study in designing GHSR-targeted probes was in 2009 by Rosita et al.
where the structure of the ghrelin peptide was significantly modified to carry SPECT and
PET radioisotopes, while maintaining binding to GHSR. They determined that ghrelin
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could be truncated to ghrelin(1-14) and modified on the Ser-3 side chain to carry SPECT
and PET isotopes and still maintain GHSR binding similar to that of native ghrelin. The
lead PET analog, ghrelin(1-14)-12C-F, had a fluorine addition with a strong binding
affinity to GHSR of 28nM. They showed that binding to GHSR could be preserved even
though the octanoyl side chain on Ser3, which comprises the receptor binding domain of
ghrelin, had been altered. In another study by Charron et al., a [68Ga]-ghrelin analogue
([Dpr3(octanoyl),Lys19(Ga-DOTA)]ghrelin(1- 19)) showed strong affinity to GHSR
(5.9nM) in a xenograft mouse model. This analogue was tested in vivo where there was
significant uptake in the xenograft although no uptake was seen in the cardiovascular
system7. This study confirmed the manipulation and radiolabeling of ghrelin to target
GHSR in vivo with motivation to further optimize tracers for GHSR PET imaging. Up until
this point, peptide derivates of ghrelin had been used to target GHSR in vivo but peptides
are inherently unstable in circulation. To generate tracers with improved plasma stability,
small molecule ligands to GHSR have been developed. A small molecule developed by
Chollet et al8, Nα-NODAGA(68Ga)-KwFwLL-CONH2, was evaluated in vivo in rats. This
compound exhibited high stability in the blood, good clearance in kidneys and liver, and
detectable but minimal uptake in the heart. Therefore, the tracer profile should be further
developed for optimal detection of cardiac GHSR8. Another study by Potter et al. evaluated
a small molecule labelled with 11C, (S)- 6-(4-fluorophenoxy)-3-((1-[11C]methylpiperidin3-yl)methyl)-2-o-tolylquinazolin-4(3H)-one, targeted to GHSR where there was increased
stability and clearance with significant uptake in the brain region but minimal uptake in the
mouse heart9. With these improvements in ghrelin analogues, our team developed targeted
analogues for GHSR. Previously, we developed and tested a peptidomimetic, [1Nal4,Lys5(4-[18F]-FB)]G-7039, for GHSR binding (69nM) in wildtype mice and mice
lacking GHSR. There was no significant difference in tracer accumulation in the heart
between mouse models indicating mouse models may not be optimal for imaging cardiac
GHSR in vivo10. The next generation of tracer development incorporated small molecules
where the lead candidate,

18

F-LCE470, showed improved binding affinity to GHSR of

0.11nM when compared to native ghrelin (3.3nM) with in vitro studies11.
For my project, I evaluated the sensitivity and specificity of this new small molecule tracer,
18

F-LCE470, in targeting cardiac GHSR in vivo. In chapter 4, I used

18

F-LCE470 to
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measure the regional distribution of GHSR density before and after a myocardial infarction
(MI) using simultaneous PET/MRI. My work suggested that the uptake and distribution of
18

F-LCE470 are altered immediately (3 days) after a MI, with increases in uptake in the

left circumflex region and significant decreases in the infarct region, and this pattern
persisted for 11 months. The increased tracer uptake in the circumflex tissue surrounding
the infarct suggests that GHSR activation may play a role in the mechanism of
cardioprotection within the border myocardium in the weakening heart. To evaluate tracer
specificity, patterns of cardiac perfusion measured through

13

N-NH3 were compared to

binding patterns in 18F-LCE470. There was a unique binding pattern of 18F-LCE470 in the
LV of the canine heart when compared to cardiac perfusion (blood flow) as demonstrated
by 13N-NH3. I then evaluated tracer sensitivity by correlating 18F-LCE470 to tissue GHSR
expression at end point (1.5 years after MI) using a custom far-red ghrelin analog, Cy5cyclo-ghrelin(1-20), in infarct, remote, and LCX regions. The overall tissue GHSR
expression strongly correlated to GHSR density as measured by 18F-LCE470, showing the
sensitivity of tracer binding in the canine heart. These specific regional changes in GHSR
density show molecular alterations in the heart independently of changes in perfusion and
overall LV function. Therefore, I have characterized a novel PET tracer,

18

F-LCE470, to

sensitively and specifically detect molecular GHSR changes the heart in the absence of
overall cardiac dysfunction.

5.4 Can GHSR Imaging be Used for Clinical Diagnosis for
Cardiac Impairment?
Diagnosis of HD remain difficult as pathogenesis occurs in a variety of forms. The current
diagnostic tests commonly encompass cardiac biomarkers and cardiac imaging.
Conventional cardiac imaging, in the form of echocardiography, CT and MRI, detects
functional and structural changes that are characteristic of the later stages of HD
development while molecular imaging can target specific receptors or signalling pathways
to measure the subclinical changes in the heart. My work suggests that a novel molecular
PET imaging agent, 18F-LCE470, may report increases in GHSR density in vivo in regions
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surrounding a MI in the canine heart in the absence of overt global cardiac dysfunction.
The increase in GHSR density may indicate GHSR-associated subclinical biochemical
changes, as my results in human tissue biopsies showed that upregulation of GHSR is
correlated with specific signalling pathways that induce cardioprotective responses through
enhancing contractility, hypertrophy, and cell survival6,12. Alterations in cardiomyocyte
biochemical signalling are known to occur early in the progression of HD and therefore
early detection of these changes can provide significant advancements in diagnosis13.
Additionally, we have demonstrated the scalability of the ghrelin-GHSR system in HD and
hence, 18F-LCE470 has the potential to track specific regional changes in GHSR density in
the evolution of HD and HF. With the development of this novel PET imaging tool, we can
detect molecular changes of GHSR through imaging which can be a useful tool in early
diagnosis of clinical HD.

5.5 Elucidation of the Relationship Between GHSR and
Inflammation
Now that we have validated 18F-LCE470 sensitivity and specificity to GHSR in vivo in the
canine model of MI, we want to evaluate the biochemical mechanisms associated with
GHSR in vivo. One important process of interest is the relationship between GHSR and
inflammation in the injured and failing heart. After cardiac injury, an intense acute immune
and pro-inflammatory process is activated where monocytes, neutrophils, and leukocytes
migrate to the site of injury to remove dead and damaged cells. This process specifically
includes high numbers of pro-inflammatory macrophages in which glucose transporters
have been upregulated due to their high energy demand14. About 3-4 weeks after injury,
the pro-inflammatory response subsides, and the anti-inflammatory response is initiated.
During this process, fibroblasts deposit extracellular matrix proteins and cross-linked
collagen while granulation tissue becomes apoptotic and is cleared15. As discussed in the
Introduction, GHSR functions through both an inhibitory effect of the pro-inflammatory
response16,17 and activation of the anti-inflammatory response18,19 to protect the heart from
further injury and adverse cardiac events induced by a prolonged inflammatory response.
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We can measure potential in vivo relationships between GHSR and inflammation using
PET imaging techniques.
Many PET tracers have been developed to target different aspects of the cardiac
inflammatory

process20.

68

Ga-[1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic

acid]-d- Phe1,Tyr3-octreotate (DOTATATE) is a common PET tracer that targets the
somatostatin receptor 2 which is overexpressed in inflammatory macrophages.

68

G-

DOTATATE can accurately detect inflammation after a myocardial infarction with
minimal background uptake21 and can determine atherosclerotic disease severity by
differentiating high versus low risk lesions in the vasculature22. Another target for
inflammation is the receptor C-X-C motif chemokine receptor 4 (CXCR4) which is
upregulated on macrophage and T-cells associated with the pro-inflammatory process. 68Gpentixafor, targeted to CXCR4, has been used to detect the increase in pro-inflammatory
cells and vasculature lesions associated with atherosclerosis23. Another emerging target is
the mitochondrial translocator protein TSPO, which is upregulated in most macrophages
and lymphocytes; however, all cells express TSPO on the mitochondrial membrane,
thereby creating background uptake in the myocardium24. Many tracers have been
developed to target TSPO, and tracers that target TSPO specifically in cardiac
inflammation include
FEDAA110627.

18

18

F-flutriciclamide (18F-GE180)25,

11

C-PK1119526, and

18

F-

F-GE180 has been shown to be elevated globally in inflammatory

macrophages acutely after an MI25, and

11

C-PK11195 was elevated in inflammation

associated with vulnerable/ symptomatic plaques in atherosclerosis28. Therefore, increased
uptake of tracers that target TSPO measures increases in activated inflammatory cells and
mitochondrial dysfunction in failing cardiomyocytes24.
The most common clinically used tracer to detect inflammation in the heart is
fluorodeoxyglucose

(18F-FDG).

Proinflammatory

macrophages

overexpression of glucose transporters resulting in increased
important thing to note when using

18

18

have

18

F-

significant

F-FDG uptake14. One

F-FDG in studies of inflammation is that normal

myocardial glucose uptake needs to be suppressed to minimize background signal. This is
usually done with an Intralipid™ infusion in animal studies, or by requiring human subjects
to fast or have a high fat meal prior to imaging to reduce glucose metabolism and increase
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the lipid metabolism in the normal myocardium29. It is uncommon for suppression to be
ineffective; however, there may be variability in effectiveness. An example of such
variability shown in Figure 5.1 where suppression was effective at the day 28 and week 8
time points after MI. However, suppression did not work effectively at month 6, as there
is a significant amount of PET signal throughout the entire heart without any discernable
cardiac region. Regardless,

18

F-FDG is clinically used to determine inflammation

associated with HD such as endocarditis, sarcoidosis, and atherosclerosis. Additionally,
18

F-FDG is currently the clinical gold standard for determination of viable tissue in patients

after myocardial infarction and in cardiac dysfunction with accurate assessment of scar
presence30,31. Therefore, 18F-FDG is an optimal tracer to evaluate the relationship between
inflammation and GHSR in vivo in the heart.

Figure 5.1 18F-FDG imaging in the canine heart after MI.
Canine heart after MI using Intralipid™ suppression to reduce background myocardial
glucose uptake with PET imaging. Day 28 and week 8 demonstrate effective Intralipid™
suppression while month 6 indicates ineffective suppression with no clear discernible
cardiac region.
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We have performed preliminary analysis of 18F-FDG uptake in the same dogs described in
Chapter 4 with Intralipid™ suppression from day 1 to 1-year post-MI to evaluate the
temporal dynamics of glucose metabolism in inflammation. We used kinetic modeling with
Patlak analysis, an established method to quantify glucose metabolism32,33, to determine
the regional Ki values (net influx rate of the tracer). The Ki values of

18

F-FDG were

determined for three different regions including the remote, infarct and left circumflex at
days 1,7, 28, week 8, months 6 and 12 (Fig 5.2a). There was a significant increase in Ki
values in the area of infarct compared to both the remote and circumflex tissue during the
acute inflammatory phase of macrophage infiltration at days 1 and 7. We observed
increased inflammation in the infarct region acutely and there is evidence in the literature
of abundant macrophage, monocyte, and leukocyte infiltration in acute myocardial damage
that can account for this increased signal we observed15. There was no significant
inflammatory process in the remote or circumflex tissues acutely (days 1 and 7 post MI) as
there was minimal 18F-FDG uptake in these areas. The minimal 18F-FDG uptake persisted
around the same level through the chronic phase of MI (day 28 - 1 year post MI) which
may be indicative of the lack of inflammatory processes in these areas chronically.
However, there was a significant reduction of 18F-FDG uptake in the infarct region in the
chronic phase of MI (day 28 - 1 year post MI). It is known that the chronic phase of
inflammation encompasses fibroblasts deposition of extracellular matrix proteins and
cross-linked collagen with minimal macrophage presence15 which likely accounts for the
chronic decreased

18

F-FDG uptake in the infarct region. Therefore, changes in

18

F-FDG

uptake help to provide a better understanding of the biology of the infarct region acutely
and chronically.
We also measured levels of circulating cardiac inflammatory marker C-reactive protein
(CRP), which is an indicator of inflammation associated with stressed and damaged
myocardium, at the same time points as 18F-FDG imaging sessions. CRP is released from
the liver upon activation by a pro-inflammatory IL-6 specific response to cardiac stress and
injury34. In cardiac inflammation, CRP exacerbates the pro-inflammatory response by
binding to damaged cell membranes to enhance macrophage recruitment and
phagocytosis35. In our study, there was a significant increase in plasma CRP in the proinflammatory phase (days 1, 3, and 7) after cardiac injury followed by reduced
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inflammation back to baseline levels by day 21 (Fig 5.2b). That the peak of circulating
CRP coincides with the peak of 18F-FDG uptake suggests there is a significant increase in
macrophage presence in the infarct at these time points, as

18

F-FDG is known to have

significant uptake in macrophages while CRP recruits them to the site of cardiac
inflammation. The enhancement of both

18

F-FDG and CRP acutely after MI provides a

better understanding of the pro-inflammatory temporal timeline and the cell types present
in the infarct region. Further elucidating the regional inflammatory biology composition
and biochemical activation will help with understanding the evolution of HD.
To evaluate the relationship between inflammation and GHSR in the heart, we conducted
linear regression analysis with 18F-FDG Ki values and 18F-LCE470 DV values in both the
acute and chronic phases after MI (Fig 5.3). There was no correlation between GHSR
density and glucose metabolism in the acute phase; however, there was a significant
positive correlation in the chronic phase. GHSR is shown to have increased expression in
tissue that is stressed1, such as the region surrounding the infarct, no expression in dead
and fibrotic tissue6, and low expression in macrophages36. GHSR signalling is also known
to activate cardioprotective responses, including anti-inflammatory responses, in cardiac
tissue18,19. The lack of correlation between GHSR density and glucose metabolism acutely
could be due to significant increases in macrophages where GHSR density is known to be
low but

18

F-FDG uptake is increased. This lack of correlation acutely supports no

significant relationship between GHSR and pro-inflammatory signaling in this model of
MI. In contrast in the chronic phase (day 28 – 1 year post MI), macrophage presence is
known to be decreased which is supported by decreased
infarct in our study. The positive correlation of

18

18

F-FDG uptake in the area of

F-FDG and GHSR density chronically

could be due to a cardioprotective response through GHSR in non-infarcted tissue. After
MI, increases in inflammation in the heart are commonly associated with increase LV wall
stress especially in the border myocardium37. The LV dilates as a compensatory mechanism
to improve overall cardiac output38. GHSR is expected to be activated in the border
myocardium after MI and induce cardioprotective mechanisms and help improve cardiac
function39,40. Therefore, increased GHSR expression chronically after MI is likely due to
cardioprotective mechanisms, partly due to inflammation associated to LV wall stress and
dilation. To fully evaluate the relationship between GHSR and inflammation, in vivo PET
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results should be compared to circulating inflammatory markers and histological samples
of cardiac tissue.

Figure 5.2 Quantification of glucose metabolism with 18F-FDG in canine heart after
MI.
A) Ki values increased in acute pro-inflammatory phase in the infarct at days 1 and 7. In
the chronic anti-inflammatory phase, there was no significant differences between regions.
B) Circulating CRP (cardiac specific inflammatory marker) levels which increased acutely
and decreased back to low levels in the chronic inflammatory phase.

201

Figure 5.3 Correlation between inflammation (18F-FDG) and GHSR (18F-LCE470)
over time.
A) Acute (days 1 and 7 post MI) inflammatory response shows no linear regression with
GHSR in vivo. B) Chronic (day 28, week 8, month 6, and 1-year post MI) inflammatory
response indicates a positive linear regression with GHSR in vivo in the canine heart after
MI.

Our preliminary results outline a potential relationship between GHSR and inflammation
after MI, and this process should be investigated in subsequent studies. To further
determine the connections between cardiac inflammation and the regional distribution of
GHSR, baseline

18

F-FDG imaging, before MI, is needed for accurate comparison of

changes to both the acute and chronic inflammatory processes. The baseline images will
help determine the extent of the pro- and anti-inflammatory phases and how long each
phase persists. The change in 18F-FDG uptake from baseline can then be correlated to the
change in

18

F-LCE470 uptake at the same time points. To better compare GHSR to

inflammation signalling, 18F-LCE470 could be further characterized for quantitative PET
imaging. A complete metabolite analysis should be conducted to generate a metabolitecorrected image-derived input function for precision quantitative imaging of GHSR
dynamics. Although the quantitative values may change with metabolite correction, the
pattern of tracer uptake should remain consistent. In addition to the GHSR-inflammation
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relationship with PET imaging, circulating levels of inflammatory markers CRP and IL-6
along with HF markers BNP/NT-proBNP and high sensitive-Troponin T and I, should be
correlated to circulating ghrelin levels to show the temporal relationships in the blood
between ghrelin and both inflammation and HF. Furthermore, to accurately examine the
regional and temporal relationship between GHSR and inflammation, endomyocardial
biopsies of cardiac tissue, from baseline up to 1 year, should be analyzed for tissue markers
of pro- and anti- inflammation along with GHSR expression. Additionally, changes in
signalling pathways associated with contractility, metabolism, survival, and apoptosis
should be measured in these tissue samples. These analyses will provide a more complete
picture of the biology underlying the progression of cardiac dysfunction after MI.
In summary, my project successfully identified GHSR as a scalable biomarker in human
heart failure and heart disease using quantitative fluorescence microscopy. I demonstrated
specific regional changes in both the ghrelin-GHSR system and GHSR-associated
signalling. These molecular and biochemical changes were present prior to the
development of overt cardiac dysfunction. I then developed and characterized a targeted
PET imaging agent for cardiac GHSR in a large animal model of myocardial infarction. I
determined this PET tracer to sensitively and specifically bind to GHSR before and up to
one year post-MI. This work not only demonstrated significant advancement in elucidating
the biology of the myocardial ghrelin-GHSR system, but I have identified a novel in vivo
imaging tool to accurately identify specific regional changes in cardiac tissue. The
myocardial ghrelin-GHSR system can be a unique tool to non-invasively determine
alterations in the molecular and biochemical processes associated with early stages of HD.
My project focused on three specific types of HD including end-stage HF, aortic stenosis,
healthy heart, and cardiac remodeling after MI. In these specific models the ghrelin-GHSR
system correlated in a scalable manner. It is still unknown how the ghrelin-GHSR system
changes in all types of HD and therefore this system must be explored in all disease states.
There is currently no universal biomarker of HD or HF and ghrelin-GHSR must be
explored to determine which disease states have increased or decreased GHSR expression
in the myocardium. In vivo imaging has allowed for detection of GHSR changes in the
heart which can be quantified with compartmental modelling. The next step for this system

203

is to determine a quantitative threshold where GHSR is elevated, likely at earlier stages
when HF is still treatable with medications or surgery. This biomarker, GHSR, can be used
in conjunction with a panel of biomarkers to help predict which patients may proceed to
HF. This system may ultimately help to diagnose HD earlier in its progression, resulting in
favourable outcomes for more patients.
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